

# GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

## ONLINE APPENDIX

**2019**

Deleted: 2018

This online Appendix contains background and supplementary material for the Global Initiative for Asthma (GINA) **2019** Global Strategy Report for Asthma Management and Prevention. The full GINA report and other GINA resources are available at [www.ginasthma.com](http://www.ginasthma.com)

Deleted: 2018

This document is intended to provide background information for the full GINA **2019** report, as a general guide for health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessing and treating patients, health professionals are strongly advised to consult a variety of sources and to use their own professional judgment, and to take into account local or national regulations and guidelines. GINA cannot be held liable or responsible for inappropriate healthcare associated with the use of this document, including any use which is not in accordance with applicable local or national regulations or guidelines.

Deleted: 2018



## TABLE OF CONTENTS

<b>Chapter 1. The burden of asthma .....</b>	<b>7</b>
Prevalence, morbidity and mortality .....	7
Social and economic burden .....	9
Reducing the burden of asthma .....	9
<b>Chapter 2. Factors affecting the development and expression of asthma.....</b>	<b>11</b>
Background.....	11
Host factors .....	12
Environmental factors.....	13
<b>Chapter 3. Mechanisms of asthma .....</b>	<b>17</b>
Airway inflammation in asthma.....	17
Structural changes in the airways.....	20
Pathophysiology .....	20
Special mechanisms in specific contexts.....	21
<b>Chapter 4. Tests for diagnosis and monitoring of asthma .....</b>	<b>23</b>
Measuring lung function .....	23
Non-invasive markers of airway inflammation.....	26
<b>Chapter 5. Asthma pharmacotherapy .....</b>	<b>29</b>
Part A. Asthma pharmacotherapy - adults and adolescents.....	29
Route of Administration.....	29
Controller medications.....	29
Add-on controller medications.....	34
Reliever medications.....	39
Other medications .....	40
Complementary and alternative medicines and therapies.....	41
Part B. Asthma pharmacotherapy – children 6–11 years .....	43
Route of administration .....	43
Controller medications.....	44
Add-on controller medications.....	48
Reliever medications.....	50
Other medications, not recommended for use in children.....	50
Part C. Asthma pharmacotherapy – children 5 years and younger.....	51

Controller medications.....	51
Reliever medications.....	54
<b>Chapter 6. Implementing asthma management strategies in health systems .....</b>	<b>55</b>
Introduction.....	55
Planning an implementation strategy.....	56
Economic value of implementing management recommendations for asthma care .....	61
GINA dissemination and implementation resources .....	61

COPYRIGHTED MATERIAL - DO NOT COPY OR DISTRIBUTE  
 ARCHIVED - FOR REFERENCE ONLY

## TABLE OF FIGURES

Box A1-1.	World map of the prevalence of current asthma in children aged 13–14 years .....	7
Box A1-2.	Prevalence of current asthma in 2000–2003 in children aged 13–14 years (%) .....	8
Box A2-1.	Factors influencing the development and expression of asthma.....	11
Box A3-1.	Inflammatory cells in asthmatic airways .....	17
Box A3-2.	Structural cells in asthmatic airways .....	18
Box A3-3.	Key cellular mediators in asthma .....	19
Box A3-4.	Structural changes in asthmatic airways .....	20
Box A4-1.	Measuring PEF variability .....	25
Box A4-2.	Measuring airway responsiveness .....	26
Box A5-1.	Low, medium and high daily doses of inhaled corticosteroids for adults and adolescents .....	30
Box A5-2.	Inhaler devices, optimal technique, and common problems for children .....	44
Box A5-3.	Low, medium and high daily doses of ICS for children 6–11 years .....	45
Box A5-4.	Corticosteroids and growth in children .....	46
Box A5-5.	Corticosteroids and bones in children .....	46
Box A5-6.	Low daily doses of inhaled corticosteroids for children 5 years and younger .....	51
Box A6-1.	Examples of barriers to the implementation of evidence-based recommendations .....	56
Box A6-2.	Essential elements required to implement a health-related strategy .....	56
Box A6-3.	Common asthma management care gaps .....	58
Box A6-4.	Examples of high-impact interventions in asthma management .....	59
Box A6-5.	Potential key outcomes and targets to consider for implementation programs.....	60



# Chapter 1.


## The burden of asthma

### PREVALENCE, MORBIDITY AND MORTALITY

Asthma is a problem worldwide, with an estimated 300 million affected individuals.<sup>1</sup> Despite hundreds of reports on the prevalence of asthma in widely differing populations, the lack of a precise and universally accepted definition of asthma makes reliable comparison of reported prevalence from different parts of the world problematic.<sup>2</sup> Nonetheless, based on standardized methods for assessing asthma symptoms, it appears that the global prevalence of asthma ranges from 1 to 16% of the population in different countries (Boxes A1-1, A1-2).<sup>1,3</sup> There are insufficient data to determine the likely causes of the described variations in prevalence within and between populations.

There is firm evidence that international differences in asthma symptom prevalence in children have decreased over recent decades; symptom prevalence has been decreasing in Western Europe and increasing in regions where prevalence was previously low.<sup>4</sup> Asthma symptom prevalence in Africa, Latin America, Eastern Europe and Asia continues to rise. The World Health Organization *Global Burden of Disease Study* estimates that 13.8 million disability-adjusted life years (DALYs) are lost annually due to asthma, representing 1.8% of the total global disease burden.<sup>5</sup> It is estimated that asthma causes 346,000 deaths worldwide every year,<sup>6</sup> with widely varying case fatality rates that may reflect differences in management.<sup>1</sup>

Box A1-1. World map of the prevalence of current asthma in children aged 13–14 years



\*Map provided by Richard Beasley. Data are based on ISAAC III.<sup>3</sup> The prevalence of current asthma in the 13–14 year age group is estimated as 50% of the prevalence of self-reported wheezing in the previous 12 months.

**Box A1-2. Prevalence of current asthma in 2000–2003 in children aged 13–14 years (%)**

Country	% asthma	Country	% asthma	Country	% asthma
Isle of Man	15.6	Austria	7.6	Ethiopia	4.6
El Salvador	15.4	Turkey*	7.4	Morocco	4.5
Australia	15.3	Malta	7.3	Malaysia	4.5
Vietnam	14.8	Ukraine	7.3	FYR Macedonia	4.4
Scotland	13.9	Tunisia	7.2	Algeria	4.4
Wales	13.8	Nicaragua	6.9	South Korea	4.4
Costa Rica	13.7	Canada	6.9	Mexico	4.4
New Zealand	13.4	France*	6.8	Hong Kong	4.3
Republic of Ireland	13.4	Norway*	6.8	Palestine	4.3
Channel Islands	13.3	Bolivia	6.8	Philippines	4.2
England	11.5	Trinidad and Tobago	6.6	Sultanate of Oman	4.2
Sri Lanka	11.5	Nigeria	6.5	Croatia	4.2
Panama	11.5	Niue	6.4	Belgium	4.2
Romania	11.4	Sudan	6.3	Bulgaria	4.1
United States of America	11.1	Argentina	6.3	New Caledonia	4.1
Honduras	11.0	United Arab Emirates*	6.2	Italy	4.1
Reunion Island	10.8	Jordan	6.2	Kyrgyzstan	3.9
Paraguay	10.5	Netherlands	6.1	Kuwait	3.8
Barbados	10.4	Colombia	5.9	Bangladesh*	3.8
Congo	9.9	Portugal	5.9	Democratic Republic of Congo	3.8
Tokelau	9.9	Singapore	5.7	Lithuania	3.7
Peru	9.8	French Polynesia	5.7	Occupied Territory of Palestine*	3.6
Ivory Coast	9.7	Russia	5.6	Egypt	3.5
South Africa	9.6	Iran	5.4	Taiwan	3.1
Finland	9.5	Pakistan	5.4	Denmark*	3.0
Brazil	9.4	Cook Islands	5.3	India	2.9
Guinée	9.3	Spain	5.3	Hungary	2.9
Cuba	8.9	Latvia	5.3	Samoa	2.9
Germany	8.8	Fiji	5.2	Cameroon	2.9
Togo	8.4	Thailand	5.2	Syrian Arab Republic	2.6
Ecuador	8.3	Gabon	5.1	Indonesia	2.6
Uruguay	8.2	Poland	5.1	Georgia	2.6
Kingdom of Tonga	8.1	Japan	5.0	Switzerland*	2.3
Czech Republic*	8.0	Sweden	4.9	Greece*	1.9
Kenya	7.9	Serbia and Montenegro	4.8	China	1.8
Venezuela	7.7	Estonia	4.7	Albania	1.7
Chile	7.7	Uzbekistan*	4.6	Nepal*	1.5

Data are based on ISAAC III.<sup>3</sup> The prevalence of current asthma in the 13–14 year age group is estimated as 50% of the prevalence of self-reported wheezing in the previous 12 months.\*No data available from ISAAC III, figures taken from Global Burden of Asthma Report<sup>1</sup>



## SOCIAL AND ECONOMIC BURDEN

Social and economic factors are integral to understanding asthma and its care, from the perspective of both the individual person with asthma and the health care provider. In addition, quantifying the socioeconomic burden of diseases is important as it provides critical information to decision makers to efficiently allocate scarce health care resources. Attention needs to be paid to both direct medical costs (identifiable health care services and goods used for asthma such as hospital admissions, physician visits and medications) and indirect costs (productivity loss and premature death).<sup>7,8</sup>

### Direct costs

The monetary costs of asthma, as estimated in a variety of health care systems including those of the United States,<sup>9,10</sup> Canada,<sup>11</sup> Italy,<sup>12</sup> and the United Kingdom<sup>13</sup> are substantial. Few economic studies are conducted in non-western countries, but there is strong evidence that asthma imposes a significant burden in the developing world.<sup>14</sup> Exacerbations are major determinants of the direct cost of asthma, and preventing exacerbations should be an important consideration in asthma management.<sup>15</sup>

### Indirect costs

Since asthma is a chronic health condition that affects individuals across all ages, productivity loss due to asthma is substantial.<sup>16</sup> Absence from school and days lost from work are reported as substantial social and economic consequences of asthma in studies from various regions of the world.<sup>8,17</sup> Productivity loss itself can be in the form of missed work time (absenteeism), and present at work but with reduced performance (presenteeism).<sup>18</sup> Very few comparisons are available, but productivity loss due to presenteeism seems to be a more important source of economic burden than absenteeism.<sup>16</sup>

## REDUCING THE BURDEN OF ASTHMA

Poor asthma control is associated with higher medical costs, increased productivity loss, and substantial reductions in quality of life.<sup>19</sup> In closely controlled clinical trials, good asthma control can be achieved in the majority of patients.<sup>20</sup> Nevertheless, in practice there remains a substantial fraction of patients with poorly controlled asthma due to sub-optimal treatment. This signifies a care gap and potential for improvements in health and reductions in costs.<sup>19</sup> However, good management of asthma poses a challenge for individuals, health care professionals, health care organizations, and governments. Efforts are required to provide access to appropriate controller medications, and to ensure that they are prescribed appropriately by health care providers and used correctly by patients.<sup>21</sup>

Comparisons of the cost of asthma in different regions lead to the following conclusions.

- The costs of asthma depend on its prevalence, the individual patient's level of asthma control, the extent to which exacerbations are avoided, and the costs of medical care and medications.
- Emergency treatment is more expensive than planned treatment and preventing hospitalizations is an achievable goal for health services.
- The non-medical economic costs of asthma are substantial. Specifically, presenteeism seems to be particularly high in patients with asthma.
- The presence of many individuals with uncontrolled asthma signifies a preventable source of socioeconomic burden.

Additional information about the burden of asthma can be found in the 2004 report *Global Burden of Asthma* ([www.ginasthma.org](http://www.ginasthma.org)) and from the World Health Organization *Global Burden of Disease* project ([www.who.int/healthinfo/global\\_burden\\_disease](http://www.who.int/healthinfo/global_burden_disease)). Ongoing audit and research on the social and economic burden of asthma and the cost-effectiveness of treatment are needed in both developed and developing countries.



# Chapter 2.

## Factors affecting the development and expression of asthma

### BACKGROUND

Factors that influence the risk of developing asthma include host and environmental factors (Box A2-1).<sup>22</sup> However, the mechanisms whereby these factors influence the development and expression of asthma are complex and interactive; for example, genes are likely to interact both with other genes and with environmental factors to determine asthma susceptibility.<sup>23,24</sup> In addition, developmental aspects such as the maturation of the immune response, development of atopy, and the timing of infectious exposures during the first years of life, are emerging as important factors that modify the risk of asthma in the genetically susceptible person. Strategies that may be useful to prevent the development of asthma are described in the *Global Strategy for Asthma Management and Prevention* 2019, Chapter 7.<sup>25</sup>

Deleted: 2018

Deleted: 25

Box A2-1. Factors influencing the development and expression of asthma

Host factors	↔	Environmental factors
<ul style="list-style-type: none"><li>Genetic (e.g. genes predisposing to atopy, airway hyperresponsiveness, airway inflammation)</li><li>Obesity</li><li>Sex</li><li>Pre-term or with small size for gestational age</li></ul>		<ul style="list-style-type: none"><li>Allergens<ul style="list-style-type: none"><li>Indoor: domestic mites, furred animals (e.g. dogs, cats, mice), cockroaches, fungi, molds, yeasts</li><li>Outdoor: pollen, molds</li></ul></li><li>Occupational sensitizers and allergens (e.g. flour, laboratory rodents, paints)</li><li>Infections (predominantly viral)</li><li>Microbiome</li><li>Exposure to tobacco smoke<ul style="list-style-type: none"><li>Passive smoking</li><li>Active smoking</li></ul></li><li>Outdoor or indoor air pollution</li><li>Diet</li><li>Stress</li></ul>

Links between asthma and socioeconomic status, with a higher prevalence of asthma in developed than in developing nations; in poor compared with affluent populations in developed nations; and in affluent compared with poor populations in developing nations; are likely to reflect lifestyle differences such as exposure to allergens, infections, diet, and access to health care. Much of what is known about risk factors for the development of asthma comes from studies of young children; the risk factors in adults, particularly *de novo* in adults who did not have asthma in childhood, are less well defined.

The heterogeneity of asthma, the previous lack of a clear definition, and lack of a biological 'gold standard' marker for asthma present significant problems in studying the role of different risk factors in the development of this complex disease. Characteristics that are commonly found in patients with asthma (e.g. airway hyperresponsiveness, atopy and allergic sensitization) are themselves products of complex gene–environment interactions and are therefore both features of asthma and risk factors for the development of the disease.

## HOST FACTORS

### Genetic

Asthma has a complex heritable component. Current data show that multiple genes may be involved in the pathogenesis of asthma,<sup>26</sup> and different genes may be involved in different ethnic groups.<sup>27</sup> The search for genes linked to the development of asthma has focused on four major areas: production of allergen-specific immunoglobulin E (IgE) antibodies (atopy); expression of airway hyperresponsiveness; generation of inflammatory mediators such as cytokines, chemokines and growth factors; and determination of the ratio between T helper lymphocyte Th1 and Th2 immune responses (as relevant to the hygiene hypothesis of asthma).<sup>28</sup> Family studies and case-control association analyses have identified a number of chromosomal regions that are associated with asthma susceptibility. For example, a tendency to produce an elevated level of total serum IgE is co-inherited with airway hyperresponsiveness, and a gene (or genes) governing airway hyperresponsiveness is located near a major locus that regulates serum IgE levels on chromosome 5q.<sup>29</sup>

A meta-analysis of genome-wide association studies (GWAS) for IgE identified a variant near HLA-DQB1 as a predictor of total serum IgE levels in multiple race and ethnic groups.<sup>30</sup> Another GWAS study defined the potential importance of genes such as IL33, IL1RL1, IL18R1 and TSLP that are involved in epithelial cell danger signal pathways.<sup>31</sup> To further complicate the issue, researchers have found associations for variants in innate immunity genes with asthma and suggest that these may play a role, in conjunction with early-life viral exposures, in the development of asthma.<sup>32</sup>

In addition to genes that predispose to asthma there are genes that are associated with the response to asthma treatments. For example, variations in the gene encoding the beta<sub>2</sub>-adrenoreceptor have been linked to differences in some subjects' responses to short-acting beta<sub>2</sub>-agonists.<sup>33</sup> Other genes of interest modify the responsiveness to corticosteroids<sup>34</sup> and leukotriene receptor antagonists.<sup>35</sup> Genetic markers will likely become important, not only as risk factors in the pathogenesis of asthma, but also as determinants of responsiveness to treatment.

### Sex

In childhood, male sex is a risk factor for asthma. Prior to the age of 14, the prevalence of asthma is nearly twice as great in boys as in girls.<sup>36</sup> As children grow older, the difference in prevalence between the sexes narrows, and by adulthood the prevalence of asthma is greater in women than in men. The reasons for this sex-related difference are not clear; one potential contributor is differences in lung and airway size, which are smaller in males than in females in infancy,<sup>37</sup> but larger in females in adulthood.<sup>38</sup>

### Early growth characteristics

Early growth characteristics might persistently affect lung function and thereby contribute to the risk of obstructive respiratory diseases in later life. Younger gestational age, lower birth weight, and greater infant weight gain are independently associated with persistent changes in childhood lung function. Stratified analyses of birth cohorts have shown that children born very preterm with a relatively low birth weight had the lowest FEV<sub>1</sub> and FEV<sub>1</sub>/FVC ratio. Preterm birth, low birth weight, and greater weight gain were all associated with an increased risk of childhood asthma.<sup>39</sup>

### Obesity

The prevalence and incidence of asthma are increased in obese subjects (body mass index >30 kg/m<sup>2</sup>), particularly in women with abdominal obesity.<sup>40,41</sup> Inappropriate attribution of shortness of breath may contribute to over-diagnosis, but one study found that over-diagnosis of asthma was no more common in obese than in non-obese patients.<sup>42</sup> It is not known why asthma develops more frequently in the obese. Potential contributing factors include changes in airway function due to the effects of obesity on lung mechanics; the development of a pro-inflammatory state in obesity; and an increased prevalence of comorbidities, genetic, developmental, hormonal or neurogenic influences.<sup>41</sup>

## Depression

While depression is a common comorbidity of asthma, the temporal relationship between the two conditions has not been clear. A systematic review and meta-analysis of six prospective studies with follow-up of 8-20 years found that depression was associated with a 43% increased risk of developing adult-onset asthma, after adjustment for potential confounding factors such as age, sex, smoking and body mass index. On the other hand, the two studies examining the relationship between asthma and risk of subsequent depression found no significant association, but this may have been due to insufficient studies being available.<sup>43</sup>

## ENVIRONMENTAL FACTORS

### Allergens

Although indoor and outdoor inhalant allergens are well-known triggers of asthma exacerbations in people with established asthma, their specific role in the initial development of asthma is still not fully resolved. Birth cohort studies have shown that sensitization to house dust mite allergens, cat dander, dog dander,<sup>44,45</sup> and *Aspergillus* mold<sup>46</sup> are independent risk factors for asthma-like symptoms in children up to 3 years of age. For children at risk of asthma, dampness, visible mold and mold odor in the home environment are associated with increased risk of developing asthma.<sup>47</sup> However, the relationship between allergen exposure and sensitization in children is not straightforward, depending on interactions between the allergen, the dose, the time of exposure, the child's age, and genetics.

For some allergens, such as those derived from house dust mites and cockroaches, the prevalence of sensitization appears to be directly correlated to exposure.<sup>45,48</sup> However, while some data suggest that exposure to house dust mite allergens may be a causal factor in the development of asthma<sup>49</sup> other studies have questioned this interpretation.<sup>50,51</sup> Cockroach infestation has been shown to be an important cause of allergic sensitization, particularly in inner-city homes.<sup>52</sup>

Some epidemiological studies have found that early exposure to cats or dogs may protect a child against allergic sensitization or the development of asthma.<sup>53-55</sup> Conversely others suggest that such exposure may increase the risk of allergic sensitization.<sup>54,56-58</sup> A study of over 22,000 school-age children from 11 birth cohorts in Europe showed no association between pets in the home early in the child's life and higher or lower prevalence of asthma.<sup>59</sup>

Sensitization to ingested allergens in early life remains a risk factor for subsequent asthma;<sup>60</sup> however, there are insufficient data to permit intervention, and no strategies can be recommended to prevent allergic sensitization pre-natally. In particular, there is no evidence that antenatal peanut or tree nut exposure increases the risk for subsequent asthma in children.<sup>61</sup>

Rhinitis in individuals without asthma is a risk factor for development of asthma both in adults and children. In adults, asthma development in individuals with rhinitis is often independent of allergy; in childhood, it is frequently associated with allergy.<sup>62,63</sup>

A meta-analysis of studies examining the effect of allergen immunotherapy concluded that allergen immunotherapy did not result in a statistically significant reduction in the risk of developing a first allergic disease, but that, among those with allergic rhinitis, there was evidence of a reduced short-term risk of developing asthma. However, it is unclear whether this benefit was maintained over the longer term.<sup>64</sup>

### Occupational sensitizers

Occupational asthma is asthma caused by exposure to an agent encountered in the work environment.<sup>65,66</sup> Asthma is the most common occupational respiratory disorder in industrialized countries, and occupational agents are estimated to cause about 15% of cases of asthma among adults of working age.<sup>67</sup> Over 300 substances have been associated with occupational asthma, including highly reactive small molecules such as isocyanates; irritants that may cause an alteration in airway responsiveness; immunogens such as platinum salts; and complex plant and animal biological

products that stimulate the production of IgE (e.g. flour, laboratory rodents, wood dust). Occupations associated with a high risk of occupational asthma include farming and agricultural work, laboratory animal facilities, painting (including vehicle spray painting), cleaning work, and plastic manufacturing.<sup>66</sup>

Most occupational asthma is immunologically mediated and has a latency period of months to years after the onset of exposure.<sup>68</sup> Both IgE-mediated allergic reactions and cell-mediated allergic reactions are involved.<sup>69</sup> Levels above which sensitization frequently occurs have been proposed for many occupational sensitizers; however, the factors that cause some people but not others to develop occupational asthma in response to exposure to the same agent are not well identified. Very high exposures to inhaled irritants may cause 'irritant-induced asthma' (including reactive airways dysfunctional syndrome (RADS) even in non-atopic individuals.<sup>70</sup> Atopy and tobacco smoking may increase the risk of occupational sensitization, but screening individuals for atopy is of limited value in preventing occupational asthma.<sup>65</sup> The most important method of preventing occupational asthma is to eliminate or reduce exposure to occupational sensitizers. However, occupational asthma, once present, persists in most patients even after removal from exposure.<sup>65</sup>

Infections

Infection with a number of viruses during infancy has been associated with the inception of the asthmatic phenotype. Respiratory syncytial virus (RSV), human rhinovirus (HRV) and parainfluenza virus produce a pattern of symptoms including bronchiolitis that parallel many features of childhood asthma.<sup>71,72</sup> Several long-term prospective studies of children admitted to hospital with documented RSV infection have shown that approximately 40% will continue to wheeze or have asthma into later childhood.<sup>71,72</sup> On the other hand, some respiratory infections early in life, including measles and sometimes even RSV, appear to protect against the development of asthma.<sup>73</sup> The data do not allow specific conclusions to be drawn. With the advent of improved molecular techniques for detecting viral pathogens, the important contributions of community-based wheezing illnesses due to HRV during infancy and early childhood with the subsequent development of asthma have now been well recognized.<sup>74,75</sup> Both allergic sensitization<sup>76</sup> and certain genetic loci<sup>77</sup> appear to interact with HRV wheezing illnesses in early life to increase the risk of developing asthma in childhood. Common bacterial pathogens may also be associated with wheezing illnesses in early life.<sup>78</sup> Parasitic infections do not in general protect against asthma, but infection with hookworm may reduce the risk.<sup>79</sup>

The 'hygiene hypothesis' proposes that exposure to infections early in life influences the development of a child's immune system along a 'non-allergic' pathway, and leads to a reduced risk of asthma and other allergic diseases.<sup>28</sup> This mechanism may explain observed associations between family size, birth order, day-care attendance, and the risk of asthma. For example, young children with older siblings and those who attend day care are at increased risk of infections, but enjoy protection later in life against the development of allergic diseases, including asthma.<sup>80-82</sup> The hygiene hypothesis continues to be investigated.

Recent observations indicate that the microbiome (i.e. the collection of microorganisms and their genetic material), both within the host and in the host's surrounding environment, may contribute to the development and/or prevention of allergic diseases and asthma.<sup>83</sup> For example, delivery by ~~cesarean section~~ has been associated with an increased risk of asthma up to the age of 12 years compared with vaginal delivery.<sup>84-86</sup> In rural settings, the prevalence of childhood asthma is reduced and this has been linked to the presence of bacterial endotoxin in these environments.<sup>87</sup> In rural settings, the diversity of microbial exposure in house dust has been correlated inversely with the risk of developing asthma.<sup>88</sup>

The interaction between atopy and viral infections appears to be complex in that the atopic state can influence the lower airway response to viral infections; viral infections can then influence the development of allergic sensitization; and interactions can occur when individuals are exposed simultaneously to both allergens and viruses.<sup>89,90</sup> However, allergic sensitization in the first 3 years of life is more likely to precede viral-associated wheezing illnesses and may actually be causal in nature.<sup>74</sup> In children with allergic asthma, anti-IgE therapy decreased the duration of rhinovirus infections, viral shedding, and the risk and severity of rhinoviral illnesses,<sup>91</sup> suggesting that in allergic patients, blocking IgE may limit rhinovirus replication.

- Deleted: C
- Deleted: a
- Deleted: is a significant risk factor for development of

## Socioeconomic inequalities

In all communities, poverty is strongly related to ill health. This has not generally been the pattern for asthma, where the lifetime prevalence of symptoms was usually higher in more affluent societies.<sup>92</sup> However, in recent years, data from many studies have challenged this view. There have been consistent demonstrations of a positive association between lower socioeconomic status and risk of wheezing, both in high- and in low- and middle-income countries (LMIC), indicating a more complex interaction between factors, some protective and others causative. In children living in inner cities in the USA, the burden of asthma is high and appears to be independent of ethnicity and income.<sup>93</sup> In addition, the relationship between poverty and asthma may change over time. For example, a study from Sweden has shown a reversal of the association between socioeconomic status and asthma prevalence; military conscripts of low socioeconomic status who three decades ago had the lowest, now have the highest prevalence of asthma, with increasing prevalence in successive generations.<sup>94</sup> In a cohort of Brazilian children, symptoms of asthma have been associated with unhygienic living conditions and infections.<sup>95,96</sup>

## Stress

Asthma prevalence is increased in low income, inner-city neighborhoods, where family stress levels are high.<sup>97</sup> Parental stress, both in the first year of life<sup>98</sup> and from birth to early school age,<sup>99</sup> has been associated with increased risk of asthma in school-age children. Lower cortisol levels in response to acute stress are observed in such children, suggesting a mechanistic explanation for increased asthma prevalence.<sup>100</sup> Challenges may be faced by patients with asthma following large-scale disasters.

## Tobacco smoke

Exposure to tobacco smoke, either pre-natally<sup>101</sup> or after birth,<sup>101</sup> is associated with harmful effects including a greater risk of developing asthma-like symptoms in early childhood. Distinguishing the independent contributions of pre-natal and post-natal maternal smoking is problematic.<sup>102</sup> However, maternal smoking during pregnancy has an influence on lung development,<sup>37</sup> and infants of smoking mothers are four times more likely to develop wheezing illnesses in the first year of life,<sup>102</sup> although there is little evidence that maternal smoking during pregnancy has an effect on allergic sensitization.<sup>103</sup> Exposure to environmental tobacco smoke (passive smoking) also increases the risk of lower respiratory tract illnesses in infancy<sup>104</sup> and childhood.<sup>105</sup>

In people with established asthma, tobacco smoking is associated with an accelerated decline in lung function;<sup>106</sup> may render patients less responsive to treatment with inhaled<sup>107,108</sup> and systemic<sup>109</sup> corticosteroids; and reduces the likelihood of asthma being well controlled.<sup>110</sup> In a study of patients with adult-onset asthma, frequent exacerbations in current or past smokers were associated with higher blood neutrophils, whereas in never-smokers, frequent exacerbations were associated with higher blood eosinophils.<sup>111</sup>

## Outdoor and indoor air pollution

Children raised in a polluted environment have diminished lung function,<sup>112</sup> and exposure to outdoor air pollutants has significant effects on asthma morbidity in children and adults.<sup>113-115</sup> Similar associations have been observed in relation to indoor pollutants (e.g. smoke and fumes from gas or biomass fuels that are used for heating and cooling, molds, and cockroach infestations).<sup>116</sup> Exposure to outdoor pollutants, such as, living or attending schools near high-traffic density roads increased the incidence and prevalence of childhood asthma and wheeze.<sup>117,118</sup> Prenatal NO<sub>2</sub>, SO<sub>2</sub>, and PM10 exposures are associated with an increased risk of asthma in childhood,<sup>119</sup> but it is difficult to separate pre- and post-natal exposure.

Deleted: but the role of air pollution in causing asthma remains controversial. A recent meta-analysis found that

## Diet

For some time, the mother's diet during pregnancy has been a focus of concern relating to the development of allergy and asthma in the child. There is no firm evidence that ingestion of any specific foods during pregnancy increases the

risk for asthma. However, a recent study of a pre-birth cohort observed that maternal intake of foods commonly considered allergenic (peanut and milk) was associated with a *decrease* in allergy and asthma in the offspring.<sup>120</sup> Similar data have been shown in a very large Danish National birth cohort, with an association between ingestion of peanuts, tree nuts and/or fish during pregnancy and a decreased risk of asthma in the offspring.<sup>61,121</sup>

Data suggest that maternal obesity and weight gain during pregnancy pose an increased risk for asthma in children. A recent meta-analysis of 14 studies<sup>122</sup> showed that maternal obesity in pregnancy was associated with higher odds of ever asthma or wheeze or current asthma or wheeze; each 1 kg/m<sup>2</sup> increase in maternal BMI was associated with a 2% to 3% increase in the odd of childhood asthma. High gestational weight gain was associated with higher odds of ever asthma or wheeze. However, unguided weight loss in pregnancy should not be encouraged.

The role of post-natal diet, particularly breast-feeding, in relation to the development of asthma has been extensively studied and, in general, the data reveal that infants fed formulas of intact cow's milk or soy protein have a higher incidence of wheezing illnesses in early childhood compared with those fed breast milk.<sup>123</sup>

Some data also suggest that certain characteristics of Western diets, such as increased use of processed foods and decreased antioxidants (in the form of fruits and vegetables), increased omega-6 polyunsaturated fatty acid (found in margarine and vegetable oil), and decreased omega-3 polyunsaturated fatty acid (found in oily fish) intakes are associated with recent increases in asthma and atopic disease.<sup>124</sup> A systematic review of randomized controlled trials on maternal dietary intake of fish or long-chain polyunsaturated fatty acids during pregnancy showed no consistent effects on the risk of wheeze, asthma or atopy in the child.<sup>125</sup> One recent study demonstrated decreased wheeze/asthma in pre-school children at high risk for asthma when mothers were given a high dose fish oil supplement in the third trimester;<sup>126</sup> however 'fish oil' is not well defined, and the optimal dosing regimen has not been established.

#### **Vitamin D**

There has been substantial interest in recent years in the role of vitamin D intake during pregnancy. A systematic review of cohort, case control and cross-sectional studies concluded that maternal intake of vitamin D, and of vitamin E, was associated with lower risk of wheezing illnesses in children.<sup>127</sup> This was not confirmed in randomized controlled trials of vitamin D supplementation during pregnancy, although a significant effect was not ruled out.<sup>128,129</sup> Evidence is still inconclusive, and further randomized controlled trials are needed.

#### **Paracetamol (acetaminophen)**

Several epidemiological studies have shown a relationship between frequency of paracetamol use in children or in pregnancy,<sup>130,131</sup> and a diagnosis of asthma in children. Interpretation is confounded by the fact that in infancy, paracetamol is often administered for viral respiratory infections, which themselves may either contribute to the development of asthma or be an early manifestation of asthma. In a prospective cohort study, paracetamol use was not associated with diagnosis of asthma after adjusting for respiratory infections, or when paracetamol was used only for non-respiratory indications.<sup>132</sup> Frequent use of paracetamol by pregnant women has been associated with asthma in their children,<sup>131</sup> but non-causal associations have not been ruled out.<sup>133,134</sup>



### Chapter 3.

## Mechanisms of asthma

Asthma is an inflammatory disorder of the airways, which involves multiple inflammatory cells and mediators that contribute to characteristic clinical and pathophysiological changes.<sup>135</sup> In ways that are still not well understood, this inflammation is strongly associated with early life exposures,<sup>136</sup> airway hyper-responsiveness and asthma symptoms. However, although heterogeneity is seen in response to asthma treatments, no clear relationship has yet been found between the majority of clinical phenotypes and specific underlying mechanisms or treatment responses.<sup>135</sup> There is a clear need to continue investigation into the root causes of asthma so that targeted diagnostics and therapeutics can be developed.<sup>137</sup>

### AIRWAY INFLAMMATION IN ASTHMA

The clinical spectrum of asthma is highly variable and shows different sputum cellular patterns (Box A3-1).<sup>138,139</sup> However, the presence of chronic airway inflammation is generally a consistent feature in most patients before treatment. Airway inflammation in asthma persists even when symptoms are episodic, and the relationship between the severity of asthma and the intensity of inflammation has not been clearly established.<sup>140</sup> The inflammation affects all airways, including the upper respiratory tract and nose in most patients, but its physiological effects are most pronounced in medium-sized bronchi.

Box A3-1. Inflammatory cells in asthmatic airways

Cell type	Action
Mucosal mast cells	Release the bronchoconstrictor mediators histamine, cysteinyl leukotrienes and prostaglandin D2 when activated. <sup>141</sup> Mucosal mast cells are activated by allergens through high-affinity immunoglobulin E (IgE) receptors as well as by osmotic stimuli, which accounts for exercise-induced bronchoconstriction, and neural connections.
Eosinophils	Usually present in increased numbers in asthmatic airways, eosinophils release basic proteins that may damage airway epithelial cells. They also produce cysteinyl leukotrienes and growth factors. <sup>142</sup> In rare cases of steroid-resistant asthma with eosinophilia, an anti-interleukin 5 antibody can reduce asthma exacerbations. <sup>143,144</sup>
T lymphocytes	Present in increased numbers in asthmatic airways, T lymphocytes release specific cytokines, including interleukins (IL) 4, 5, 9, and 13, which orchestrate eosinophilic inflammation and IgE production by B lymphocytes. <sup>145</sup> An increase in Th2 cell activity may be due, in part, to a reduction in the regulatory T cells that normally inhibit Th2 cells. In severe asthma, there is also an increase in innate type 2 T cells (ILC2), and also Th1 and Th17 cells. <sup>145</sup>
Dendritic cells	These cells sample allergens from the airway surface and migrate to regional lymph nodes where they interact with regulatory T cells to ultimately stimulate production of Th2 cells from naive T cells. <sup>146</sup>
Macrophages	Present in increased in numbers in asthmatic airways, macrophages may be activated by allergens through low-affinity IgE receptors to release inflammatory mediators and cytokines that amplify the inflammatory response, especially in severe asthma. <sup>147</sup>
Neutrophils	These cells are increased in the airways and sputum of patients with severe asthma and in smoking asthmatics. The pathophysiological role of these cells is uncertain and their increase may even be due to corticosteroid therapy. <sup>148</sup>

The characteristic pattern of inflammation that is found in other allergic diseases is also seen in allergic asthma,<sup>149</sup> with activated mast cells, increased numbers of activated eosinophils, and increased numbers of the T-cell receptor invariants, natural killer T cells and T helper 2 lymphocytes (Th2), which release mediators that contribute to symptoms (Box A3-1).

Innate type 2 lymphocytes (ILC2), regulated by epithelial cell mediators such as interleukin (IL)-25 and IL-33, have also been implicated in airway inflammation in asthma.<sup>150</sup> In some cases (especially severe asthma) neutrophils may also contribute to this response.<sup>139</sup>

Structural cells of the airways also produce inflammatory mediators, and contribute to the persistence of inflammation in various ways, as outlined in Box A3-2.

**Box A3-2. Structural cells in asthmatic airways**

Cell type	Action
Airway epithelial cells	These cells sense their mechanical environment, express multiple inflammatory proteins, and release cytokines, chemokines, and lipid mediators in response to physical perturbation. <sup>121</sup> Viruses and air pollutants also interact with epithelial cells.
Airway smooth muscle cells	These cells show increased proliferation (hyperplasia) and growth (hypertrophy) and express similar inflammatory proteins to epithelial cells. <sup>149</sup>
Endothelial cells	Endothelial cells of the bronchial circulation play a role in recruiting inflammatory cells from the circulation into the airway.
Fibroblasts and myofibroblasts	These cells produce connective tissue components, such as collagens and proteoglycans that are involved in airway remodeling.
Airway nerves	Cholinergic nerves may be activated by reflex triggers in the airways and cause bronchoconstriction and mucus secretion. Sensory nerves that may be sensitized by inflammatory stimuli, including neurotrophins, cause reflex changes and symptoms such as cough and chest tightness, and may release inflammatory neuropeptides.

Key cellular mediators of asthma

Over 100 different mediators are now recognized to be involved in asthma and mediate the complex inflammatory response in the airways (Box A3-3).

Box A3-3. Key cellular mediators in asthma

Mediators	Action
Chemokines	Important in the recruitment of inflammatory cells into the airways; mainly expressed in airway epithelial cells. <sup>151</sup> CCL11 (eotaxin), is relatively selective for eosinophils, whereas CCL17 and CCL22 recruit Th2 cells.
Cysteinyl leukotrienes	Potent bronchoconstrictors and pro-inflammatory mediators mainly derived from mast cells and eosinophils. They are the only mediators that, when inhibited, have been associated with an improvement in lung function and asthma symptoms. <sup>152</sup>
Cytokines	Orchestrate the inflammatory response in asthma and determine its severity. <sup>153</sup> Important cytokines include: <ul style="list-style-type: none"><li>• IL-1-beta and TNF-<math>\alpha</math>, which amplify the inflammatory response</li><li>• GM-CSF, which prolongs eosinophil survival in the airways</li><li>• Th2-derived cytokines, which include<ul style="list-style-type: none"><li>◦ IL-5, that is required for eosinophil differentiation and survival</li><li>◦ IL-4, that is important for Th2 cell differentiation and IgE expression</li><li>◦ IL-13, that is needed for IgE expression.</li></ul></li></ul>
Histamine	Released from mast cells, histamine contributes to bronchoconstriction and to the inflammatory response. Antihistamines however, have little role in asthma treatment because of their limited efficacy, side-effects, and the apparent development of tolerance. <sup>154</sup>
Nitric oxide	A potent vasodilator produced predominantly from the action of inducible nitric oxide synthase in airway epithelial cells. <sup>155</sup>
Prostaglandin D2	A bronchoconstrictor derived predominantly from mast cells. It is involved in Th2 cell recruitment into the airways.

CCL: chemokine ligand; Th2: T helper 2 lymphocytes; IL: interleukin; TNF: tumor necrosis factor; GM-CSF: granulocyte macrophage colony-stimulating factor.

**Deleted:** In patients with asthma selected for a Th2 profile, anti-IL 5, anti-IL13 and anti-IL4 and 13 antibody have been shown to have a minor therapeutic benefit

**Deleted:** <sup>152</sup>

STRUCTURAL CHANGES IN THE AIRWAYS

In addition to the inflammatory response, characteristic structural changes, often described as 'airway remodeling', are seen in the airways of asthma patients (Box A3-4). Some of these changes are related to the severity of the disease and may result in relatively irreversible narrowing of the airways.<sup>156,157</sup> These changes may represent repair in response to chronic inflammation, or may occur independently of inflammation.<sup>135,158</sup>

Box A3-4. Structural changes in asthmatic airways

Tissue	Changes in asthma
Subepithelial fibrosis	A deposition of collagen fibers and proteoglycans under the basement membrane that is seen in most asthmatic patients, even before the onset of symptoms, but there is a large overlap with normals. Fibrosis also occurs in other layers of the airway wall, with deposition of collagen and proteoglycans. <sup>131</sup>
Increased airway smooth muscle	A consequence of both hypertrophy (increased size of individual cells) and hyperplasia (increased cell proliferation), which contributes to the increased thickness of the airway wall. <sup>156</sup> This process may relate to disease severity and is caused by inflammatory mediators, such as growth factors.
Increased blood vessels in airway walls	These amplify the influence of growth factors such as vascular endothelial growth factor, YKL-40 and tissue factor and may contribute to increased airway wall thickness <sup>159</sup>
Mucus hypersecretion	Results from increased numbers of goblet cells in the airway epithelium and increased size of sub-mucosal glands. <sup>160</sup>

PATHOPHYSIOLOGY

Airway narrowing

Airway narrowing is the final common pathway leading to symptoms and physiological changes in asthma; with airway narrowing itself likely to be an additional stimulus for remodeling.<sup>158</sup> Several factors contributing to the development of airway narrowing in asthma are listed here.

- *Airway smooth muscle contraction*: this occurs in response to multiple bronchoconstrictor mediators and neurotransmitters and is the predominant mechanism of airway narrowing. It is largely reversed by bronchodilators.
- *Airway edema*: this is due to increased microvascular leakage in response to inflammatory mediators. Airway edema may be particularly important during acute exacerbations.
- *Airway thickening*: this results from structural changes, often termed 'remodeling'. Airway thickening is not fully reversible using current therapies and may be important in more severe disease.
- *Mucus hypersecretion*: a product of increased mucus secretion and inflammatory exudates, mucus hypersecretion may lead to luminal occlusion ('mucus plugging').

Airway hyperresponsiveness

Airway hyperresponsiveness, a characteristic functional abnormality of asthma, results in airway narrowing in a patient with asthma in response to a stimulus that would be innocuous in a healthy person. This airway narrowing leads to variable airflow limitation and intermittent symptoms. Airway hyperresponsiveness is linked to both inflammation and to the repair of the airways, and is partially reversible with therapy. The mechanisms of airway hyperresponsiveness are incompletely understood but include the following.

- *Excessive contraction of airway smooth muscle*: this may result from increased volume and/or contractility of airway smooth muscle cells.<sup>161</sup>
- *Uncoupling of airway contraction*: a result of inflammatory changes in the airway wall that may lead to excessive narrowing of the airways, and a loss of the maximum plateau of contraction that is found in normal airways when bronchoconstrictor substances are inhaled.
- *Thickening of the airway wall*: edema and structural changes amplifies airway narrowing due to contraction of airway smooth muscle for geometric reasons.<sup>156</sup>
- *Sensory nerves*: these may be sensitized by inflammation, leading to exaggerated bronchoconstriction in response to sensory stimuli.<sup>161</sup>

SPECIAL MECHANISMS IN SPECIFIC CONTEXTS

Exacerbations

Short-term worsening of asthma may occur as a result of exposure to 'triggers' (e.g. exercise, cold air, air pollutants,<sup>162</sup> and even certain weather conditions such as thunderstorms in association with grass pollen.<sup>163,164</sup> More severe worsening of asthma usually occurs with viral infections of the upper respiratory tract (particularly rhinovirus and respiratory syncytial virus)<sup>165</sup> and/or allergen exposure.<sup>89,90</sup> Infections and allergen exposure increase inflammation in the lower airways (acute or chronic inflammation) that may persist for several days or weeks.

Deleted: Transient  
Deleted: risk factors for asthma symptoms, or

Nocturnal asthma

The mechanisms accounting for the worsening of asthma at night are not completely understood, but may be driven by circadian rhythms of circulating hormones such as epinephrine, cortisol and melatonin, and neural mechanisms such as cholinergic tone. The reported nocturnal increase in airway inflammation may reflect a reduction in endogenous anti-inflammatory mechanisms.<sup>166</sup>

Persistent airflow limitation

Deleted: Irreversible  
Deleted: (fixed)

Some patients with severe or long-standing asthma develop progressive airflow limitation that is not fully reversible with currently available therapy. This may reflect changes in airway structure (Box A3-4).<sup>167</sup> These patients may be described as having asthma-COPD overlap. Mechanisms are likely to be heterogeneous. For example, long-term studies suggest that about half of patients with persistent airflow limitation in adult life reached this position by rapid decline from normal lung function in early adulthood, whereas the other half had a normal rate of decline from low initial lung function in early adulthood.<sup>168</sup> More information about asthma-COPD overlap is provided in the *Global Strategy for Asthma Management and Prevention* 2019, Chapter 5.<sup>25</sup>

Deleted: (ACO)

Deleted: 2018  
Deleted: <sup>167</sup>

Difficult-to-treat asthma

The reasons why some patients develop asthma that is difficult to manage and relatively insensitive to the effects of corticosteroids are not well understood.<sup>169</sup> Common associations are poor adherence with treatment and psychological and psychiatric disorders. However, genetic factors may contribute in some cases as many of these patients have difficult-to-treat asthma from the onset of the disease, rather than progressing from milder asthma. In these patients, there may be inflammation of peripheral airways that leads to airway closure, air trapping and hyperinflation. Although

the pathology appears broadly similar to other forms of asthma, there are more neutrophils, more involvement of small airways, and more structural changes than in other patients.<sup>170</sup>

### Smoking and asthma

Asthma patients who smoke tobacco have asthma that is more difficult to control, have more frequent exacerbations and hospital admissions, and experience a more rapid decline in lung function and an increased risk of death than asthma patients who are non-smokers.<sup>171</sup> Asthma patients who smoke may have a neutrophil-predominant inflammation in their airways and are poorly responsive to corticosteroids.<sup>107,109</sup>

### Obesity and asthma

Multiple factors may contribute to the increased incidence and prevalence of asthma in obesity,<sup>41</sup> including:

- Mechanical changes
- The development of a pro-inflammatory state, with increased production of pro-inflammatory cytokines and chemokines, increased oxidative stress, increased leptin and reduced adiponectin levels
- An increased prevalence of comorbidities such as gastroesophageal reflux disease, obstructive sleep apnea and metabolic syndrome
- Shared etiological factors such as common genetic and *in utero* influences
- Dietary and environmental factors.

The use of systemic corticosteroids and a sedentary lifestyle may promote obesity in patients with severe asthma, but in most instances, obesity precedes the development of asthma.<sup>40</sup>

### Exercise-induced asthma

The increased ventilation of exercise results in increased osmolality in airway lining fluid. This triggers surface mast cells to release mediators such as leukotriene D<sub>4</sub>, resulting in bronchoconstriction.<sup>172</sup> In elite athletes, the long-term effects of environmental exposures during training may also contribute to the development of airway hyperresponsiveness and asthma, due to airway epithelium injury, airway inflammatory and structural changes (remodeling). These features have been observed in elite athletes, even without asthma or airway hyperresponsiveness.<sup>172</sup>

### Aspirin-exacerbated respiratory disease

This distinct asthma phenotype is associated with intolerance to cyclooxygenase-1 inhibition and increased release of cysteinyl-leukotrienes due to increased expression of leukotriene C<sub>4</sub> synthase in mast cells and eosinophils.<sup>173</sup> More detail is provided in the *Global Strategy for Asthma Management and Prevention* 2019, Chapter 3, 'Managing asthma in specific populations or settings'.<sup>25</sup>

Deleted: 2018

Deleted: special

# Chapter 4.

## Tests for diagnosis and monitoring of asthma

### MEASURING LUNG FUNCTION

The diagnosis of asthma is based on the history of characteristic respiratory symptoms and the demonstration of variable expiratory airflow limitation (see *Global Strategy for Asthma Management and Prevention* 2019, Box 1-2).<sup>25</sup> A number of methods are available to assess airflow limitation, but two methods have gained widespread acceptance for use in patients over 5 years of age. These are spirometry, particularly the measurement of forced expiratory volume in 1 second (FEV<sub>1</sub>) and forced vital capacity (FVC) and their ratio (FEV<sub>1</sub>/FVC), and the measurement of peak expiratory flow (PEF).

Deleted: 2018

Deleted:

Although measurements of lung function do not correlate strongly with symptoms or other measures of asthma control in either adults<sup>174</sup> or children,<sup>175</sup> these measures provide complementary information about different aspects of asthma control. Patients with asthma frequently have poor perception of the severity of their airflow limitation, especially if their asthma is long standing.<sup>176</sup>

#### Spirometry

Spirometry is the recommended method of measuring airflow limitation and reversibility to establish a diagnosis of asthma. Measurements of FEV<sub>1</sub> and FVC are made during a forced expiratory maneuver using a spirometer. Recommendations for the standardization of spirometry have been published.<sup>177</sup> The degree of reversibility in FEV<sub>1</sub>, that exceeds the variation in a healthy population and is consistent with a diagnosis of asthma **in patients with typical symptoms**, is generally accepted as 12% and 200 mL from the pre-bronchodilator value.<sup>38</sup> However most asthma patients, particularly those already on controller treatment, will not exhibit reversibility at each assessment, and the test therefore lacks sensitivity.<sup>178</sup> Repeated testing at different visits, or after withholding of bronchodilator medications, is advised if confirmation of the diagnosis of asthma is needed. Spirometry is effort-dependent, so proper instructions on how to perform the forced expiratory maneuver must be given to patients in order to obtain reproducible results. The highest value of three recordings is taken.

Because many lung diseases may result in reduced FEV<sub>1</sub>, a useful assessment of airflow limitation is the ratio of FEV<sub>1</sub> to FVC. The FEV<sub>1</sub>/FVC ratio is **usually** greater than 0.75–0.80 **in adults**, and **usually** greater than 0.90 in children. Any values less than these suggest airflow limitation. **In respiratory literature, the terms 'airflow limitation' and 'airway obstruction' are often used interchangeably when lung function test results are being described.**

Deleted: normally

Deleted: T

Predicted values of FEV<sub>1</sub>, FVC, and PEF based on age, sex and height have been obtained from population studies. These are being continually revised, and with the exception of PEF, for which the range of predicted values is too wide, they are useful for judging whether a given value is likely to be 'abnormal' or not. Multi-ethnic reference values have recently been published for ages 3–95 years.<sup>179</sup> The normal range of values is wider in young people (younger than 20 years) and in the elderly (older than 70 years).<sup>179</sup> In children, FEV<sub>1</sub> may be insensitive for mild obstructive disorders.

#### Peak expiratory flow

PEF measurements are made using a peak flow meter and can be an important aid in both the diagnosis and monitoring of asthma. Modern PEF meters are relatively inexpensive, portable, and ideal for patients to use in home settings for day-to-day measurements of airflow limitation. However, measurements of PEF are not interchangeable with other measurements of lung function such as FEV<sub>1</sub> in either adults or children,<sup>180</sup> and FEV<sub>1</sub> and PEF expressed as a percentage of predicted are not equivalent. PEF can underestimate the degree of airflow limitation, particularly as airflow limitation and gas trapping worsen. Because values for PEF obtained with different peak flow meters vary and the range of predicted values is wide, PEF measurements should be compared to the patient's own previous best ('personal best')

measurement<sup>181</sup> using the same peak flow meter. The personal best measurement is usually obtained while patients are asymptomatic or on full treatment, and it serves as a reference value for monitoring the effects of changes in treatment.

Careful instruction is required to reliably measure PEF because PEF measurements are effort-dependent. Most commonly, PEF is measured first thing in the morning before treatment when values are often close to their lowest, and then in the afternoon or evening when values are usually higher. On each occasion, the highest of three PEF measurements should be recorded. Various calculations of PEF variability have been used, including the following:<sup>182</sup>

- For diurnal variability the upper limit of normal with twice-daily PEF measurement is 8% in adults, 9.3% in adolescents, and 12.3% in healthy children. Diurnal variability is calculated as follows: for each day, calculate the diurnal variability as [day's highest PEF minus day's lowest PEF], divided by the mean of these two values; then average these daily variability results over 1 week.<sup>183</sup>
- The minimum morning pre-bronchodilator PEF over 1 week, expressed as a percent of the patient's recent best (Min%Max) is a simple index for clinical practice (Box A4-1).<sup>184</sup>

#### **Which patients should carry out PEF monitoring?**

##### *Short-term PEF monitoring*

Monitoring of PEF twice daily for 2–4 weeks may be useful in the following contexts:

- To confirm the diagnosis of asthma. Although spirometry is the preferred method of documenting variable expiratory airflow limitation, the following PEF measurements suggest a diagnosis of asthma:
  - Improvement in PEF after inhalation of a bronchodilator by 60 L/min or  $\geq 20\%$  from the pre-bronchodilator value,<sup>185</sup> or
  - Diurnal variation in PEF of  $>10\%$  from twice daily readings<sup>186</sup> ( $>20\%$  if calculated from more frequent daily readings).<sup>187</sup>
- To assess response to treatment
- To establish a baseline for management of exacerbations. After starting ICS treatment, personal best PEF (from twice daily readings) is reached on average within 2 weeks.<sup>90</sup> Average PEF continues to increase, and diurnal PEF variability to decrease, for about 3 months.<sup>76,90</sup>

##### *Long-term PEF monitoring*

Ongoing monitoring of PEF is valuable in a sub-set of patients:


- To assist in managing the patient's asthma. This is useful for patients who have limited ability to perceive airflow limitation,<sup>176</sup> or for some patients with severe asthma or frequent or sudden exacerbations. For PEF-based written asthma action plans, those based on personal best PEF improve asthma outcomes, whereas those based on predicted PEF do not.<sup>188</sup>
- To identify environmental (including occupational) causes of asthma symptoms: this involves the patient monitoring PEF several times each day over periods of suspected exposure to risk factors in the home or workplace, or during exercise or other activities that may cause symptoms, and also during periods in which they have no exposure to the suspected agent.

Displaying PEF results on a standardized laterally compressed chart (showing 2 months on a landscape format page) may improve the accuracy of identification of exacerbations.<sup>158</sup> A suitable chart is available to download from

[www.woolcock.org.au/moreinfo/](http://www.woolcock.org.au/moreinfo/).



#### Box A4-1. Measuring PEF variability




The figure shows PEF data of a 27-year old man with long-standing poorly controlled asthma, before and after the start of inhaled corticosteroid treatment. With inhaled corticosteroid treatment, PEF levels increased, and PEF variability decreased, as seen by the increase in Min%Max (lowest morning PEF over 1 week/highest PEF over the same week, %).

#### Measurement of airway responsiveness

For patients who have symptoms consistent with asthma but normal lung function, measuring airway responsiveness to direct airway challenges (e.g. inhaled methacholine or histamine) or indirect airway challenges (e.g. inhaled mannitol or an exercise challenge) may help establish a diagnosis of asthma.<sup>189</sup> The test results are usually expressed as the provocative concentration (or dose) of the agonist causing a given fall (often 15% or 20%) in FEV<sub>1</sub> (Box A4-2). Recent guidelines on exercise-induced bronchoconstriction recommend 10% fall in FEV<sub>1</sub> as the criterion for a positive exercise challenge; the authors also noted that a criterion of 15% would provide greater specificity.<sup>190</sup>

These tests are sensitive for a diagnosis of asthma but have limited specificity; airway hyperresponsiveness has been described in patients with allergic rhinitis, and in those with airflow limitation caused by conditions other than asthma, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease (COPD).<sup>189</sup> Consequently, a negative test can be useful to exclude a diagnosis of asthma in a patient who is not taking ICS treatment, but a positive test does not always mean that a patient has asthma.<sup>191</sup>

## Box A4-2. Measuring airway responsiveness



This graph shows airway responsiveness to inhaled methacholine or histamine in a healthy subject, and in a person with asthma who has mild, moderate or severe airway hyperresponsiveness. People with asthma have both an increased sensitivity to the agonist (as indicated by FEV<sub>1</sub> falling at a lower concentration of agonist), and an increased maximal bronchoconstrictor response to the agonist (as indicated by a greater fall in FEV<sub>1</sub> at a given concentration), compared with those without asthma. Asthma is also characterized by the loss of the plateau in the response-dose curve that is seen in normal healthy subjects. With direct challenges, the response to the agonist is usually expressed as the provocative concentration or dose of agonist causing a 20% decrease in FEV<sub>1</sub> (PC<sub>20</sub> and PD<sub>20</sub> respectively).

## NON-INVASIVE MARKERS OF AIRWAY INFLAMMATION

### Sputum analysis

Airway inflammation may be evaluated by examining spontaneously produced or hypertonic saline-induced sputum for eosinophilic or neutrophilic inflammation.<sup>192,193</sup> Sputum analysis does not assist in the diagnosis of asthma, as sputum eosinophilia may also be found in eosinophilic bronchitis, COPD and hypereosinophilic syndromes, and asthma may also have a neutrophilic or mixed inflammatory pattern.<sup>148,193</sup> In the 'future risk' domain of asthma control, sputum eosinophilia is associated with an increased risk of exacerbations during corticosteroid reduction or cessation.<sup>194-196</sup> In clinical trials in patients most of whom had moderate to severe asthma, exacerbations were reduced when treatment was guided by sputum eosinophil percentage.<sup>197</sup> However, this test is generally only available in specialized centers, and careful standardization and training of staff for both sputum induction and cell counting are required for reliable results.<sup>193</sup>

### Fractional concentration of exhaled nitric oxide

#### Diagnosis of asthma

Measurement of fractional concentration of exhaled nitric oxide is becoming more widely available. There is a modest association between blood and sputum eosinophils and FENO in asthma patients<sup>198</sup> and the relationship may vary over time.<sup>199,200</sup> FENO is usually elevated in non-smokers with eosinophilic asthma who are not taking ICS, and in many patients with asthma who are taking ICS. Elevated FENO may also be found in conditions such as allergic rhinitis,

Deleted: in some countries

eosinophilic bronchitis and hypersensitivity pneumonitis,<sup>201</sup> making it important to consider the context and differential diagnosis when an elevated FENO is found. Unlike sputum eosinophilia, elevated FENO is generally not predictive of asthma exacerbations during ICS reduction or cessation.<sup>201</sup>

#### **FeNO-guided ICS dose-titration studies**

In children and young adults with asthma, FENO-guided treatment was associated with a significant reduction in the number of patients with  $\geq 1$  exacerbation (OR 0.67 [95% CI 0.51-0.90]) and in exacerbation rate (mean difference -0.27 [-0.49- -0.06] per year) compared with guidelines-based treatment (Evidence A); similar differences were seen in comparisons with non-guidelines-based algorithms.<sup>202</sup> However, in non-smoking adults with asthma, no significant reduction was seen in the risk of exacerbations, or in exacerbation rates, with FENO-guided treatment compared with guidelines-based treatment.<sup>203</sup> In several studies of FENO-guided treatment, problems with the design of the intervention and/or control algorithms make comparisons and conclusions difficult.<sup>204</sup> Results of FENO measurement at a single point in time should be interpreted with caution.<sup>201,205</sup>

At present, neither sputum- nor FENO-guided treatment is recommended for the general asthma population. Sputum-guided treatment is recommended for adult patients with moderate or severe asthma who are managed in centers experienced in this technique,<sup>206</sup> (Evidence A). However, further studies are needed to identify the populations most likely to benefit from sputum-guided or FENO-guided treatment,<sup>202,203</sup> and the optimal frequency of FENO monitoring.

Deleted: (Box 3-14, p.70)

Deleted: FeNO-guided treatment reduces exacerbation rates compared with guidelines-based treatment, at least in children (Evidence A).<sup>200</sup>

#### **Measurements of allergic status**

The presence of atopy or allergic disease such as eczema or allergic rhinitis increases the probability of a diagnosis of allergic asthma in patients with respiratory symptoms. The identification of specific allergic reactions by skin prick testing or measurement of a specific immunoglobulin E (IgE) in serum can help identify the factors responsible for triggering asthma symptoms in individual patients.

Allergy skin prick tests are the primary diagnostic tool for determining a patient's atopic status. They are simple and rapid to perform, and have a low cost and high sensitivity. Optimal results are dependent on the use of standardized allergen extracts and on the skill of the tester.<sup>207</sup> The choice of the allergen panel will depend on the local context.

Measurement of allergen-specific IgE in serum is more expensive and generally less sensitive than skin prick testing for identifying sensitization to inhaled allergens.<sup>207</sup> Measurement of total IgE in serum has no value as a diagnostic test for atopy, and a normal total IgE does not exclude clinical allergy.<sup>207</sup>

Provocation of the airways with a suspected allergen or sensitizing agent may be helpful in the setting of occupational asthma but is not routinely recommended; it is rarely useful in establishing a diagnosis, requires considerable expertise, and can result in life-threatening bronchospasm.<sup>207</sup>

In patients with respiratory symptoms, the main limitation of allergy testing is that a positive test does not necessarily mean that the disease is allergic in nature or that allergy is causing the patient's asthma. The relevant exposure and its relationship to the patient's asthma symptoms must be confirmed by the patient's history.



## Chapter 5.

# Asthma pharmacotherapy

### PART A. ASTHMA PHARMACOTHERAPY - ADULTS AND ADOLESCENTS

**Comment [A1]:** The order of sections of this chapter has been reorganized, without tracking unless the text has been changed

#### ROUTE OF ADMINISTRATION

Inhaled administration delivers drugs directly into the airways, producing higher local concentrations with significantly less risk of systemic side effects. Inhaled medications for asthma are available as pressurized metered-dose inhalers (pMDIs), breath-actuated pMDIs, dry powder inhalers (DPIs), soft mist inhalers, and nebulized or "wet" aerosols. Inhaler devices differ in their efficiency of drug delivery to the lower respiratory tract, depending on the form of the device, formulation of medication, particle size, velocity of the aerosol cloud or plume (where applicable), and ease with which the device can be used by the majority of patients. Individual patient preference, convenience, and ease of use may influence not only the efficiency of drug delivery but also patient adherence to treatment. Problems with incorrect inhaler technique are common in community-based studies, regardless of the device, and are associated with worse asthma control.<sup>208</sup>

Pressurized MDIs (pMDIs) require training and skill to coordinate activation of the inhaler and inhalation. In the past, medications in pMDIs were dispensed as suspensions in chlorofluorocarbon propellants (CFCs), but most are now dispensed with hydrofluoroalkane (HFAs) propellant, either as suspensions or as solutions in ethanol. The aerosol plume of HFA inhalers is generally softer and warmer than that of CFC products.<sup>209</sup> For some corticosteroids, the particle size for HFA aerosols is smaller than for the corresponding CFC product, resulting in less oral deposition (with associated reduction in oral side effects), and greater lung deposition.<sup>209</sup> There are theoretical reasons why smaller particle ICS could be more effective than larger particle ICS, but methodologic issues with the available studies preclude a clear answer. A real-world study reported fewer exacerbations with extra-fine vs fine-particle ICS,<sup>210</sup> but the analysis was not adjusted for clustering or for physician characteristics that could have influenced not only the choice of ICS but also other management decisions relevant to exacerbation outcomes. A meta-analysis found no high-quality evidence of clinical benefit with fine vs standard particle size ICS.<sup>211</sup>

Pressurized MDIs may be used by patients with asthma of any severity, including during exacerbations. However, patients require training and skill to coordinate activation of the inhaler and inhalation, and this is often easier with use of a valved spacer. Breath-actuated aerosols may be helpful for patients who have difficulty using conventional pMDIs.<sup>209</sup> Dry powder inhalers are generally easier to use than pMDIs, but sufficient inspiratory flow (which varies between different DPI devices) is required to disaggregate the powder, and this may prove difficult for some patients to generate. DPIs differ with respect to the fraction of ex-actuator dose delivered to the lung. For some drugs, the dose may need to be adjusted when switching between different types of devices. Nebulized aerosols are rarely indicated for the treatment of chronic asthma in adults.<sup>212</sup>

Some inhaler devices and techniques for their use are illustrated on the GINA website ([www.ginasthma.org](http://www.ginasthma.org)) and the ADMIT website ([www.inhalers4u.org/](http://www.inhalers4u.org/)).

Deleted: ([www.admit-online.info](http://www.admit-online.info))

#### CONTROLLER MEDICATIONS

##### Inhaled corticosteroids

###### Role in therapy

ICS are the most effective anti-inflammatory medications for the treatment of persistent asthma. Studies have demonstrated their efficacy in reducing asthma symptoms, improving quality of life, improving lung function, reducing the frequency and severity of exacerbations and reducing asthma mortality,<sup>213-219</sup> as well as decreasing airway

hyperresponsiveness<sup>214,220</sup> and controlling airway inflammation.<sup>221</sup> However, they do not cure asthma, and when they are discontinued approximately 25% of patients experience an exacerbation within 6 months.<sup>222</sup> Patients not receiving ICS appear to be at increased risk of airway remodeling and loss of lung function.<sup>223,224</sup>

ICS differ in their potency and bioavailability,<sup>225</sup> but because of relatively flat dose-response relationships in asthma relatively few studies have been able to confirm the clinical relevance of these differences.<sup>226</sup>

Box A5-1 lists 'low', 'medium' and 'high' doses of different ICS. It is not a table of equivalence, but of estimated clinical comparability. The classification is based on published information and available studies, including direct comparisons where available. Most of the clinical benefit from ICS is seen at low doses, and clear evidence of dose-response relationships is seldom available within the dose ranges evaluated for regulatory purposes. 'High' doses are arbitrary, but for most ICS are those that, with prolonged use, are associated with increased risk of systemic side-effects. The efficacy of some products varies when administered via different inhaler devices.<sup>227</sup> Doses may be country-specific depending on labelling requirements.

**Box A5-1. Low, medium and high daily doses of inhaled corticosteroids for adults and adolescents**

Low dose ICS provides most of the clinical benefit of ICS for most patients with asthma. However, ICS responsiveness varies between patients, so some patients may need medium dose ICS if their asthma is uncontrolled despite good adherence and correct technique with low dose ICS (with or without LABA). High dose ICS (in combination with LABA or separately) is needed by very few patients, and its long-term use is associated with an increased risk of local and systemic side-effects, which must be balanced against the potential benefits.

This is not a table of equivalence, but of estimated clinical comparability, based on available studies and product information.

Drug	Daily dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (CFC)*	200–500	>500–1000	>1000
Beclometasone dipropionate (HFA)	100–200	>200–400	>400
Budesonide (DPI)	200–400*	>400–800	>800
Ciclesonide (HFA)	80–160	>160–320	>320
Fluticasone furoate (DPI)	100	n.a.	200
Fluticasone propionate( DPI)	100–250	>250–500	>500
Fluticasone propionate (HFA)	100–250	>250–500	>500
Mometasone furoate	110–220	>220–440	>440
Triamcinolone acetonide	400–1000	>1000–2000	>2000

CFC: chlorofluorocarbon propellant; DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; n.a. not applicable

\*Beclometasone dipropionate CFC is included for comparison with older literature.

For new preparations, manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent. For more detailed discussion see Raissy et al.<sup>225</sup>

Most of the benefit from ICS is achieved in adults at relatively low doses, equivalent to 400 mcg of budesonide per day.<sup>228</sup> *Post-hoc* analysis of a large 3-year randomized controlled trial in patients with mild recent-onset asthma<sup>229</sup> showed that the risk of serious exacerbations was halved with low dose ICS even in patients with infrequent symptoms at entry (0-1 days/week).<sup>230</sup> Increasing to higher doses provides little further benefit in terms of asthma control but increases the risk of side effects.<sup>228,231</sup> However, there is marked individual variability of responsiveness to ICS, at least

partly due to heterogeneity of airway inflammation. Because of this and the recognized poor adherence to treatment with ICS, some patients will require higher ICS doses to achieve full therapeutic benefit.<sup>20</sup> Tobacco smoking reduces the responsiveness to ICS, so higher doses may be required in patients who smoke.<sup>108</sup>

To achieve good asthma control, add-on therapy with another class of controller such as a long-acting beta<sub>2</sub>-agonist (LABA, [see below](#)) is preferred over increasing the dose of ICS.<sup>20,215</sup> ~~For maintenance treatment, there is a relationship~~ between the dose of ICS and the prevention of severe exacerbations of asthma,<sup>215</sup> although there may be differences in response according to clinical or inflammatory phenotype.<sup>232</sup> Therefore, some patients with severe asthma may benefit from long-term treatment with higher doses of ICS.

Deleted: T

Deleted: , however,

#### Adverse effects

Local adverse effects from ICS include oropharyngeal candidiasis, dysphonia, and (occasionally) coughing from upper airway irritation.<sup>233</sup> For pressurized MDIs the prevalence of these effects may be reduced by using a spacer device.<sup>234</sup> Mouth washing (rinsing with water, gargling, and spitting out) after inhalation may reduce oral candidiasis.<sup>234</sup> The use of pro-drugs that are activated in the lungs but not in the pharynx (e.g. ciclesonide and HFA beclometasone) and new formulations and devices that reduce oropharyngeal deposition may reduce such effects. The use of ICS may be associated with periodontal disease, but effects may be confounded by comorbidities, asthma severity, and use of (highly acidic) salbutamol.<sup>235</sup> There is also a strong association between periodontal disease and ED visits/hospitalizations for asthma.<sup>235</sup>

ICS are absorbed from the lung, accounting for some degree of systemic bioavailability. The risk of systemic adverse effects from an ICS depends upon its dose and potency, the delivery system, systemic bioavailability, first-pass metabolism (conversion to inactive metabolites) in the liver, and the half-life of the fraction of systemically absorbed drug (from the lung and possibly gut).<sup>225</sup> Therefore, the systemic effects differ among the various ICS. Evidence suggests that in adults, systemic effects of ICS are not a problem at doses of 400 mcg or less of budesonide or equivalent daily.<sup>236</sup>

Use of a questionnaire for patient-reported symptoms provides evidence of many more, predominantly mild, dose-dependent effects of ICS use,<sup>204,205</sup> underlining the need to step down treatment to the lowest dose that maintains good symptom control and prevents exacerbations.<sup>237-239</sup>

The systemic side effects of long-term treatment with high doses of inhaled corticosteroids include easy bruising,<sup>240</sup> adrenal suppression<sup>241-243</sup> and decreased bone mineral density.<sup>244</sup> A meta-analysis indicated that, among patients with asthma, adrenal insufficiency was less common after use of JCS (6.8% of patients) than oral and other forms of corticosteroids (43.7% of patients). For ICS, the proportion of patients with adrenal insufficiency was higher with increasing dose (1.5% for low, 5.4% for medium, 18.5% for high dose) and with increasing duration (1.3% for short, 9.0% for medium and 20.3% for long duration treatment).<sup>245</sup> The threshold to test corticosteroid users for adrenal insufficiency should be low in clinical practice, especially for patients with nonspecific symptoms after cessation of corticosteroid treatment.<sup>245</sup> A meta-analysis of case-control studies of non-vertebral fractures in adults using ICS indicated that in older adults, the relative risk of non-vertebral fractures increased by about 12% for each 1000 mcg/day (BDP equivalent) increase in the dose, but that the magnitude of this risk was considerably less than other common risk factors for fracture in the older adult.<sup>246</sup> ICS have also been associated with cataracts in cross-sectional studies,<sup>247-249</sup> but there is no evidence of posterior-subcapsular cataracts in prospective studies.<sup>250,251</sup> Even at high doses, ICS do not appear to increase the risk of glaucoma.<sup>248,252</sup> One difficulty in establishing the clinical significance of such adverse effects lies in dissociating the effect of high dose ICS from the effect of courses of oral corticosteroids taken by patients with severe asthma.

Deleted: inhaled

Exposure to high doses of ICS may increase the risk of tuberculosis, particularly in regions with high prevalence of tuberculosis.<sup>253,254</sup> However ICS are not contraindicated in patients with active tuberculosis.<sup>255</sup> A recent case control study found that asthmatics using ICS have an increased risk of pneumonia or lower respiratory infection when compared with asthmatics who did not have a prescription for an ICS in the last three months.<sup>256</sup> The risk is greater at higher ICS doses, and may vary between different ICS.<sup>256</sup> In a meta-analysis of clinical trials, the risk of adverse or serious adverse events reported as pneumonia for people with asthma receiving budesonide was not increased

compared with placebo.<sup>257</sup> A meta-analysis found no significant difference in the risk of pneumonia between children receiving ICS and placebo.<sup>258</sup>

Deleted: recent

## ICS/LABA combinations

### Role in therapy

Low dose ICS-formoterol, used as needed for symptom relief, is a preferred controller treatment in mild asthma. In patients with mild asthma, low dose budesonide-formoterol reduced the severe exacerbation rate by 64% compared with SABA alone,<sup>259</sup> and was non-inferior to daily low dose ICS plus as-needed SABA for the rate of severe exacerbations.<sup>259,260</sup> This reduction in exacerbations was achieved with an ICS dose less than a quarter of that in the comparator ICS plus SABA arm.<sup>259,260</sup> The existing data for as-needed ICS-formoterol are with budesonide-formoterol, but beclometasone-formoterol should be able to be used in a similar way, as its efficacy in maintenance and reliever therapy has been established.<sup>261</sup> At present, use of ICS-formoterol as needed, without maintenance treatment, is off-label in most countries, but the safety of as-needed ICS-formoterol has been well established in studies of maintenance and reliever therapy.<sup>262,263</sup> and no new safety issues emerged during the recent studies in mild asthma.<sup>259,260</sup>

In patients prescribed regular maintenance ICS, when a low dose of ICS alone fails to achieve good control of asthma, addition of LABA is the preferred option, preferably as a combination ICS/LABA inhaler. The addition of LABA to ICS improves clinical asthma outcomes and reduces the number of exacerbations in patients  $\geq 12$  years old.<sup>215,264-272</sup> In very large studies in adults and adolescents, severe exacerbations were reduced by 17-21% with maintenance ICS/LABA combination vs the same dose of ICS, but differences in symptom control and SABA use were small.<sup>271-273</sup>

Deleted: W

Deleted: medium

Deleted: recent

Controlled studies have shown that delivering ICS and LABA in a combination inhaler is as effective as giving each drug separately.<sup>274</sup> Fixed combination inhalers are more convenient for patients, may increase adherence compared with using separate inhalers,<sup>275</sup> and ensure that the LABA is always accompanied by ICS.

In addition, low dose combination inhalers containing the rapid-acting beta<sub>2</sub>-agonist formoterol with either budesonide or beclometasone may be used for both maintenance and reliever therapy.<sup>261,276,277</sup> to further reduce the risk of exacerbations in at-risk adult and adolescent patients. When budesonide/formoterol was used as the reliever medication by patients receiving maintenance budesonide/formoterol, both components contributed to enhanced protection from severe exacerbations compared with SABA as reliever.<sup>278</sup> In patients with a history of one or more severe exacerbations in the previous year, this strategy provides a reduction in exacerbations and similar improvements in asthma control at relatively low doses of ICS compared with conventional maintenance therapy with ICS or ICS/LABA.<sup>276</sup> In open-label studies without a requirement for a history of exacerbations, maintenance and reliever therapy was associated with a similar risk of exacerbations as maintenance ICS-LABA plus as-needed SABA, with a lower average ICS dose.<sup>279</sup>

Deleted: treatment

Deleted: T

Currently approved combination ICS/LABA inhalers for maintenance treatment in asthma at Steps 3–5 include:

- Beclometasone/formoterol
- Budesonide/formoterol
- Fluticasone furoate/vilanterol trifenoate (once daily)
- Fluticasone propionate/formoterol.
- Fluticasone propionate/salmeterol
- Mometasone/formoterol.

Currently approved low dose combination ICS/LABA inhalers for maintenance and reliever treatment in asthma include:

- Beclometasone/formoterol
- Budesonide/formoterol.

Earlier studies showed that LABAs may provide longer protection for exercise-induced bronchoconstriction than SABAs, but the duration of effect wanes with long-term use in adults<sup>280</sup> and adolescents.<sup>281</sup> Salmeterol and formoterol provide a similar duration of bronchodilation and protection against bronchoconstrictor agents, but there are pharmacological



differences between them: formoterol has a more rapid onset of action than salmeterol<sup>282,283</sup> which may make formoterol suitable for symptom relief as well as symptom prevention.<sup>284</sup> However, LABAs including formoterol and salmeterol, are indicated in asthma only when given in addition to ICS, preferably in a combination inhaler. For pre-exercise use in patients with mild asthma, a 6-week study showed that use of low dose budesonide-formoterol for symptom relief and before exercise reduced exercise-induced bronchoconstriction to a similar extent as regular daily low dose ICS with SABA for symptom relief and before exercise.<sup>285</sup>

#### Adverse effects

Adverse effects of ICS are described on p.31. Therapy with LABAs may be associated with headache or cramps, but systemic adverse effects such as cardiovascular stimulation, skeletal muscle tremor, and hypokalemia, are less common than with oral beta-agonist therapy. The regular use of beta<sub>2</sub>-agonists in both short- and long-acting forms may lead to relative refractoriness to beta<sub>2</sub>-agonists.<sup>286</sup> Based on data indicating a possible increased risk of asthma-related death associated with the use of salmeterol in a small number of individuals,<sup>287</sup> and increased risk of exacerbations when LABA is used regularly as monotherapy,<sup>288</sup> LABAs should never be used as a substitute for inhaled or oral corticosteroids, and should only be used in combination with an appropriate dose of ICS as determined by a physician, preferably in a single inhaler.<sup>289,290</sup> In the past there had been concerns that using LABA alone or in combination with ICS might increase asthma mortality.<sup>291,292</sup> However, large randomized controlled trials with ICS/LABA combination maintenance treatment showed no inferiority to ICS alone for serious adverse events (death, intubation and hospitalization due to asthma).<sup>271-273</sup> Based on these studies<sup>271-273</sup>, systematic reviews of randomized controlled trials<sup>289,290</sup> and observational studies,<sup>293</sup> LABA is considered safe when used in combination with ICS.<sup>294</sup>

No influence of beta<sub>2</sub>-adrenergic receptor phenotypes upon the efficacy or safety of ICS/LABA therapy has been observed in adults whether by the single inhaler for maintenance and reliever regimen or at a regular fixed dose.<sup>295,296</sup>

#### Leukotriene modifiers

##### Role in therapy

Leukotriene modifiers include cysteinyl-leukotriene 1 (CysLT1) receptor antagonists (LTRA) (montelukast, pranlukast, and zafirlukast) and a 5-lipoxygenase inhibitor (zileuton). Clinical studies have demonstrated that leukotriene modifiers have a small and variable bronchodilator effect, reduce symptoms including cough,<sup>297</sup> improve lung function, and reduce airway inflammation and asthma exacerbations.<sup>298</sup> They may be used as an alternative treatment for adult patients with mild persistent asthma,<sup>299-301</sup> and some patients with aspirin-sensitive asthma respond well to leukotriene modifiers.<sup>302</sup> However, when used alone as controller therapy, the effect of leukotriene modifiers are generally less than that of low doses of ICS, and, in patients already on ICS, leukotriene modifiers cannot substitute for this treatment without risking the loss of asthma control.<sup>303</sup>

Leukotriene modifiers used as add-on therapy may reduce the dose of ICS required by patients with moderate to severe asthma.<sup>304</sup> For patients with persistent asthma and with suboptimal asthma control with daily use of ICS, the addition of anti-leukotrienes is beneficial for reducing moderate and severe asthma exacerbations and for improving lung function and asthma control compared with the same dose of ICS.<sup>305</sup> However, leukotriene modifiers are less effective than LABA as add-on therapy.<sup>306</sup>

##### Adverse effects

Leukotriene modifiers are well tolerated, and few if any class-related effects have so far been recognized. Zileuton has been associated with liver toxicity<sup>307</sup> and monitoring of liver tests is recommended during treatment with this medication. Prescribing information for the use of zileuton should be consulted. No association has been found between Churg-Strauss syndrome and the use of leukotriene modifiers after controlling for asthma drug use, although it is not possible to rule out an association given that Churg-Strauss syndrome is very rare and highly correlated with asthma severity.<sup>308</sup> Post-marketing surveillance reports led to concerns about a possible association between leukotriene receptor

antagonist use and suicide risk in young adults, but a recent case-control study has found no association after adjustment for potential confounding factors.<sup>309</sup>

### Chromones: sodium cromoglycate and nedocromil sodium

#### Role in therapy

The role of sodium cromoglycate and nedocromil sodium in long-term treatment of asthma in adults is limited. Their anti-inflammatory effect is weak and they are less effective than low-dose ICS.<sup>310</sup> Meticulous daily cleaning of the inhalers is required to avoid blockage.

#### Adverse effects

Side effects are uncommon and include cough upon inhalation and pharyngeal discomfort. Some patients find the taste of nedocromil sodium unpleasant.

## ADD-ON CONTROLLER MEDICATIONS

### Long-acting anticholinergics (also called long-acting antimuscarinics, LAMA)

#### Role in therapy

The long-acting anticholinergic, tiotropium has been studied in adolescents and adults with uncontrolled asthma in a variety of contexts: added to ICS compared with doubling the dose of ICS or adding salmeterol,<sup>311</sup> and added to ICS<sup>312</sup> or to ICS/LABA with or without other controllers<sup>313,314</sup> compared with adding placebo<sup>313,314,315</sup>. Comparable bronchodilator effects to salmeterol have been shown in patients with the B16-Arg/Arg genotype, with no significant changes in asthma control.<sup>316</sup> In an open-label genotype-stratified study comparing the addition of LABA or tiotropium in African American patients receiving ICS, no differences were seen in time to first asthma exacerbation or measures of asthma control regardless of B16 genotype.<sup>296</sup> A Phase II study showed that adding tiotropium to patients with asthma not well-controlled on ICS and LABA improved lung function but not symptoms.<sup>313</sup> Two large one-year replicate trials in patients with at least one severe exacerbation in the previous year confirmed improvements in lung function, and also showed a 21% reduction in the risk of a severe exacerbation and 31% reduction in risk of asthma worsening, but inconsistent improvement were seen in symptom control and quality of life.<sup>314</sup> Direct evidence of LAMA versus LABA as add-on therapy to low dose ICS for Step 3 or medium dose ICS for Step 4 is currently limited to studies of less than six months' duration comparing tiotropium (Respimat) to salmeterol. Given the much larger evidence base for adding LABA vs placebo when asthma is not well-controlled on ICS alone, the current evidence is not strong enough to say that LAMA can be substituted for LABA as add-on therapy; but it may be an alternative option in patients with LABA side-effects.<sup>317,318</sup>

#### Adverse effects

The safety of tiotropium in these studies, with all patients also taking ICS, was similar to that of salmeterol.<sup>311,313,314</sup> Dry mouth, a characteristic side effect of this class of medication, was reported by fewer than 2% of the patients. There are no published long-term data (>1 year) on tiotropium safety in asthma.

### Anti-IgE

#### Role in therapy

Anti-immunoglobulin E (anti-IgE, omalizumab) is a treatment option for patients aged ≥6 years with severe persistent allergic asthma, with typical criteria including that asthma is uncontrolled on treatment with corticosteroids (moderate/high dose inhaled and/or oral) and LABA,<sup>319,320</sup> The dose of omalizumab is based on serum IgE and patient weight, with the criteria for dose and eligibility varying between regulatory authorities.

**Deleted:** and elevated serum IgE whose asthma

**Deleted:** , or who require high doses of such treatment to maintain good asthma control

Anti-IgE therapy is expensive and requires regular subcutaneous injections every 2-4 weeks, and observation after each injection. Therefore, it should only be considered when common causes of uncontrolled asthma, including incorrect inhaler technique and poor adherence, have been checked and addressed, and the contribution of comorbidities and modifiable risk factors to respiratory symptoms and exacerbations has been identified and minimized. For more details, see GINA Pocket Guide on Difficult-to-Treat and Severe Asthma in Adults and Adolescents.<sup>321</sup>

### Asthma outcomes

Patients may benefit by having fewer exacerbations and need for lower doses of OCS, with modest improvement in quality of life and in asthma symptom control as reflected by fewer symptoms and less need for reliever medications.<sup>319</sup> The efficacy of omalizumab is supported by evidence from many real-life studies.<sup>322</sup> A meta-analysis of treatment outcomes in 25 uncontrolled non-randomized real-life studies examined outcomes at 4-6, 12 and 24 months of treatment in patients who were symptomatic on ICS plus LABA. Despite marked heterogeneity of patients and clinical sites, the analysis found improvements in symptom control (ACQ), quality of life (AQLQ), lung function, exacerbations and hospitalizations, reductions in doses of ICS, and overall assessment of benefit (Global Evaluation of Treatment Effectiveness score).<sup>322</sup> A long-term prospective cohort study showed improvements in symptom control and work, school and activity impairment over 5 years.<sup>323</sup>

In one study, the reduction in severe exacerbations with omalizumab compared with placebo was greatest in patients with higher baseline blood eosinophil levels ( $\geq 260$  eosinophils/ $\mu$ L), higher baseline FENO ( $\geq 24$  ppb), or higher baseline periostin level ( $\geq 53$  ng/mL) while taking high dose ICS.<sup>324,325</sup> If a patient does not respond clinically within 4 months of initiating treatment, it is considered unlikely that further administration of omalizumab will be beneficial.<sup>206</sup> Of patients with a good clinical response to omalizumab, about half relapse if it is discontinued, at a median of 13 months after discontinuation.<sup>326</sup> One placebo-controlled withdrawal study suggested that a high blood eosinophil count prior to omalizumab withdrawal or an increase in FeNO at 12 weeks after withdrawal may be associated with greater risk of post-withdrawal exacerbation.<sup>327</sup> Studies are needed to evaluate stretching the interval between doses.

### Other outcomes

Nasal polyposis is not a specific indication for therapy with omalizumab, but patients with severe allergic asthma with concomitant chronic rhinosinusitis with nasal polyposis (CRSwNP) demonstrated a moderate improvement in nasal polyp score with add-on treatment with omalizumab.<sup>328</sup>

In one study in children and adolescents, add-on omalizumab started 4-6 weeks prior to return to school was associated with fewer fall-time exacerbations than with add-on placebo; there was no difference between omalizumab and ICS boost.<sup>329,330</sup> Analysis demonstrated a reduction in the duration and peak level of viral shedding during rhinoviral infection, and had a modest impact on frequency and severity of rhinovirus illnesses.<sup>91</sup>

### Adverse effects

Anti-IgE appears to be safe as add-on therapy,<sup>319</sup> including in inner-city children generally considered to be at high risk for exacerbations.<sup>331</sup> Injection site reactions are more common with omalizumab than placebo.<sup>319</sup> In a cohort study, there was no significant increase in risk of malignancy with omalizumab treatment.<sup>332</sup> Monitoring of patients receiving omalizumab showed no significant difference in cardiovascular or cerebrovascular events over 5 years compared with patients not receiving omalizumab, after adjustment for known confounding factors including OCS use.<sup>333</sup> Withdrawal of corticosteroids facilitated by anti-IgE therapy has led to unmasking the presence of Churg-Strauss syndrome in a small number of case reports.<sup>334</sup> Clinicians should be aware of the potential for this to occur and monitor patients closely.

## **Anti-IL5/5R treatments**

### *Role in therapy*

Interleukin 5 (IL-5) is a Type 2 cytokine that is required for eosinophil maturation and survival. Antibody therapies directed at IL-5 or its receptor are a treatment option for patients with severe eosinophilic asthma whose asthma is

**Deleted:** A 2010 review by the GINA Science Committee of evidence for improved patient outcomes with omalizumab compared with placebo, using GRADE methodology, led to the recommendation that 'For allergic patients, with an elevated IgE, not controlled on high-dose ICS and a LABA and who continue to have exacerbations, a trial of omalizumab can be considered. This recommendation is based on a modest response rate for the main endpoint exacerbations, and its high cost.' The recent ERS/ATS Task Force on Severe Asthma, based on a similar GRADE-type analysis, recommended that 'Those adults and children aged 6 and above, with severe asthma who are considered for a trial of omalizumab, should have confirmed IgE-dependent allergic asthma uncontrolled despite optimal pharmacological and non-pharmacological management and appropriate allergen avoidance if their total serum IgE level is 30 to 700 IU/mL (in 3 studies the range was wider – 30–1300 IU/mL). Treatment response should be globally assessed by the treating physician taking into consideration any improvement in asthma control, reduction in exacerbations and unscheduled healthcare utilisation, and improvement in quality of life. ¶

uncontrolled on treatment with corticosteroids (moderate/high dose inhaled +/- oral) and LABA (or another controller). Three therapies have been approved by one or more major regulators for patients with severe eosinophilic asthma: mepolizumab and reslizumab, which are monoclonal anti-IL5 antibodies, and benralizumab, which is a monoclonal anti-IL5 receptor  $\alpha$  antibody.

Deleted: , or who require high doses of such treatment to maintain good asthma control

These medications are expensive, so they should only be considered when common causes of uncontrolled asthma, including incorrect inhaler technique and poor adherence, have been checked and addressed, and the contribution of comorbidities and modifiable risk factors to respiratory symptoms and exacerbations has been identified and minimized. There is debate over the optimal blood eosinophil criterion for patient selection. This report does not state specific criteria for eligibility for biologic therapies, as these vary between countries and jurisdictions. [For more details, see GINA Pocket Guide on Difficult-to-Treat and Severe Asthma in Adults and Adolescents.](#)<sup>321</sup>

Deleted: ¶

#### Asthma outcomes

**Mepolizumab:** for patients aged  $\geq 12$  years, administered monthly (100 mg) by subcutaneous injection. In clinical trials of patients with severe eosinophilic asthma and two or more severe exacerbations in the previous year, mepolizumab reduced exacerbations by ~55% compared with placebo.<sup>335,336</sup> The reduction in exacerbations was greater with increasing baseline blood eosinophil count and increasing number of exacerbations in the previous year; no significant reduction in exacerbations was seen with baseline blood eosinophils  $<150/\mu\text{L}$ .<sup>337</sup> Modest improvements were seen in lung function and asthma symptom control.<sup>335,336</sup> In patients requiring maintenance OCS, mepolizumab allowed a reduction in [median](#) OCS dose by ~50% compared with placebo, with reduced exacerbations and improved symptom control.<sup>338</sup>

Deleted: 50

**Reslizumab:** for patients aged  $\geq 18$  years, administered monthly (3 mg/kg body weight) by intravenous infusion. In clinical trials of patients with uncontrolled asthma symptoms despite moderate-high dose ICS, at least one severe exacerbation in the previous year, and baseline blood eosinophils of  $\geq 400/\mu\text{L}$ , reslizumab led to ~50% reduction in moderate or severe exacerbations compared with placebo, with a modest improvement in lung function and small improvement in symptom control.<sup>339</sup> [Reslizumab produced greater reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.](#)<sup>340</sup>

Deleted: 330

**Benralizumab:** for patients aged  $\geq 12$  years, administered 8-weekly (30mg, first 3 doses 4-weekly) by subcutaneous injection. In clinical trials of patients with severe eosinophilic asthma, with blood eosinophils  $\geq 300/\mu\text{L}$  in the previous 12 months while taking high dose ICS+LABA, and  $\geq 2$  severe exacerbations in the previous year, benralizumab reduced exacerbations by ~35-50% and improved lung function, compared with placebo.<sup>341,342</sup> Modest improvements in asthma symptoms were seen in some groups.<sup>341,342</sup> In patients requiring maintenance oral corticosteroids, benralizumab allowed a significant reduction in OCS dose compared with placebo, while also reducing exacerbations.<sup>343</sup> [In patients with mild to moderate persistent asthma receiving low/medium dose ICS or low dose ICS/LABA, there was no clinically-important benefit for pre-bronchodilator FEV<sub>1</sub> with add-on benralizumab over 12 weeks compared with placebo.](#)<sup>344</sup>

#### Other outcomes

[Nasal polyposis is not a specific indication for therapy with anti-IL5/5R, but patients with severe allergic asthma with concomitant chronic rhinosinusitis with nasal polyposis \(CRSwNP\) demonstrated a moderate improvement in nasal polyp score with add-on treatment with reslizumab or high dose mepolizumab.](#)<sup>328</sup>

#### Adverse effects

Adverse effects are infrequent; they include injection site reactions for mepolizumab, myalgia with reslizumab and headache with benralizumab. Anaphylactic reactions have been rare with these therapies. A small number of cases of herpes zoster have been reported in patients receiving mepolizumab. Patients with known parasitic infections were excluded from clinical trials of these therapies; at-risk patients should be screened for parasitic infections and, if found, treated before commencing therapy aimed at reducing eosinophils.

## **Anti-IL4 receptor $\alpha$**

### **Role in therapy**

Dupilumab binds to interleukin-4 (IL-4) receptor alpha, blocking both IL-4 and IL-13 signaling. It is a treatment option for patients aged  $\geq 12$  years with severe eosinophilic asthma whose asthma is uncontrolled on treatment with moderate-high dose ICS and LABA, and for patients requiring maintenance OCS therapy for severe asthma. It is also indicated for treatment of moderate-severe atopic dermatitis.<sup>345</sup>

Dupilumab is currently approved for ages  $\geq 12$  years, as 200mg or 300mg administered by SC injection every 2 weeks for severe eosinophilic/Type 2 asthma, and 300mg by SC injection every 2 weeks for OCS-dependent severe asthma or if there is concomitant moderate/severe atopic dermatitis. Self-administration may be an option.

Like other biologic agents for severe asthma, this medication is expensive, so it should only be considered when common causes of uncontrolled asthma, including incorrect inhaler technique and poor adherence, have been checked and addressed, and the contribution of comorbidities and modifiable risk factors to respiratory symptoms and exacerbations has been identified and minimized. This report does not state specific criteria for eligibility for biologic therapies, as these vary between countries and jurisdictions. For more details, see GINA Pocket Guide on Difficult-to-Treat and Severe Asthma in Adults and Adolescents.<sup>321</sup>

### **Asthma outcomes**

Randomized controlled trials in patients with uncontrolled severe asthma with at least one exacerbation in the last year was associated with ~50% reduction in severe exacerbations, and significantly improved quality of life, symptom control and lung function.<sup>346</sup> In patients with OCS-dependent severe asthma, without minimum requirements of blood eosinophil count or FeNO, treatment with anti-IL4R reduced median OCS dose by 50% versus placebo.<sup>347</sup>

Potential predictors of a good asthma response to anti-IL4R include higher blood eosinophils, which are strongly predictive,<sup>346</sup> and higher FeNO.<sup>346</sup>

### **Other outcomes**

Nasal polyposis is not currently a specific indication for anti-IL4R therapy, but a randomized placebo-controlled trial showed improved symptoms and reduced nasal polyps on endoscopy at 16 weeks.<sup>348</sup>

### **Adverse effects**

Adverse effects include injection-site reactions which are common but minor. Transient blood eosinophilia occurs in 4-13% of patients.

## **Systemic corticosteroids**

### **Role in therapy**

Long-term treatment with oral corticosteroids (OCS) (that is, for periods longer than two weeks) may be required for severely uncontrolled asthma, but its use is limited by the risk of significant adverse effects. The therapeutic index (effect/side effect) of long-term ICS is always more favorable than long-term systemic corticosteroids in asthma.<sup>349,350</sup> If OCS are to be administered on a long-term basis, attention must be paid to measures that minimize the systemic side effects. Oral preparations are preferred over parenteral (intramuscular or intravenous) for long-term therapy because of their lower mineralocorticoid effect, relatively short half-life, and lesser effects on striated muscle, as well as the greater flexibility of dosing that permits titration to the lowest acceptable dose that maintains control.

Short-term use of systemic corticosteroids is important in the treatment of severe acute exacerbations because they prevent progression of the exacerbation, reduce the need for referral to emergency departments and hospitalization, prevent early relapse after emergency treatment, and reduce morbidity. The main clinical effects of systemic corticosteroids in acute asthma are only evident after 4 to 6 hours. Oral therapy is preferred and is as effective as

intravenous hydrocortisone.<sup>351</sup> A typical short course of OCS for an exacerbation is 40-50 mg prednisolone given daily for 5 to 10 days<sup>351</sup> depending on the severity of the exacerbation. When symptoms have subsided and lung function has improved, the OCS can be stopped abruptly<sup>352, 352,353</sup> (or tapered, if taken for >2 weeks), provided that treatment with ICS continues. Intramuscular injection of corticosteroids has no advantage over a short course of OCS in preventing relapse.<sup>354</sup> In a randomized controlled trial, a single dose of dexamethasone was inferior to prednisone for 5 days in adult asthma patients presenting at ED with a moderate asthma exacerbation.<sup>355</sup>

#### Adverse effects

The systemic side effects of long-term oral or parenteral corticosteroid treatment include osteoporosis, arterial hypertension, diabetes, hypothalamic-pituitary-adrenal axis suppression, obesity, cataracts, glaucoma, skin thinning leading to cutaneous striae and easy bruising, and muscle weakness. Patients with asthma who are on long-term systemic corticosteroids in any form should receive an assessment for osteoporosis risk and based on this assessment receive preventive treatment for osteoporosis, as recommended in 2010 guidelines from the American College of Rheumatology.<sup>356</sup> Factors increasing the risk of corticosteroid-induced osteoporosis include low body mass index (BMI), current smoking, parental history of hip fracture, >3 standard alcoholic drinks/day, and higher daily or cumulative corticosteroid treatment.<sup>356</sup> Withdrawal of oral corticosteroids can also (rarely) elicit adrenal failure or unmask underlying disease, such as Churg-Strauss Syndrome.<sup>357</sup> Caution and close medical supervision are recommended when considering the use of systemic corticosteroids.

Adverse effects of short-term high dose systemic therapy (corticosteroid 'bursts') are uncommon but include reversible abnormalities in glucose metabolism, increased appetite, fluid retention, weight gain, rounding of the face ('moon facies'), mood alteration, insomnia, hypertension, peptic ulcer, and aseptic necrosis of the femoral head.

#### Macrolides

##### Role in therapy

The role of the long-term use of macrolides in asthma remains under study. A meta-analysis of randomized controlled trials of macrolides or placebo for more than three weeks in asthma found no significant difference in FEV<sub>1</sub> or decrease in exacerbations; evidence was limited by incomplete reporting and heterogeneous inclusion criteria and outcomes.<sup>358</sup> Further studies in more homogeneous asthma populations and with standardized outcomes are needed to determine whether macrolides have a place in asthma management, particularly for neutrophilic asthma. Macrolide use may be associated with nausea, vomiting, and abdominal pain and, occasionally, liver toxicity. They should be used with caution in patients at risk of arrhythmias.<sup>359</sup>

In a study in adult patients with uncontrolled asthma despite high dose ICS and a history of  $\geq 2$  exacerbations requiring OCS or respiratory infections requiring antibiotics in the previous year, low-dose azithromycin 250mg three times per week improved quality of life; in the subset with non-eosinophilic severe asthma, azithromycin reduced severe exacerbations.<sup>360</sup> In another study of adult patients with uncontrolled persistent asthma on medium-to-high dose ICS plus a LABA, add-on maintenance treatment with azithromycin 500 mg three times per week reduced asthma exacerbations and improved asthma-related quality of life.<sup>361</sup>

##### Adverse effects

Gastro-intestinal symptoms (e.g. diarrhoea) were more common with the higher dose of azithromycin.<sup>361</sup> Since macrolides such as azithromycin can elicit ototoxicity and cardiac arrhythmia, asthma patients with hearing impairment<sup>361</sup> or abnormal prolongation of the corrected QT interval<sup>360,361</sup> were excluded from the studies. Before considering add-on therapy with azithromycin (off-label) in adult patients with uncontrolled (severe) asthma, sputum should be checked for atypical mycobacteria, and the risk of increasing antimicrobial resistance at the patient and the population level should be taken into account.

## RELIEVER MEDICATIONS

### Short-acting inhaled beta<sub>2</sub>-agonists (SABA)

#### Role in therapy

Inhaled SABAs are used for relief of bronchospasm during acute exacerbations of asthma and for the pretreatment of exercise-induced bronchoconstriction. They include salbutamol, terbutaline, levalbuterol HFA, reproterol, and pirbuterol. Formoterol, a LABA, is approved for symptom relief because of its rapid onset of action, but it should not be used without concomitant ICS therapy.<sup>362</sup>

Deleted: the medications of choice

SABAs should be used only on an as-needed basis at the lowest dose and frequency required. Increased use, especially daily use, is a warning of deterioration of asthma control and indicates the need to reassess treatment. Similarly, failure to achieve a quick and sustained response to SABA treatment during an exacerbation mandates medical attention, and may indicate the need for short-term treatment with OCS. A population-based survey reported that one-quarter of the SABA-only population had needed urgent asthma healthcare in the previous year.<sup>363</sup>

Deleted: only be used for this purpose in patients on regular controller therapy with ICS

From 2019, GINA no longer recommends SABA-only treatment of asthma in adults or adolescents. Because adherence with ICS is often extremely poor, particularly in patients with infrequent symptoms, and because a feasible alternative is now available, SABAs are no longer the preferred reliever of choice in mild asthma. Although SABAs are highly effective for the quick relief of asthma symptoms<sup>364</sup> (Evidence A), patients whose asthma is treated with SABA alone are at risk of asthma-related death<sup>219</sup> (Evidence A) and urgent asthma-related healthcare<sup>365</sup> (Evidence A), even if they have good symptom control.<sup>363</sup> One long-term study of regular SABA in patients with newly-diagnosed asthma showed worse outcomes and lower lung function than in patients who were treated with daily low dose ICS from the start.<sup>366</sup>

#### Adverse effects

Tremor and tachycardia are commonly reported with initial use of SABA, but tolerance to these effects usually develops rapidly. Dispensing of ≥3 SABA canisters per year (average ≥1.5 puffs per day) is associated with increased risk of ED visit or hospitalization, independent of asthma severity.<sup>367</sup> Heavy use of SABAs (e.g. averaging more than one canister per month) is associated with increased risk of asthma-related death.<sup>368</sup>

### Low dose ICS-formoterol

#### Role in reliever therapy

Low dose ICS-formoterol, taken only as needed for symptom relief, is a preferred treatment option for adults and adolescents with mild asthma. This recommendation is supported by evidence from a large double-blind study showing a 64% reduction in severe exacerbations compared with SABA-only treatment,<sup>259</sup> and two large studies in mild asthma showing non-inferiority for severe exacerbations compared with regular ICS plus as-needed SABA.<sup>259,260</sup> The evidence to date is with low dose budesonide-formoterol, but low dose beclometasone-formoterol should also be suitable. At present, as-needed ICS-formoterol is off-label in most countries, but these medications are well-established for as-needed use as part of maintenance and reliever therapy in GINA Steps 3-5,<sup>262</sup> and no new safety signals were seen in the large studies with as-needed budesonide-formoterol in mild asthma.<sup>216,260</sup>

In patients with mild asthma, low dose budesonide-formoterol taken as-needed for symptom relief and before exercise reduced exercise-induced bronchoconstriction to a similar extent over 6 weeks as regular daily low dose ICS plus SABA for symptom relief and before exercise.<sup>285</sup>

Low dose ICS-formoterol is also the preferred reliever for patients prescribed maintenance and reliever therapy, in which a low dose of budesonide-formoterol or beclometasone-formoterol is taken as both regular daily maintenance treatment and as the patient's reliever therapy. See section on Controller medications above for details. ICS-formoterol should not be used as the reliever medication for patients taking combination ICS-LABA medications with a different (non-formoterol) LABA.



### Adverse effects

In the large studies of as-needed budesonide-formoterol, no notable differences in adverse events were seen compared with those with daily low dose ICS plus as-needed SABA.

## **Short-acting anticholinergics**

### *Role in therapy*

Short-acting anticholinergic bronchodilators used in asthma include ipratropium bromide and oxitropium bromide. Inhaled ipratropium bromide is a less effective reliever medication in asthma than SABAs. A meta-analysis of trials of inhaled ipratropium bromide use added to SABA in acute asthma showed that the anticholinergic produced a statistically significant, albeit modest, improvement in pulmonary function, and significantly reduced the risk of hospital admission.<sup>369,370</sup>

The benefits of ipratropium bromide in the *long-term* management of asthma have not been established, although it is recognized as an alternative bronchodilator for patients who experience such adverse effects as tachycardia, arrhythmia, and tremor from rapid-acting beta<sub>2</sub>-agonists.

### *Adverse effects*

Inhalation of ipratropium or oxitropium can cause dryness of the mouth and a bitter taste.

## **OTHER MEDICATIONS**

### **Theophylline**

#### *Role in therapy*

*Long-term therapy.* Theophylline is a relatively weak bronchodilator and when given in a low dose, has modest anti-inflammatory properties.<sup>371</sup> It is available in sustained-release formulations that are suitable for once-or twice-daily administration. Theophylline is an add-on option for adult patients whose asthma is not well controlled with ICS or ICS/LABA.<sup>372-374</sup> In such patients, the withdrawal of sustained-release theophylline has been associated with deterioration of asthma control.<sup>375</sup> However, for patients taking ICS, theophylline is less effective as add-on therapy than LABA.<sup>376</sup>

*Short term therapy:* In patients with acute asthma treated with inhaled SABA, the addition of intravenous aminophylline compared with placebo did not result in significant additional bronchodilation. Moreover, for every hundred patients treated with aminophylline there were an additional 20 patients with vomiting and 15 with arrhythmias.<sup>377</sup>

#### *Adverse effects*

Side effects of theophylline, particularly at higher doses (10 mg/kg body weight/day or more), are significant and reduce its usefulness. Side effects can be reduced by careful dose selection and monitoring, and generally decrease or disappear with continued use. Adverse effects include gastrointestinal symptoms, diarrhea, cardiac arrhythmias, seizures, and even death. Nausea and vomiting are the most common early events. Monitoring of blood levels is advised when a high dose is started, if the patient develops an adverse effect on the usual dose, if expected therapeutic aims are not achieved, and when conditions known to alter theophylline metabolism exist. For example, febrile illness, pregnancy, and anti-tuberculosis medications<sup>378</sup> reduce blood levels of theophylline, while liver disease, congestive heart failure, and certain drugs including cimetidine, some quinolones, and some macrolides increase the risk of toxicity. Lower doses of theophylline, that have been demonstrated to provide the full anti-inflammatory benefit of this drug,<sup>372</sup> are associated with fewer side effects, and plasma theophylline levels in patients on low dose therapy need not be measured unless overdose is suspected.

During short-term treatment, theophylline has the potential for significant adverse effects, although these can generally be avoided by appropriate dosing and monitoring. Short-acting theophylline should not be administered to patients



already on long-term treatment with sustained-release theophylline unless the serum concentration of theophylline is known to be low and/or can be monitored.

## Oral beta-agonists

### Role in therapy

Short-acting oral beta-agonists may be considered in the few patients who are unable to use inhaled medication. However, their use is associated with a higher prevalence of adverse effects.

Long acting oral beta-agonists include slow release formulations of salbutamol, terbutaline, and bambuterol, a pro-drug that is converted to terbutaline. They are used only on rare occasions when additional bronchodilation is needed.

### Adverse effects

The side effect profile of oral long-acting beta-agonists is higher than that of inhaled beta<sub>2</sub>-agonists, and includes cardiovascular stimulation (tachycardia), anxiety, and skeletal muscle tremor. Adverse cardiovascular reactions may also occur with the combination of oral beta-agonists and theophylline. Regular use of long-acting oral beta-agonists as monotherapy is likely to be harmful and these medications must always be given in combination with ICS.

## Oral anti-histamines

Oral anti-allergy compounds have been introduced in some countries for the treatment of mild to moderate allergic asthma. A meta-analysis of 19 studies on the effects of anti-histamines in adult asthma does not support the use of these medications in asthma treatment.<sup>379</sup> Sedation is a potential side effect of some of these medications.<sup>379</sup>

## Immunosuppressants

Several steroid-sparing drugs have been proposed for patients with severe asthma. The data to support their use is weak and they should be used only in selected patients under expert supervision, as their potential steroid-sparing effects may not outweigh the risk of serious side effects. Two meta-analyses of the steroid-sparing effect of low dose methotrexate showed a small overall benefit, but a relatively high frequency of adverse effects.<sup>380,381</sup> This small potential to reduce the impact of corticosteroid side effects is probably insufficient to offset the adverse effects of methotrexate (gastrointestinal symptoms, and on rare occasions hepatic and diffuse pulmonary parenchymal disease, and hematological and teratogenic effects).<sup>382</sup> Cyclosporin<sup>383</sup> and gold<sup>384,385</sup> have also been shown to be effective in some patients. The use of intravenous immunoglobulin is not recommended for treatment of asthma.<sup>386-388</sup>

## Vitamin D

Vitamin D supplementation may be effective in reducing asthma exacerbations requiring systemic corticosteroids in patients with low baseline serum levels of Vitamin D (high quality evidence), based on a meta-analysis of 7 RCTs in children and adults with asthma. No effect on time to first exacerbation or exacerbation rates was seen. In view of the low cost of this intervention and the economic burden associated with asthma exacerbations, vitamin D supplementation in patients with documented vitamin D deficiency may represent a potentially cost-effective strategy.<sup>389</sup>

In a placebo-controlled trial in 408 adults with mild-moderate asthma who underwent ICS dose reduction, add-on high dose cholecalciferol (100,000 IU load plus 4000 IU/day) for 28 weeks vs placebo did not reduce the risk of asthma exacerbations<sup>390</sup> or severity or frequency of colds.<sup>391</sup>

## COMPLEMENTARY AND ALTERNATIVE MEDICINES AND THERAPIES

### Role in therapy

The roles of complementary and alternative medicine in adult asthma treatment are limited because these approaches have been insufficiently researched and their effectiveness is largely unproven, or has not been validated by

conventional standards.<sup>392</sup> Although the psychotherapeutic role of the therapist forms part of the placebo effect of all treatments, this aspect is viewed as an integral part of the so-called holistic approach used by practitioners of complementary and alternative methods, and mitigates against performance of the large, multicenter, placebo-controlled randomized studies required to confirm efficacy. However, without these the relative efficacy of these alternative measures will remain unknown.

Complementary and alternative therapies include acupuncture, homeopathy, herbal medicine, ayurvedic medicine, ionizers, osteopathy and chiropractic manipulation, and speleotherapy among others. Apart from those mentioned below, there have been no satisfactory studies from which conclusions about their efficacy can be drawn.

Dietary supplements, including selenium therapy<sup>393</sup> are not of proven benefit and the use of a low sodium diet as an adjunctive therapy to normal treatment has no additional therapeutic benefit in adults with asthma. In addition, a low sodium diet has no effect on bronchial reactivity to methacholine.<sup>394</sup> Evidence from the most rigorous studies available to date indicates that spinal manipulation is not an effective treatment for asthma.<sup>395</sup> Systematic reviews indicate that homeopathic medicines have no effects beyond placebo.<sup>396</sup> A Cochrane review of yoga interventions for asthma (with or without breathing, posture or meditation) compared to usual care (or sham intervention)<sup>397</sup> found moderate quality evidence of benefit for quality of life; there was no benefit for lung function or medication use. Few studies were matched for contact with health professionals, and few data were available about adverse effects.<sup>397</sup>

A systematic review of studies of breathing and/or relaxation exercises for asthma and/or dysfunctional breathing, including the Buteyko method and the Papworth method, reported **significant but small** improvements in symptoms, quality of life and/or psychological measures, but not in physiological outcomes **or risk of exacerbations**.<sup>398</sup> A subsequent large pragmatic study of breathing training in patients with impaired asthma-related quality of life showed significant but small improvements in quality of life, but no difference in asthma symptom control or risk of exacerbations. Results with three face-to-face physiotherapy sessions and DVD-based training were similar.<sup>399</sup> Breathing exercises used in some of these studies are available for free download from [www.breathestudy.co.uk](http://www.breathestudy.co.uk) and [www.woolcock.org.au/moreinfo](http://www.woolcock.org.au/moreinfo).<sup>400</sup> In order for studies of non-pharmacological strategies such as breathing exercises to be considered high quality, control groups should be appropriately matched for level of contact with health professionals and for asthma education. A study of two physiologically contrasting breathing techniques, in which contact with health professionals and instructions about rescue inhaler use were matched, showed similar improvements in reliever and ICS use in both groups.<sup>400</sup> This suggests that perceived improvement with breathing exercises may be largely due to factors such as relaxation, voluntary reduction in use of SABA medication, or engagement of the patient in their own care. Breathing exercises may thus provide a useful supplement to conventional asthma management strategies, including in anxious patients or those habitually over-using rescue medication. The cost of some programs is a potential limitation.

#### Adverse effects

With acupuncture, adverse effects including hepatitis B, pneumothorax, and burns have been described. Side effects of other alternative and complementary medicines are largely unknown. However, some popular herbal medicines could potentially be dangerous, as exemplified by the occurrence of hepatic veno-occlusive disease associated with the consumption of the commercially available herb, comfrey. Comfrey products are sold as herbal teas and herbal root powders, and their toxicity is due to the presence of pyrrolizidine alkaloids.

## PART B. ASTHMA PHARMACOTHERAPY – CHILDREN 6–11 YEARS

### ROUTE OF ADMINISTRATION

Inhaled therapy is the cornerstone of asthma treatment for children of all ages. Almost all children can be taught to effectively use inhaled therapy. Different age groups require different inhalers for effective therapy, so the choice of inhaler must be individualized. Information about the lung dose for a particular drug formulation is seldom available for children, and marked differences exist between the various inhalers. This should be considered whenever one inhaler device is substituted with another. In addition, the choice of inhaler device should include consideration of the efficacy of drug delivery, costs, safety, ease of use, convenience, and documentation of its use in the patient's age group.<sup>212,401</sup>

Many children with asthma do not use their inhalers correctly and consequently gain little or no therapeutic benefit from prescribed treatment.<sup>401</sup> Therefore, for each age group, a major focus of inhalation therapy should be on which inhalers are the easiest to use correctly, and how much training is required to achieve correct technique. More than 50 different inhaler/drug combinations are now available for the treatment of asthma. Although such a variety increases the likelihood of finding an appropriate inhaler for each individual patient, it also increases the complexity of inhaler choice, and it may also reduce the health care provider's experience with each device. Therefore, it may be better for the individual health care provider to focus on a limited number of inhalers to gain better experience with them.

Both initial training and repeated follow-ups are crucial for correct inhaler use in children.<sup>402</sup> Prescription of inhaled therapy to a child should always be accompanied by thorough training in correct inhaler use, and repeatedly checking that the child can demonstrate correct technique. The number of cycles of correction and demonstration of technique depend on age and the psychomotor skills of the child. Inhaler technique continues to improve when skills training is repeated at subsequent visits.<sup>403</sup>

Options for inhalers include pressurized metered dose inhaler (pMDI) with or without a spacer device, and dry powder inhaler (DPI). These differ with respect to construction, aerosol cloud generation, optimal inhalation technique and ease of use. For children, prescription of pMDI alone (without spacer) is not generally recommended as they are more difficult to use correctly than pMDI with spacer, DPI or breath-actuated pMDI. DPIs and breath-actuated pMDIs are often preferred for use outside the home, as they are more convenient to carry than pMDI and spacer.

Spacers retain large drug particles that would normally be deposited in the oropharynx; this reduces oral and gastrointestinal absorption and thus systemic availability of the inhaled drug. This is important for ICS that have low first-pass metabolism (beclomethasone dipropionate, flunisolide, triamcinolone). Use of a spacer also reduces oropharyngeal side effects. During asthma exacerbations, a spacer should always be used with a pMDI, as in this situation a child may be unable to correctly coordinate inhalation with pMDI actuation. Nebulizers have rather imprecise dosing, are expensive, are time consuming to use and care for, and require maintenance. They are mainly reserved for children who cannot use other inhaler devices. In severe asthma exacerbations a nebulizer is often used, although in mild or moderate exacerbations, pMDI with a spacer is equally effective.<sup>404</sup>

Common inhaler devices for use by children aged over 5 years, together with features of optimal inhalation technique, and some common problems with their use are summarized in Box A5-2.

# Box A5-2. Inhaler devices, optimal technique, and common problems for children

Device	Age group/context	Optimal technique	Common problems
pMDI with valved spacer	All ages	Slow deep inhalation (30 L/min.) followed by 5 second breath-hold	Static electricity reduces output* (output is reduced after cleaning unless rinsed with detergent and air-dried) Multiple actuations into spacer
	All ages with acute severe wheeze ICS with low first pass metabolism (see text)	Slow tidal breathing (5–10 cycles) starting immediately after actuation.	
pMDI	> 8 years	Exhalation away from device, then inhaler actuation early during a slow (30 L/min) deep inhalation, followed by 5 second breath-hold	Coordination of actuation and inhalation
Breath-actuated pMDI	> 7 years	Exhalation away from device followed by a slow (30 L/min) deep inhalation followed by 5 second breath-hold	Slow inhalation is difficult
Dry powder inhalers	> 5 years	Exhalation away from device followed by a deep, forceful inhalation (minimal effective flow varies between devices)	Dose lost if child exhales through the inhaler

\* Device dependent

## CONTROLLER MEDICATIONS

Controller medications for children include inhaled corticosteroids (ICS), combination ICS/long-acting beta<sub>2</sub>-agonists (ICS/LABA), leukotriene receptor antagonists (LTRA) and chromones.

### Inhaled corticosteroids

#### Role in therapy

ICS are the most effective controller therapy, and are therefore the recommended maintenance treatment for asthma, including for children.<sup>405</sup> Box A5-3 lists low, medium and high doses of different ICS for children 6–11 years.

Dose-response studies and dose titration studies in children<sup>406,407</sup> demonstrate marked and rapid clinical improvements in symptoms and lung function at low doses of ICS,<sup>226,408,409</sup> and mild disease is well controlled by low doses in the majority of patients.<sup>218</sup> Some children require higher doses to achieve optimal asthma control and effective protection against exercise-induced asthma, but incorrect inhaler technique and poor adherence may contribute. Only a minority of patients require treatment with high doses of ICS.<sup>226</sup>

In children, as in adults, maintenance treatment with ICS controls asthma symptoms, reduces the frequency of acute exacerbations, the need for additional asthma medication and the number of hospital admissions, improves quality of life, lung function, and bronchial hyperresponsiveness, and reduces exercise-induced bronchoconstriction.<sup>220</sup> Symptom control and improvements in lung function occur rapidly (after 1–2 weeks), although longer treatment (over months) and sometimes higher doses may be required to achieve maximum improvements in airway hyperresponsiveness.<sup>220</sup> When corticosteroid treatment is discontinued, asthma control deteriorates within weeks to months.<sup>222</sup>

**Deleted:** – regular treatment

**Deleted:** In children aged 2–12 years with acute asthma, adding a single dose of nebulized ICS to an initial dose of prednisolone was no better than adding placebo in preventing admission.<sup>410</sup>

**Box A5-3. Low, medium and high daily doses of ICS for children 6–11 years**

Low dose ICS provides most of the clinical benefit of ICS for most patients with asthma. However, ICS responsiveness varies between patients, so some patients may need medium dose ICS if their asthma is uncontrolled despite good adherence and correct technique with low dose ICS (with or without LABA). High dose ICS (in combination with LABA or separately) is needed by very few patients, and its long-term use is associated with an increased risk of local and systemic side-effects, which must be balanced against the potential benefits.

This is not a table of equivalence, but of estimated clinical comparability, based on available studies and product information.

Drug	Daily dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (CFC)*	100–200	>200–400	>400
Beclometasone dipropionate (HFA)	50–100	>100–200	>200
Budesonide (DPI)	100–200	>200–400	>400
Budesonide (nebulas)	250–500	>500–1000	>1000
Ciclesonide	80	>80–160	>160
Fluticasone furoate (DPI)	n.a.	n.a.	n.a.
Fluticasone propionate (DPI)	100–200	>200–400	>400
Fluticasone propionate (HFA)	100–200	>200–500	>500
Mometasone furoate	110	≥220–<440	≥440
Triamcinolone acetonide	400–800	>800–1200	>1200

CFC: chlorofluorocarbon propellant; DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; n.a. not applicable

\*Beclometasone dipropionate CFC is included for comparison with older literature.

For children 0–5 years, see Box A5-6, p47.

This is not a table of equivalence, but of estimated clinical comparability. Categories of 'low', 'medium', and 'high' doses are based on published information and available studies, including direct comparisons where available. Doses may be country-specific depending on labelling requirements. Most of the clinical benefit from ICS is seen at low doses, and clear evidence of dose-response relationships is seldom available within the dose ranges evaluated for regulatory purposes. 'High' doses are arbitrary, but for most ICS are those that, with prolonged use, are associated with increased risk of systemic side-effects.

For new preparations, manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent. For more detailed discussion see Raissy et al.<sup>225</sup>

*Role in therapy - intermittent and as-needed treatment*

A recent meta-analysis assessed two studies in school-age children comparing regular ICS with either intermittent ICS (episodic) or as-needed (prn) ICS. the latter taken whenever SABA was taken.<sup>410</sup> ~~However, these two regimens are~~ likely to differ in their clinical effectiveness. Daily treatment was reported to be superior to intermittent or prn treatment in several indicators of lung function, airway inflammation, asthma control and reliever use. Both treatments appeared safe, but growth was slower (0.4 cm/year) in the regular treatment group. None of the studies recorded lifestyle factors such as daily physical activity or changes in fitness, which have been found to be reduced in children when their asthma is not optimally controlled.<sup>411</sup> The authors concluded that there was low quality evidence that intermittent and daily ICS strategies were similarly effective in the use of rescue oral corticosteroids and the rate of severe adverse health events,

**Deleted:** in school-age children,

**Deleted:** although

but that equivalence between the two options could not be assumed. Thus, regular treatment remains the preferred option; this is supported by another meta-analysis including the same studies.<sup>412</sup>

Adverse effects

**Growth.** When assessing the effects of ICS on growth in children with asthma, it is important to remember that uncontrolled or severe asthma adversely affects growth and final adult height.<sup>413</sup> Potential confounding factors also affect interpretation. For example, many children with asthma, especially severe asthma, experience a reduction in growth rate toward the end of the first decade of life. This continues into the mid-teens and is associated with a delay in the onset of puberty. This deceleration of growth velocity resembles growth retardation, but is also associated with a delay in skeletal maturation, so that the child's bone age corresponds to his or her height. Ultimately, adult height is not decreased, although it is reached at a later than normal age.<sup>413,414</sup> One study suggested that 400 mcg inhaled budesonide or equivalent per day to control asthma has less impact on growth than a low socioeconomic status.<sup>414</sup> A summary of the findings of studies on ICS and growth is provided in Box A5-4.<sup>413,415,416</sup>

Box A5-4. Corticosteroids and growth in children

- Uncontrolled or severe asthma adversely affects growth and final adult height.<sup>413</sup>
- Daily use of 100–200 mcg ICS is generally considered to be without any clinically important adverse effects on growth.
- Growth retardation in both short- and medium-term studies is dose dependent. Growth retardation may be seen with moderate or high doses of all ICS.
- Important differences seem to exist between the growth-retarding effects of different ICS and different devices.
- Corticosteroid-induced changes in growth rate during the first year of treatment are not progressive or cumulative.
- In several studies, children with asthma treated with ICS for several years have been found to attain normal adult height.<sup>218,413,414</sup> However, one randomized, controlled trial of 5 years treatment with inhaled budesonide 400 mcg/day found that the initial 1.2 cm reduction in height was still detectable in adulthood (<1% of adult height), particularly in children who started treatment before 10 years of age.<sup>415</sup> Evidence favors the use of low dose ICS where possible.<sup>417</sup>

**Bones.** Several cross-sectional and longitudinal epidemiologic studies have assessed whether long-term ICS treatment is associated with osteoporosis and fractures.<sup>418–424</sup> The conclusions are summarized in Box A5-5.

Deleted: the effects of

Deleted: on

Box A5-5. Corticosteroids and bones in children

- No studies have reported an increased risk of fractures in children taking ICS.
- Use of oral or systemic corticosteroids increases the risk of fracture. The risk increases with the number of treatments, with a 32% increase after four courses (lifetime). ICS reduce the need for systemic corticosteroid courses.
- Controlled longitudinal studies of 2–5 years' duration, and several cross-sectional studies, found no adverse effects of ICS on bone mineral density.
- ICS use has the potential for reducing bone mineral accretion in male children progressing through puberty, but this risk is likely to be outweighed by the ability to reduce the amount of oral corticosteroids used in these children.<sup>425</sup>

Deleted: ever

*Hypothalamic-pituitary-adrenal (HPA) axis:* Although differences exist between different ICS and inhaler devices, treatment with ICS doses of less than 200 mcg budesonide or equivalent daily is not normally associated with any significant suppression of the HPA axis in children.<sup>220</sup> At higher doses, small changes in HPA axis function can be detected with sensitive methods.<sup>422</sup> The clinical relevance of these findings is not known, since there have been no reports of adrenal crisis in clinical trials of ICS in children. However, adrenal crisis has been reported in children treated in clinical practice with excessively high ICS doses.<sup>426</sup>

*Cataracts:* ICS have not been associated with an increased occurrence of cataract development in children.<sup>250,427</sup>

*Central nervous system effects:* Although isolated case reports have suggested that hyperactive behavior, aggressiveness, insomnia, uninhibited behavior, and impaired concentration may be seen with ICS treatment, no increase in such effects has been found in two long-term controlled trials of inhaled budesonide involving more than 10,000 treatment years.<sup>218,220</sup>

*Oral candidiasis, hoarseness, and bruising:* Clinical thrush is seldom a problem in children treated with ICS or oral corticosteroids. This side effect seems to be related to concomitant use of antibiotics, high daily doses, dose frequency, and inhaler device. Spacers reduce the incidence of oral candidiasis.<sup>428</sup> Mouth rinsing is beneficial.<sup>429</sup> The occurrence of hoarseness or other noticeable voice changes during budesonide treatment is similar to placebo.<sup>250</sup> Treatment with an average daily dose of 500 mcg budesonide for 3–6 years is not associated with an increased tendency to bruise.<sup>250</sup>

*Dental side effects:* ICS treatment is not associated with increased incidence of caries. However, the increased level of dental erosion reported in children with asthma<sup>430</sup> may be due to a reduction in oral pH from inhalation of beta<sub>2</sub>-agonists.<sup>431</sup>

*Other local side effects:* The long-term use of ICS in children is not associated with an increased incidence of lower respiratory tract infections, including tuberculosis.

## Combination ICS/LABAs

### Role in therapy

In children 6 years and older, LABAs are primarily used as add-on therapy for those whose asthma is insufficiently controlled by medium doses of ICS. Combination ICS/LABA products are preferred to use of separate inhalers, to ensure that the LABA is always accompanied by ICS. With add-on LABA, significant improvements in peak flow and other lung function measurements have been found in most studies.<sup>432–434</sup> However, the effects on other outcomes such as symptoms and need for reliever medication have been less consistent, and only observed in about half of the trials conducted. A cross-over study in children whose asthma was uncontrolled despite good adherence with low-dose ICS (n=182) found that adding LABA was most likely to produce the best clinical response over 16 weeks for a composite measure including lung function, compared with adding a LTRA or doubling the ICS dose.<sup>435</sup> A large (n=6,208) randomized controlled study in children 4–11 years comparing fluticasone propionate and combination fluticasone propionate/salmeterol maintenance treatment found no difference in rescue-free days or asthma symptom control.<sup>436</sup>

For exacerbations in children, by contrast with findings in adults, meta-analyses of randomized controlled trials showed no significant difference in exacerbations requiring systemic corticosteroids, when LABA was added to current treatment (which may or may not have included ICS),<sup>437</sup> when LABA was added to ICS,<sup>438</sup> or when ICS/LABA was compared with double dose ICS.<sup>439</sup> A large (n=6,208) study in children 4–11 years found no significant difference in serious exacerbations requiring hospitalization, or in severe exacerbations requiring oral corticosteroids, between fluticasone propionate and same dose combination fluticasone propionate/salmeterol.<sup>436</sup>

Not all combination ICS/LABA medications and devices are approved for use in children.

### Adverse effects

There have been concerns that using LABA might increase asthma risks including mortality.<sup>440</sup> However, a large randomized controlled trial with fluticasone propionate/salmeterol combination inhaler in children 4–11 years showed no

inferiority to fluticasone propionate alone for serious adverse events (death, intubation and hospitalization due to asthma).<sup>294,436</sup> Based on this study<sup>436</sup> and a systematic review<sup>440</sup> there is no apparent increase in risk for serious exacerbations in children with LABA when it is used in a combination inhaler with ICS.

### Leukotriene receptor antagonists

#### *Role in therapy*

LTRAs provide clinical benefit in this age group at all levels of severity,<sup>303,441-443</sup> but the benefit is generally less than that of low dose ICS.<sup>405</sup> LTRAs provide partial protection against exercise-induced bronchoconstriction within hours after administration with no loss of bronchoprotective effect over time.<sup>190,444</sup> A systematic review of LTRAs as add-on treatment in children whose asthma was insufficiently controlled by low doses of ICS showed no significant improvement in outcomes, including in exacerbations.<sup>445</sup> Add-on therapy with montelukast was less effective in controlling asthma in children with uncontrolled persistent asthma than increasing ICS to moderate dose.<sup>446</sup> Montelukast has not been demonstrated to be an effective ICS-sparing alternative in children with moderate-to-severe persistent asthma.<sup>447</sup>

#### *Adverse effects*

No safety concerns have been demonstrated from the use of LTRA in children in clinical trials. Post-marketing surveillance reports suggested a slight increase in the rate of (rare) neuropsychiatric disorders potentially associated with use of leukotriene receptor antagonists in children and young adults, but no evidence was found in a case-control study.<sup>309</sup>

### Chromones: sodium cromoglycate and nedocromil sodium

#### *Role in therapy*

Sodium cromoglycate and nedocromil sodium have a limited role in the long-term treatment of asthma in children. One meta-analysis concluded that long-term treatment with sodium cromoglycate is not significantly better than placebo for management of asthma in children.<sup>448</sup> Another meta-analysis confirmed superiority of low-dose ICS over sodium cromoglycate in persistent asthma; no difference between treatments was seen in safety.<sup>310</sup>

Nedocromil sodium has been shown to reduce exacerbations, but its effect on other asthma outcomes is not superior to placebo.<sup>220</sup> A single dose of sodium cromoglycate or nedocromil sodium attenuates bronchospasm induced by exercise or cold air.<sup>449</sup>

Sodium cromoglycate and nedocromil sodium inhalers require daily washing to prevent blockage.

#### *Adverse effects*

Cough, throat irritation, and bronchoconstriction occur in a small proportion of patients treated with sodium cromoglycate. A bad taste, headache, and nausea are the most common side effects of nedocromil.<sup>450</sup>

## **ADD-ON CONTROLLER MEDICATIONS**

### **Long-acting anticholinergics (also called long-acting antimuscarinics, LAMA)**

#### *Role in therapy*

A meta-analysis of over 900 patients 6-11 years showed the addition of tiotropium to medium or high dose ICS with or without a second controller was associated with significant improvements in FEV1 and Asthma Control Questionnaire responders, and reduced the number of patients with one or more exacerbations, but with no differences in reliever use. The approved dose for children varies between regulatory authorities.<sup>451</sup>



## Anti-IgE

### Role in therapy

Anti-IgE (omalizumab) has proven effect in children aged  $\geq 6$  years with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. [The efficacy of anti-IgE in children and adolescents is supported by the findings of effectiveness studies.](#)<sup>452</sup> A 28-week, randomized, placebo-controlled study<sup>453</sup> included 334 children aged 6–12 years with moderate to severe allergic asthma, whose asthma was well controlled on ICS doses equivalent to 200–500 mcg/day of beclometasone. There were no differences in clinical effects between placebo and anti-IgE during a 16-week stable ICS dose period. During a 12-week tapering period, urgent unscheduled physician visits were significantly reduced by 30.3% in the anti-IgE group compared with placebo (12.9%) group,<sup>453</sup> and there were significant improvements in quality of life in the patients receiving anti-IgE, both during stable ICS dosing and during tapering.<sup>454</sup> The remaining outcomes were similar in the two treatment groups.

A one-year study evaluated the efficacy and safety of anti-IgE in 627 children aged 6–11 years with IgE-mediated asthma inadequately controlled on ICS at doses equivalent to or higher than 200 mcg/day fluticasone propionate (mean dose 500 mcg/day).<sup>455</sup> Anti-IgE treatment was associated with a significantly lower exacerbation rate, and the overall incidence of serious adverse events was significantly lower in the children receiving anti-IgE than placebo.

A 60-week study in 419 inner-city patients aged 6–20 years found that omalizumab significantly reduced symptoms and exacerbations, including seasonal exacerbations, compared with placebo.<sup>331</sup>

A substantial number of children with difficult asthma have higher IgE levels than the upper limit of IgE recommended for therapy (1,300 IU).<sup>456</sup> It is unknown if these patients will still benefit from omalizumab therapy.

The recent ERS/ATS Task Force on Severe Asthma recommended that 'Those adults and children aged 6 and above, with severe asthma who are considered for a trial of omalizumab, should have confirmed IgE-dependent allergic asthma uncontrolled despite optimal pharmacological and non-pharmacological management and appropriate allergen avoidance if their total serum IgE level is 30 to 700 IU/mL (in 3 studies the range was wider – 30–1300 IU/mL). Treatment response should be globally assessed by the treating physician taking into consideration any improvement in asthma control, reduction in exacerbations and unscheduled healthcare utilisation, and improvement in quality of life. If a patient does not respond within 4 months of initiating treatment, it is unlikely that further administration of omalizumab will be beneficial.'<sup>206</sup>

### Adverse effects

Drug-related adverse events in anti-IgE treated patients are mild to moderate in severity and include injection site pain, urticaria, rash, flushing, and pruritus.<sup>453</sup> The long-term (beyond one year) safety and efficacy have not yet been studied in children.

## Systemic corticosteroids

Because of the side effects of prolonged use, oral corticosteroids in children with asthma should be restricted to the treatment of acute severe exacerbations, whether viral-induced or otherwise. Even short-courses of oral corticosteroids, if used repeatedly, increase the risk of side-effects. In a prospective study, short courses of oral corticosteroids were associated with reduced bone density in boys.<sup>425</sup> In an epidemiological study, risk of fracture was increased with  $\geq 4$  courses of oral corticosteroids, although the contribution of disease severity could not be estimated.<sup>421</sup>

RELIEVER MEDICATIONS

Short-acting beta-agonists (SABA)

Role in therapy

SABAs are the most effective bronchodilators approved for this agegroup, and therefore the preferred treatment for acute asthma in children of all ages. The inhaled route results in more rapid bronchodilation at a lower dose and with fewer side effects than oral or intravenous administration.<sup>457</sup> Furthermore, inhaled therapy offers significant protection against exercise-induced bronchoconstriction and other challenges for 0.5 to 2 hours.<sup>190</sup> This is not seen after systemic administration.<sup>458</sup> Oral therapy is rarely needed and is reserved mainly for the small proportion of young children who cannot use inhaled therapy.

Deleted: available

Adverse effects

Skeletal muscle tremor, headache, palpitations, and some agitation are the most common complaints associated with high doses of beta-agonists in children. These complaints are more common after systemic administration and disappear with continued treatment.

Anticholinergics

Role in therapy

Inhaled anticholinergics such as ipratropium bromide are not recommended for long-term management of asthma in children.<sup>459</sup> They may be tried in patients who are very sensitive to the side effects of SABAs, but their onset of action and maximum effect are generally lower than those of SABAs.

OTHER MEDICATIONS. NOT RECOMMENDED FOR USE IN CHILDREN

Theophylline

Role in therapy

Due to its high toxicity, theophylline is not recommended for use in children, unless ICS are not available. Theophylline has only modest effects as monotherapy compared with placebo,<sup>460</sup> and as add-on treatment to inhaled or oral corticosteroids in children with severe asthma.<sup>461,462</sup> It has a marginal protective effect against exercise-induced bronchoconstriction.<sup>463</sup> Most clinical evidence in children has been obtained from studies in which plasma theophylline levels were maintained within the therapeutic range of 55–110 umol/L (5–10 mcg/ml). Theophylline elimination may vary up to tenfold between individuals, and measurement of plasma theophylline levels is recommended in otherwise healthy children when daily doses exceed 10 mg/kg/day.

Adverse effects

The most common side effects of theophylline are anorexia, nausea, vomiting, and headache,<sup>464</sup> mainly seen at doses higher than 10 mg/kg/day. The risk of adverse effects is reduced if treatment is initiated with daily doses around 5 mg/kg/day and then gradually increased to 10 mg/ kg/day. More serious side effects such as epileptic seizures may occur, and severe overdosing with theophylline can be fatal.

Long-acting oral beta-agonists

Treatment with long-acting oral beta-agonists such as slow release formulations of salbutamol, terbutaline, and bambuterol reduces nocturnal symptoms of asthma.<sup>465,466</sup> However, due to their potential side effects of cardiovascular stimulation, anxiety, and skeletal muscle tremor, their use is not encouraged. Oral long-acting beta<sub>2</sub>-agonist therapy offers little or no protection against exercise-induced bronchoconstriction.

Deleted: If used, dosing should be individualized, and the therapeutic response monitored to limit side effects.<sup>466</sup>

PART C. ASTHMA PHARMACOTHERAPY – CHILDREN 5 YEARS AND YOUNGER

CONTROLLER MEDICATIONS

Inhaled corticosteroids

Role in therapy

*Regular ICS treatment.* A meta-analysis of 29 randomized controlled trials of ≥4 weeks' duration in children aged 1 month to 5 years, with a clinical diagnosis of wheezing or asthma for at least 6 months before study entry, found that those who received maintenance ICS had significantly less wheezing, fewer asthma exacerbations, fewer withdrawals caused by wheezing or asthma exacerbations, less albuterol use and more clinical and functional improvement than those on placebo<sup>467</sup> (Evidence A). A meta-analysis of 8 studies in children with persistent asthma showed reduced exacerbations with daily ICS compared with placebo, and in one study, with daily ICS compared with montelukast.<sup>468</sup>

Dose-response relationships have been less well studied in this age group. The clinical response may differ depending on the specific device used for delivery and the child's ability to use it correctly. For children whose asthma is not well-controlled with low dose ICS (Box A5-6), near-maximum benefits are achieved in the majority of patients with twice these doses, when given as regular, long-term treatment and with correct use of a spacer device.<sup>469,470</sup> Use of ICS for children up to 2 years of age has not been found to induce remission of asthma; symptoms almost always return when treatment is stopped<sup>471</sup> (Evidence B). In children aged 2–12 years with acute asthma, adding a single dose of nebulized ICS to an initial dose of prednisolone was no better than adding placebo in preventing admission.<sup>472</sup>

Box A5-6. Low daily doses of inhaled corticosteroids for children 5 years and younger

Low dose ICS provides most of the clinical benefit for most children with asthma. Higher doses are associated with an increased risk of local and systemic side-effects, which must be balanced against potential benefits.

This is not a table of equivalence, but of estimated clinical comparability, based on available studies and product information.

Drug	Low daily dose (mcg) (age-group with adequate safety and effectiveness data)
Beclomethasone dipropionate (HFA)	100 (ages ≥5 years)
Budesonide nebulized	500 (ages ≥1 year)
Fluticasone propionate (HFA)	50 (ages ≥4 years)
Mometasone furoate	110 (ages ≥4 years)
Budesonide pMDI + spacer	Not sufficiently studied in this age group
Ciclesonide	Not sufficiently studied in this age group
Triamcinolone acetonide	Not sufficiently studied in this age group

HFA: hydrofluoralkane propellant; pMDI: pressurized metered dose inhaler  
This is not a table of clinical equivalence. A low daily dose is defined as the lowest approved dose for which safety and effectiveness have been adequately studied in this age group.  
This table is also found in the [2019 Global Strategy for Asthma Management and Prevention](#).<sup>25</sup>

Deleted: 100

Deleted: 2018

Deleted: 167

**Episodic ICS treatment versus placebo.** In children with intermittent asthma or viral-induced wheeze, meta-analysis of 5 studies (422 children) found that the preemptive use of high-dose episodic ICS compared with placebo resulted in reduced risk of exacerbation.<sup>468</sup> Because of the potential for side-effects, this option should be considered only where the physician is confident that the medications will be used appropriately.

**Episodic ICS treatment versus regular ICS.** The MIST study recruited pre-schoolers with recurrent wheeze, a positive asthma predictive index (API), and wheezing episodes on an average of one third of days, with two-thirds of the children taking ICS prior to entry. This study compared regular daily low-dose nebulized budesonide with episodic high-dose nebulized budesonide given each night for seven days with respiratory tract illnesses.<sup>473</sup> This study showed similar outcomes for regular and intermittent ICS. Cumulative ICS dose was higher with regular versus episodic treatment.

**As-needed ICS treatment (taken when SABA is required) versus regular ICS or placebo.** The 'BEST for Children' study was a 3 month placebo-controlled study in 276 pre-schoolers with frequent wheeze comparing regular twice-daily nebulized beclometasone, as-needed nebulized beclometasone/salbutamol (given for symptom relief), and as-needed salbutamol alone.<sup>474</sup> This study showed similar clinical outcomes for regular vs as-needed ICS, but regular ICS was better than placebo for the primary outcome measure of symptom-free days. Cumulative ICS dose was lower with as-needed versus regular ICS.

The choice between regular, intermittent and as-needed controller treatment in clinical practice in pre-school children is still under discussion. A meta-analysis found strong evidence to support daily ICS for preventing exacerbations in preschool children with recurrent wheeze, specifically in children with persistent asthma.<sup>468</sup> For preschool children with viral-triggered wheezing and no apparent symptoms between the wheezing episodes, there is evidence to support intermittent ICS for preventing exacerbations.<sup>468</sup>

#### Adverse effects

The majority of studies evaluating the systemic effects of ICS have been undertaken in children older than 5 years. However, the available data in children 5 years and younger suggest that, as in older children, clinically effective doses of ICS are safe and the potential risks are well balanced by the clinical benefits.<sup>471,475,476</sup> Generally, low doses of ICS (Box A5-6) have not been associated with any clinically serious adverse systemic effects in clinical trials and are considered safe<sup>469,470,475-483</sup> (Evidence A). However, higher doses have been associated with detectable systemic effects on growth particularly in the first year of treatment and on the hypothalamic-pituitary-adrenal (HPA) axis.<sup>469-471,475-483</sup> These effects are similar to those reported in studies of older children that find no evidence that the initial effect on growth is accumulated with continued long term treatment.<sup>413-415</sup> The effects of the early reduction in growth on adult height has not been studied in children who started ICS before the age of 5 years. In children who had been treated with fluticasone propionate for 2 years from the age of 2 or 3 years,<sup>471</sup> catch-up in growth was seen at 2 years after cessation of ICS; however, in a *post hoc* analysis no catch-up was seen in children who at study entry were <2 years old and weighed <15 kg.<sup>484</sup>

Local side effects, such as hoarseness and candidiasis, are rare in children 5 years and younger.<sup>225,481</sup>

#### Combination ICS/long-acting beta<sub>2</sub>-agonists (ICS/LABA)

The effect of LABA or combination ICS/LABA products has not been adequately studied in children 4 years and younger. In a small study, formoterol showed bronchodilator and bronchoprotective effects for >8 hours in this age group<sup>485</sup> (Evidence D). However, there are no placebo-controlled trials in this age group on the addition of LABA to ICS.

#### Leukotriene receptor antagonists (LTRA)

##### Role in therapy

**LTRA versus placebo:** In a three-month placebo-controlled study of 689 children with persistent wheeze, montelukast reduced days with symptoms and days with rescue beta<sub>2</sub>-agonist use by approximately 6 percentage points. The

proportion of children experiencing an asthma 'attack' was not significantly reduced, but the proportion needing a course of prednisolone was reduced from 28% to 19%.<sup>486</sup> In a 12-month placebo-controlled study of 549 young children with recurrent viral-induced wheezing, regular montelukast improved some asthma outcomes compared with placebo, but did not reduce the frequency of hospitalizations, courses of prednisone, or symptom-free days.<sup>487</sup> These findings were confirmed by a further study in children with intermittent wheezing.<sup>488</sup> Montelukast has also been shown to reduce airway hyperresponsiveness to methacholine<sup>489</sup> or hyperventilation with cold dry air.<sup>490</sup>

*Regular LTRA versus regular ICS:* Two studies compared ICS with LTRA in pre-school children. A one-year, randomized, open study compared montelukast with nebulized budesonide in 400 children with mild persistent asthma; overall outcomes favored budesonide.<sup>491</sup> In a 3 month blinded, placebo-controlled study of 63 children, fluticasone propionate treatment significantly improved symptoms over placebo, whereas montelukast did not; fluticasone propionate also improved lung function measured by forced oscillation technique<sup>492</sup> (Evidence B).

*Episodic LTRA treatment versus placebo.* In a 12-month placebo-controlled study in children with intermittent asthma that included 162 children aged 2–5 years, parent-initiated montelukast for 7–14 days had a modest effect on health care utilization.<sup>493</sup> In a placebo-controlled study of 979 children aged 3 months to 2 years, and hospitalized with RSV bronchiolitis, montelukast had no effect on post-bronchiolitic wheeze or cough.<sup>494</sup> A large 12-month study comparing daily and intermittent montelukast with placebo showed no significant difference in health care utilization. There were numerical differences in symptoms and reliever use during respiratory infections with regular and episodic montelukast compared with placebo.<sup>488</sup>

A placebo-controlled trial of the addition of montelukast to usual asthma therapy for 45 days in the fall, including 42 children aged 2–5<sup>495</sup> found that this treatment reduced the number of days with worsening of asthma symptoms in boys but not in girls.

In summary, LTRAs improve some asthma outcomes in young children with intermittent wheezing or persistent asthma (Evidence A). However, the role of LTRAs as add-on therapy in children 5 years and younger whose asthma is uncontrolled on ICS has not been sufficiently evaluated.

#### **Adverse effects**

No safety concerns have been demonstrated in clinical trials of LTRAs in young children. Product information for montelukast describes (rare) adverse effects such as nightmares in this age group.

#### **Chromones (sodium cromoglycate and nedocromil sodium)**

A Cochrane review concluded that there was no beneficial effect of inhaled sodium cromoglycate compared with placebo in preschool children<sup>496</sup> (Evidence A). Two studies of nearly 1,000 children in this age group<sup>497,498</sup> have confirmed the superiority of ICS over chromones for almost all endpoints assessing asthma control (Evidence A). Nedocromil sodium has not been studied in preschool children. Chromones cannot be recommended in this age group.

#### **Oral and other systemic corticosteroids**

Because of the side effects associated with prolonged use, oral corticosteroids in young children with asthma should be restricted to the treatment of severe exacerbations, whether viral-induced or otherwise<sup>499</sup> (Evidence D).

#### **Azithromycin**

Antibiotics are not currently recommended for treatment of asthma exacerbations in adults or children, but they are commonly used in clinical practice. Two studies have examined the effect of azithromycin in selected children with a history of severe wheezing with respiratory infections. In a large study, children 1-5 years were randomized to receive 5 days of azithromycin or placebo for respiratory infections; this study showed a significant reduction in the risk of more severe lower respiratory episodes.<sup>500</sup> In a smaller study in children 1-3 years, each respiratory infection lasting ≥3 days was randomly allocated to treatment with azithromycin or placebo for 3 days, with most children also receiving ICS; this

study showed a significant reduction in symptom duration with azithromycin.<sup>501</sup> Neither study found a difference in need for urgent health care (which was uncommon in both studies), or an increase in time to subsequent respiratory infections. Development of antibiotic resistance was slightly increased when examined in a small number of subjects.<sup>500</sup> It is still unclear which children should be considered for azithromycin treatment, and there is concern about the potential for greater antibiotic resistance in broader populations where adherence may be lower; more clinical trials are needed, using standardized outcome measures, before any recommendations can be made.

## RELIEVER MEDICATIONS

### Inhaled short-acting beta<sub>2</sub>-agonists (SABA)

Inhaled SABA are the preferred reliever treatment for asthma in children 5 years and younger (Evidence A). In most cases, a pMDI with spacer is an effective way for delivering reliever therapy for as-needed use or in acute exacerbations.<sup>404,502</sup> (Evidence A). A face mask is added for children under 4 years. When delivery is not optimal because of lack of cooperation or distress, or when the child is hypoxic, nebulizer therapy is also an option.

### Other bronchodilators

There is no evidence to support the use of anticholinergic agents such as inhaled ipratropium bromide in the routine daily management of asthma in children 5 years and younger.<sup>503</sup> (Evidence A) However, there is increasing evidence that ipratropium is effective when added to other therapy in patients with severe exacerbations.<sup>504</sup>

Oral bronchodilator therapy is not recommended due to its slower onset of action and the higher rate of side effects.

### Other therapies

#### Theophylline

Although a few studies in children 5 years and younger suggest clinical benefit from regular use of theophylline, the effects are small and mostly non-significant.<sup>460</sup> The efficacy of theophylline as initial therapy is less than that of low dose ICS, and side effects are more common,<sup>460</sup> so theophylline is only recommended for use when ICS are not available (Evidence D).

#### Allergen immunotherapy

Immunotherapy is not recommended for the treatment or prophylaxis of asthma in children 5 years and younger (Evidence D).

## Chapter 6.

# Implementing asthma management strategies in health systems

### KEY POINTS

- In order to improve asthma care and patient outcomes, evidence-based recommendations must be not only developed, but also adequately disseminated and implemented at a national and local level, and integrated into current practice.
- Implementation requires an evidence-based strategy involving professional groups and stakeholders, and should take into account local cultural and socioeconomic conditions and cost-effectiveness, so a decision can be made to pursue or modify them.
- GINA aims to guide implementation of its recommendations, provide examples of current implementation strategies, and offer a series of tools to help achieve this goal worldwide.

### INTRODUCTION

Due to the exponential increase in medical research publications, practical syntheses are needed to guide health care providers in delivering evidence-based care. Where asthma care is consistent with evidence-based recommendations, outcomes improve.<sup>505-507</sup> Strategy documents such as the *Global Strategy for Asthma Management and Prevention* provide a common template for health professionals to identify the main goals of treatment and the actions required to ensure their fulfilment in their own health system, as well as to facilitate the establishment of standards of care.

Guidelines and clinical practice recommendations now generally utilize specific methodology for evaluating and adapting evidence, ensuring development of unbiased, well-adapted recommendations.<sup>508,509</sup> However, increasing effort should be devoted to dissemination of recommendations and, most importantly, to their implementation at different levels so that integration into care is promoted and facilitated.

The recent adoption of rigorous methodologies such as GRADE<sup>508</sup> for the development of clinical practice recommendations, and the ADAPTE and similar approaches for assisting the adaptation of recommendations for local country and regional conditions, has assisted in reducing biased opinion as the basis for asthma programs worldwide. However, use of the GRADE method is costly and often requires expertise that is not available locally, and regular revision to remain abreast of developments (drug availability and new evidence) is not easily achieved.<sup>508,509</sup> In addition, there is generally very limited high quality evidence addressing the many decision nodes in comprehensive clinical practice guidelines, particularly in developing countries.

GINA provides assistance for the processes of adaptation and implementation through provision of the *Global Strategy for Asthma Management and Prevention* report,<sup>25</sup> which contains evidence relevant to asthma diagnosis, management and prevention that may be used in the formulation and adaptation of local guidelines; where evidence is lacking, the GINA report provides approaches for consideration. An implementation 'toolkit' is also being developed, to provide a guide to local adaptation and implementation, with materials and advice from successful examples of asthma clinical practice guideline development and implementation in different settings.

Many barriers to, and facilitators of, implementation procedures have been described.<sup>510-513</sup> Some of these are related to delivery of care, while others relate to patients' attitudes and behaviors (Box A6-1). Cultural and economic barriers can particularly affect the application of recommendations.

Deleted: Chapter

Deleted: 7.

Deleted: A7

Deleted: 7

Box **A6-1** Examples of barriers to the implementation of evidence-based recommendations

Deleted: A7

Health care providers	Patients
<ul style="list-style-type: none"><li>• Insufficient knowledge of recommendations</li><li>• Lack of agreement with recommendations or expectation that they will be effective</li><li>• Resistance to change</li><li>• External barriers (organizational, health policies, financial constraints)</li><li>• Lack of time and resources</li><li>• Medico-legal issues</li></ul>	<ul style="list-style-type: none"><li>• Low health literacy</li><li>• Insufficient understanding of asthma and its management</li><li>• Lack of agreement with recommendations</li><li>• Cultural and economic barriers</li><li>• Peer influence</li><li>• Attitudes, beliefs, preferences, fears and misconceptions</li></ul>

## PLANNING AN IMPLEMENTATION STRATEGY

Implementation of asthma management strategies can be carried out at national, regional or local levels.<sup>514</sup> Ideally, this should be a multidisciplinary effort involving many stakeholders, and using methods of knowledge translation that are considered cost effective.<sup>513-515</sup> Any implementation initiative needs to consider the structure and function of the relevant health network and its components. Moreover, goals and implementation strategies will vary from country to country and within countries based on economics, culture and the physical and social environment.

The essential elements required to implement a health-related strategy are summarized in Box **A6-2**. The goals and processes for each of these components are summarized in the paragraphs that follow.

Deleted: A7

Box **A6-2**. Essential elements required to implement a health-related strategy

Deleted: A7

1. Develop a multidisciplinary working group
2. Assess the current status of asthma care delivery, care gaps and current needs
3. Select the material to be implemented, agree on main goals, identify key recommendations for diagnosis and treatment, and adapt them to the local context or environment
4. Identify barriers to, and facilitators of, implementation
5. Select an implementation framework and its component strategies
6. Develop a step-by-step implementation plan:
  - Select target populations and evaluable outcomes
  - Identify local resources to support implementation
  - Set timelines
  - Distribute tasks to members
  - Evaluate outcomes
7. Continuously review progress and results to determine if the strategy requires modification

Deleted: 7



## 1. Develop a multidisciplinary working group

From its initiation, the working group should ideally include representation from diverse professional groups including primary and secondary care health professionals and their associations, public health officials, non-governmental associations, patients, asthma advocacy groups, and the general public. Each member will contribute according to his or her expertise, resources and contacts. This may be done under the umbrella of national or local health societies or professional or scientific organizations, or through initiatives such as the Global Initiative for Asthma (GINA) and the Global Alliance against Chronic Respiratory Diseases (GARD).<sup>516</sup> Knowledge translation specialists can be consulted to ensure optimal evidence-based implementation methods. Ideally, a project coordinator should be involved.

Public health strategies involving a broad coalition of stakeholders in asthma care, including medical societies, health care professionals, patient support groups, government, and the private sector, have been implemented in Australia,<sup>517</sup> in the United States,<sup>518</sup> and other countries.

## 2. Assess the current status of care delivery, care gaps and current needs in the target area

The working group should assess the current status of asthma care in the target country/region in terms of mortality and morbidity, indicators of delivery of quality care and available resources for implementation. Processes for referral, current care facilities and access to asthma medications, as well as the degree of understanding of the management recommendations by practitioners/caregivers also need to be evaluated. Current 'care gaps' and their determinants<sup>513,519</sup> should be identified and their respective consequences estimated. This will aid in setting priorities (Box A6-3) and planning strategies that can fill the care gaps.

Deleted: A7

## 3. Select the material to be implemented, agree on main goals, identify key recommendations, and adapt them to the local context or environment

Once the material to be implemented has been selected (e.g. specific management recommendations from the GINA report), the working group should determine if any of the material requires adaptation to the local/regional context and environment. The working group should agree on realistic goals, and set priorities. Instruments such as the ADAPTE<sup>520</sup> tool are available to guide the process of adaptation, including recommendations on planning and set-up, the adaptation process, and the production of the final document.

## 4. Identify barriers to, and facilitators of, implementation

The next step is to identify barriers to, and facilitators of, implementation in the target country/region, and develop appropriate strategies around this. In some areas, particularly in low-income countries, asthma may not be considered a high priority health concern in comparison to other respiratory diseases like tuberculosis and pneumonia. In such areas, practical asthma management strategies could include a simple algorithm for separating non-infectious from infectious respiratory illnesses; simple objective measurements for diagnosis and management such as peak flow variability; available, affordable and low-risk medications for achieving good asthma control; a simple process for recognizing severe asthma; and simple diagnosis and management approaches relevant to the facilities and limited resources available. Other local barriers such as the lack of availability of resources/medications, organizational problems, or communication issues between caregivers should also be addressed (Box A6-3).

Deleted: A7

Deleted: 7

Box A6-3. Common asthma management care gaps

Deleted: A7

Management care gap	Barriers to reducing the gap (examples)	Possible implementation strategy	Process and outcome measures
Over/under-diagnosis of asthma	Lack of availability of lung function tests	Identification of nearby lung function facilities	% patients having lung function tests
Inadequate assessment of asthma control	Lack of knowledge of criteria	Education/continuing medical education (CME)	Survey of use of criteria
Lack of assessment of SABA use	Lack of direct questioning	Automated letter based on pharmacy dispensing	Number of canisters dispensed per year
Insufficient environmental or preventative measures	Lack of time to explain	Increase access to educators; involve patients as educators	Survey implementation of intervention
Lack of individualized pharmacotherapy	Insufficient knowledge of guideline	Education/CME	Assessment of treatment (e.g. audit)
Lack of education and guided self-management	Lack of availability of educators	Increase access to educators; involve patients as educators	% patients offered education
Absence of an asthma action plan, or failure by patients to use their action plan	Not enough time to produce and explain the plan	Increase access to educators; involve patients as educators; provide clinicians with templates	% patients receiving written asthma action plan
No assessment of patients' skills with inhalers, PEF	Lack of time or knowledge	Systematic assessment at visits; provide device-specific checklists	% patients in whom technique is checked
No assessment of adherence to therapy	Not integrated into practice	Reminders; sample wording (see GINA report, Box 2-4); automated pharmacy letter	% patients in whom adherence is checked
No regular follow up; discontinuity of care	Lack of follow-up arrangements	Improved management	% patients having follow-up visit
Variable/insufficient access to care; lack of availability of asthma controllers	Insufficient resources	Increase resources; revise process	Assess continuity of care
Poor communication between various groups of health care providers	Lack of willingness to change	Organize joint sessions on asthma care	Focus group assessing this aspect of care

Based on Boulet et al. *A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care*.<sup>514</sup>

NOTE: These are considered important care gaps according to current guidelines and consensus, but for some, specific evidence of improvement in asthma outcomes following their application is not yet available.

## 5. Select an implementation framework and its component strategies

The *Knowledge to action* model has been proposed as a framework for guideline implementation but other models can also be considered.<sup>521</sup> This framework allows a continuing circle of improvement and the integration of new evidence/guidelines updates into the intervention process. Using this framework, a series of strategies can be proposed based on their ability to address the previously identified care gaps and barriers. Box A6-4 lists examples of high-impact interventions for asthma management. Quality of care improvements are made in progressive steps with regular assessment of their performance.

Deleted: A7

Deleted: 7

Ideally, interventions should be conducted at the level of both the patient and the health care provider. Studies of the most effective means of medical education show that it may be difficult to induce changes in clinical practice. However, among the most effective methods are:

- Reminders at the point of care
- Automated letter to patient and/or prescriber based on pharmacy dispensing<sup>522,523</sup>
- Interactive workshops
- Audit and feedback
- Multifaceted interventions. These include methods such as medical audit and feedback, reminders, local consensus processes, marketing, and use of practice facilitators.<sup>524-528</sup>
- Publications in journals that are associated with multidisciplinary symposia, workshops or conferences involving national and local experts, along with involvement of the professional and mass media can help to communicate key messages.
- Embedding guidelines into electronic health records is promising,<sup>529,530</sup> but a recent review showed the challenges of developing integrated care pathways.<sup>531</sup>

A useful resource for choosing the best implementation strategy is provided in the recommendations of the Cochrane Effective Practice and Organization of Care Review Group.<sup>532</sup>

#### Box A6-4 Examples of high-impact interventions in asthma management

Deleted: A7

- Optimized ICS use for patients with a recent hospital admission and/or severe asthma<sup>533</sup>
- Early treatment with ICS, guided self-management, reduction in exposure to tobacco smoke, improved access to asthma education<sup>506</sup>
- Self-inking stamp prompting assessment of asthma control and treatment strategies<sup>534</sup>
- Use of individualized written asthma action plans as part of self-management education<sup>188</sup>
- An evidence-based care process model for acute and chronic pediatric asthma management, implemented at multiple hospitals<sup>535</sup>

ICS: inhaled corticosteroids

According to the *Knowledge to action* conceptual framework, the implementation process should include:

- *A planning phase*: in which key recommendations are prioritized for the targeted population, and key messages, main outcomes and actions to be taken are determined.
- *An assessment phase*: to review uptake by the target group and the impact of interventions.
- *A monitoring and adjustment phase*: in which outcomes selected for determination of the impact and sustainability of the intervention are assessed, and interventions are adjusted based on the findings.

Potential new tools for implementation include internet-based programs, social networks and electronic tools, although their effectiveness remains to be determined. In all cases, the messages must be simple, easily understood, practical and implementable.

## 6. Develop a step-by-step implementation plan

### Select target populations and outcomes

Efforts should be devoted to the entire asthma population, but particularly to 'at-risk' or 'high-morbidity' populations. This includes patients with poor adherence to treatment or follow up; those who experience frequent exacerbations or frequently use the health care system; adolescents; elderly patients; and those with socioeconomic, psychological, psychosocial and economic problems.<sup>536-538</sup> An alternative approach is to select a particular intervention and implement

Deleted: 7

this in a population that is already under care; for example, patients attending for another clinical problem could be offered an asthma control assessment at that time.

Key outcomes and realistic targets should be identified, and the expected degree of change estimated (Box A6-5).

**Box A6-5 Potential key outcomes and targets to consider for implementation programs**

- Reduce asthma-related hospital admissions by 50% in the next 3 years<sup>15</sup>
- Reduce emergency attendances (hospital and primary care) by 50% in the next 3 years
- Reduce asthma mortality rates by 80% in the next 5 years
- Have asthma control assessed in >80% of patients in the targeted population
- Achieve good asthma control in >80% of the patient population
- Ensure that >80% of patients with poor asthma control have had their medication optimized
- Have written asthma action plans provided to >80% of patients with diagnosed asthma
- Reduce acute health care costs related to asthma by 50%

**Identify resources**

Local support of implementation initiatives is essential, and funding should be identified at the level of governments, funding agencies, medical or professional societies and industry.

**Set timelines**

A specific agenda should be established, with timelines for roll-out and assessment of interventions.

**Distribute tasks to members**

Participants should understand their assigned tasks and agree with the agenda. The process could start on a small scale with the most motivated people. Successes are a source of motivation for all, so it is helpful to initially select interventions with the highest chance of success and with an achievable timeframe for their implementation (e.g. 3–6 months). Involvement of participants and their performance should be monitored.

**Evaluate outcomes**

An important part of the implementation process is to establish a means of evaluating the effectiveness of the program and any improvements in quality of care. The Cochrane Effective Practice and Organization of Care Group (EPOC) offers suggestions on how to assess the effectiveness of interventions.<sup>532</sup>

Evaluation involves surveillance of traditional epidemiological parameters, such as morbidity and mortality, as well as specific audits of both process and outcome within different sectors of the health care system. Each country should determine its own minimum sets of data to audit health outcomes.

A variety of assessment tools are available to facilitate consistent and objective assessment of asthma morbidity and asthma control in the target population.<sup>183</sup> Recording the results of these assessments at each clinical visit can provide the clinician with a long-term record of a patient's response to their treatment. This type of direct feedback has several benefits. It is a means for the patient and health care provider to become familiar with good versus poor control of asthma (and to start to aim for the former); an indicator of changes in asthma control in response to changes in treatment; and a reference point against which deteriorating asthma can be evaluated. Use of administrative datasets (e.g. dispensing records) or urgent health care utilization can help to identify at-risk patients or to audit the quality of health care. A strategy that includes providing health care providers with direct feedback about specific health care results of their patients may be particularly important for general practitioners, who treat many diseases in addition to asthma, and thus could not be expected to know every guideline in detail.

Deleted: A7

Deleted: A7

Deleted: 7

7. Continuously review progress and results to determine if the strategy requires modification

Following the initial evaluation of outcomes of the implementation program, the working party should determine whether the strategies or initiatives need to be changed or improved. Methods should be established for ensuring that the intervention can be sustained, and individuals who will be responsible for ensuring its continuity should be identified, especially in terms of on-going financial and organizational support. Regular communications on the project's impact on asthma outcomes may help to maintain interest in the project and ensure continued resources.

ECONOMIC VALUE OF IMPLEMENTING MANAGEMENT RECOMMENDATIONS FOR ASTHMA CARE

Cost is recognized as an important barrier to the delivery of optimal evidence-based health care in almost every country, although its impact on patients' access to treatment varies widely both between and within countries. At the country or local level, health authorities make resource availability and allocation decisions that affect populations of asthma patients by considering the balance and trade-offs between costs and clinical outcomes (benefits and harms), often in the context of competing public health and medical needs. Treatment costs must also be explicitly considered at each consultation between health care provider and patient to assure that cost does not present a barrier to achieving good asthma control.<sup>533</sup> Thus, those involved in the adaptation and implementation of asthma guidelines require an understanding of both the cost and cost effectiveness of various management recommendations in asthma care.

GINA DISSEMINATION AND IMPLEMENTATION RESOURCES

Educational materials based on the *Global Strategy for Asthma Management and Prevention* are available in several forms and can be found on the GINA Website ([www.ginasthma.org](http://www.ginasthma.org)).

Deleted: [www](http://www.ginasthma.org)

Deleted: 7

## REFERENCES

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 2004;59:469-78.
2. Van Wonderen KE, Van Der Mark LB, Mohrs J, Bindels PJE, Van Aalderen WMC, Ter Riet G. Different definitions in childhood asthma: how dependable is the dependent variable? *Eur Respir J* 2010;36:48-56.
3. Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, International Study of A, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 2009;64:476-83.
4. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax* 2007;62:758-66.
5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* 2012;380:2163-96.
6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2013;380:2095-128.
7. Ernst R. Indirect costs and cost-effectiveness analysis. *Value Health* 2006;9:253-61.
8. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. *BMC Pulm Med* 2009;9:24.
9. Barnett SBL, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. *J Allergy Clin Immunol* 2011;127:145-52.
10. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, Shiboski S, et al. A comprehensive study of the direct and indirect costs of adult asthma. *J Allergy Clin Immunol* 2003;111:1212-8.
11. Ungar WJ, Coyte PC. Prospective study of the patient-level cost of asthma care in children. *Pediatr Pulmonol* 2001;32:101-8.
12. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, Eichler HG, et al. Asthma severity and medical resource utilisation. *Eur Respir J* 2004;23:723-9.
13. Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. *Eur Respir J* 2003;21:1000-6.
14. Braman SS. The global burden of asthma. *Chest* 2006;130:4S-12S.
15. Fitzgerald JM, Bateman E, Hurd S, Boulet LP, Haahtela T, Cruz AA, Levy ML. The GINA Asthma Challenge: reducing asthma hospitalisations. *Eur Respir J* 2011;38:997-8.
16. Williams SA, Wagner S, Kannan H, Bolge SC. The association between asthma control and health care utilization, work productivity loss and health-related quality of life. *J Occup Environ Med* 2009;51:780-5.
17. Hsu J, Qin X, Beavers SF, Mirabelli MC. Asthma-Related School Absenteeism, Morbidity, and Modifiable Factors. *Am J Prev Med* 2016;51:23-32.
18. Johns G. Attendance dynamics at work: the antecedents and correlates of presenteeism, absenteeism, and productivity loss. *J Occup Health Psychol* 2011;16:483-500.
19. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, Pirina P, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. *Int Arch Allergy Immunol* 2006;141:189-98.
20. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. *Am J Respir Crit Care Med* 2004;170:836-44.
21. Hancox RJ, Souëf PL, Anderson GP, Reddel HK, Chang A, Beasley R. Asthma - time to confront some inconvenient truths. *Respirology* 2010;15:194-201.
22. Busse WW, Lemanske RF, Jr. Asthma. *N Engl J Med* 2001;344:350-62.
23. Holgate ST. Genetic and environmental interaction in allergy and asthma. *J Allergy Clin Immunol* 1999;104:1139-46.
24. Ober C, Vercelli D. Gene-environment interactions in human disease: nuisance or opportunity? *Trends Genet* 2011;27:107-15.
25. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2019. Fontana, WI, USA GINA; 2019.
26. Ober C, Yao T-C. The genetics of asthma and allergic disease: a 21st century perspective. *Immunol Rev* 2011;242:10-30.

27. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, Himes BE, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. *Nature Genetics* 2011;43:887-92.
28. Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. *Curr Opin Allergy Clin Immunol* 2013;13:70-7.
29. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, et al. Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. *N Engl J Med* 1995;333:894-900.
30. Levin AM, Mathias RA, Huang L, Roth LA, Daley D, Myers RA, Himes BE, et al. A meta-analysis of genome-wide association studies for serum total IgE in diverse study populations. *J Allergy Clin Immunol* 2013;131:1176-84.
31. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, et al. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med* 2010;363:1211-21.
32. Daley D, Park JE, He JQ, Yan J, Akhabir L, Stefanowicz D, Becker AB, et al. Associations and interactions of genetic polymorphisms in innate immunity genes with early viral infections and susceptibility to asthma and asthma-related phenotypes. *J Allergy Clin Immunol* 2012;130:1284-93.
33. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet* 2004;364:1505-12.
34. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. *J Allergy Clin Immunol* 2006;117:522-43.
35. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. *J Clin Invest* 1997;99:1130-7.
36. Horwood LJ, Fergusson DM, Shannon FT. Social and familial factors in the development of early childhood asthma. *Pediatrics* 1985;75:859-68.
37. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995;332:133-8.
38. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005;26:948-68.
39. den Dekker HT, Sonnenschein-van der Voort AMM, de Jongste JC, Annessi-Maesano I, Arshad SH, Barros H, Beardsmore CS, et al. Early growth characteristics and the risk of reduced lung function and asthma: A meta-analysis of 25,000 children. *J Allergy Clin Immunol* 2016;137:1026-35.
40. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. *Am J Respir Crit Care Med* 2007;175:661-6.
41. Boulet LP. Asthma and obesity. *Clin Exp Allergy* 2013;43:8-21.
42. Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P, Lemiere C, et al. Overdiagnosis of asthma in obese and nonobese adults. *CMAJ* 2008;179:1121-31.
43. Gao YH, Zhao HS, Zhang FR, Gao Y, Shen P, Chen RC, Zhang GJ. The relationship between depression and asthma: A meta-analysis of prospective studies. *PLoS One* 2015;10:e0132424.
44. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. *N Engl J Med* 1990;323:502-7.
45. Wahn U, Lau S, Bergmann R, Kulig M, Forster J, Bergmann K, Bauer CP, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. *J Allergy Clin Immunol* 1997;99:763-9.
46. Hogaboam CM, Carpenter KJ, Schuh JM, Buckland KF. Aspergillus and asthma--any link? *Med Mycol* 2005;43 Suppl 1:S197-202.
47. Quansah R, Jaakkola MS, Hugg TT, Heikkinen SA, Jaakkola JJ. Residential dampness and molds and the risk of developing asthma: a systematic review and meta-analysis. *PLoS ONE [Electronic Resource]* 2012;7:e47526.
48. Huss K, Adkinson NF, Jr., Eggleston PA, Dawson C, Van Natta ML, Hamilton RG. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. *J Allergy Clin Immunol* 2001;107:48-54.
49. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. *N Engl J Med* 2003;349:1414-22.
50. Charpin D, Birnbaum J, Haddi E, Genard G, Lanteaume A, Toumi M, Faraj F, et al. Altitude and allergy to house-dust mites. A paradigm of the influence of environmental exposure on allergic sensitization. *Am Rev Respir Dis* 1991;143:983-6.

51. Sporik R, Ingram JM, Price W, Sussman JH, Honsinger RW, Platts-Mills TA. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon's breath. *Am J Respir Crit Care Med* 1995;151:1388-92.
52. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, Mitchell H, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *N Engl J Med* 1997;336:1356-63.
53. Gern JE, Reardon CL, Hoffman S, Nicolae D, Li Z, Roberg KA, Neaville WA, et al. Effects of dog ownership and genotype on immune development and atopy in infancy. *J Allergy Clin Immunol* 2004;113:307-14.
54. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. *JAMA* 2002;288:963-72.
55. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. *Lancet* 2001;357:752-6.
56. Celedon JC, Litonjua AA, Ryan L, Platts-Mills T, Weiss ST, Gold DR. Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life. *Lancet* 2002;360:781-2.
57. Melen E, Wickman M, Nordvall SL, van Hage-Hamsten M, Lindfors A. Influence of early and current environmental exposure factors on sensitization and outcome of asthma in pre-school children. *Allergy* 2001;56:646-52.
58. Almqvist C, Egmar AC, van Hage-Hamsten M, Berglund N, Pershagen G, Nordvall SL, Svartengren M, et al. Heredity, pet ownership, and confounding control in a population-based birth cohort. *J Allergy Clin Immunol* 2003;111:800-6.
59. Lodrup Carlsen KC, Roll S, Carlsen KH, Mowinckel P, Wijga AH, Brunekreef B, Torrent M, et al. Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data from 11 European birth cohorts. *PLoS One* 2012;7:e43214.
60. Rhodes HL, Sporik R, Thomas P, Holgate ST, Cogswell JJ. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. *J Allergy Clin Immunol* 2001;108:720-5.
61. Maslova E, Granstrom C, Hansen S, Petersen SB, Strom M, Willett WC, Olsen SF. Peanut and tree nut consumption during pregnancy and allergic disease in children-should mothers decrease their intake? Longitudinal evidence from the Danish National Birth Cohort. *J Allergy Clin Immunol* 2012;130:724-32.
62. Rochat MK, Illi S, Ege MJ, Lau S, Keil T, Wahn U, von Mutius E. Allergic rhinitis as a predictor for wheezing onset in school-aged children. *J Allergy Clin Immunol* 2010;126:1170-5 e2.
63. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, Wjst M, et al. Rhinitis and onset of asthma: a longitudinal population-based study. *Lancet* 2008;372:1049-57.
64. Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, Larenas-Linnemann D, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. *Pediatr Allergy Immunol* 2017;28:18-29.
65. Baur X, Sigsgaard T, Aasen TB, Burge PS, Heederik D, Henneberger P, Maestrelli P, et al. Guidelines for the management of work-related asthma.[Erratum appears in *Eur Respir J*. 2012 Jun;39(6):1553]. *Eur Respir J* 2012;39:529-45.
66. Chan-Yeung M, Malo J-L, Bernstein DI. Occupational asthma. In: Malo JL, Chan-Yeung M, Bernstein DI, eds. *Asthma in the workplace*, 4th edition. Boca Raton, FL CRC Press; 2013.
67. Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K, Mapp C, Milton D, et al. American Thoracic Society Statement: Occupational contribution to the burden of airway disease. *Am J Respir Crit Care Med* 2003;167:787-97.
68. Sastre J, Vandenplas O, Park HS. Pathogenesis of occupational asthma. *Eur Respir J* 2003;22:364-73.
69. Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. *J Allergy Clin Immunol* 2009;123:531-42.
70. Labrecque M. Irritant-induced asthma. *Curr Opin Allergy Clin Immunol* 2012;12:140-4.
71. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax* 2010;65:1045-52.
72. Sly PD, Kusel M, Holt PG. Do early-life viral infections cause asthma? *J Allergy Clin Immunol* 2010;125:1202-5.
73. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999;354:541-5.
74. Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med* 2008;178:667-72.
75. Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, Sly PD. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin Immunol* 2007;119:1105-10.



76. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, Gern JE, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. *Am J Respir Crit Care Med* 2012;185:281-5.
77. Caliskan M, Bochkov YA, Kreiner-Moller E, Bonnelykke K, Stein MM, Du G, Bisgaard H, et al. Rhinovirus Wheezing Illness and Genetic Risk of Childhood-Onset Asthma. *N Engl J Med* 2013.
78. Bisgaard H, Hermansen MN, Bonnelykke K, Stokholm J, Baty F, Skytt NL, Aniscenko J, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. *BMJ* 2010;341:c4978.
79. Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. *Am J Respir Crit Care Med* 2006;174:514-23.
80. Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. *N Engl J Med* 2000;343:538-43.
81. de Meer G, Janssen NA, Brunekreef B. Early childhood environment related to microbial exposure and the occurrence of atopic disease at school age. *Allergy* 2005;60:619-25.
82. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C, Wahn U. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. *BMJ* 2001;322:390-5.
83. Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. *Pediatrics* 2012;129:950-60.
84. Roduit C, Scholtens S, de Jongste JC, Wijga AH, Gerritsen J, Postma DS, Brunekreef B, et al. Asthma at 8 years of age in children born by caesarean section. *Thorax* 2009;64:107-13.
85. Azad MB, Konya T, Maughan H, Guttman DS, Field CJ, Chari RS, Sears MR, et al. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. *CMAJ* 2013;185:385-94.
86. Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: Systematic review and meta-analysis. *PLoS Med* 2018;15:e1002494.
87. Braun-Fahrlander C. Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. *Curr Opin Allergy Clin Immunol* 2003;3:325-9.
88. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, Heederik D, et al. Exposure to environmental microorganisms and childhood asthma. *N Engl J Med* 2011;364:701-9.
89. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. *BMJ* 2002;324:763.
90. Murray CS, Poletti G, Kebabdz T, Morris J, Woodcock A, Johnston SL, Custovic A. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. *Thorax* 2006;61:376-82.
91. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, Gruchalla RS, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. *Am J Respir Crit Care Med* 2017;196:985-92.
92. Poyser MA, Nelson H, Ehrlich RI, Bateman ED, Parnell S, Puterman A, Weinberg E. Socioeconomic deprivation and asthma prevalence and severity in young adolescents. *Eur Respir J* 2002;19:892-8.
93. Aligne CA, Auinger P, Byrd RS, Weitzman M. Risk factors for pediatric asthma. Contributions of poverty, race, and urban residence. *Am J Respir Crit Care Med* 2000;162:873-7.
94. Braback L, Hjert A, Rasmussen F. Social class in asthma and allergic rhinitis: a national cohort study over three decades. *Eur Respir J* 2005;26:1064-8.
95. Alcantara-Neves NM, Veiga RV, Dattoli VC, Fiaccone RL, Esquivel R, Cruz AA, Cooper PJ, et al. The effect of single and multiple infections on atopy and wheezing in children. *J Allergy Clin Immunol* 2012;129:359-67, 67.e1-3.
96. Barreto ML, Cunha SS, Fiaccone R, Esquivel R, Amorim LD, Alvim S, Prado M, et al. Poverty, dirt, infections and non-atopic wheezing in children from a Brazilian urban center. *Respir Res* 2010;11:167.
97. Wade S, Weil C, Holden G, Mitchell H, Evans R, 3rd, Kruszon-Moran D, Bauman L, et al. Psychosocial characteristics of inner-city children with asthma: a description of the NCICAS psychosocial protocol. National Cooperative Inner-City Asthma Study. *Pediatr Pulmonol* 1997;24:263-76.
98. Klinnert MD, Nelson HS, Price MR, Adinoff AD, Leung DY, Mrazek DA. Onset and persistence of childhood asthma: predictors from infancy. *Pediatrics* 2001;108:E69.
99. Kozyrskyj AL, Mai XM, McGrath P, Hayglass KT, Becker AB, Macneil B. Continued exposure to maternal distress in early life is associated with an increased risk of childhood asthma. *Am J Respir Crit Care Med* 2008;177:142-7.
100. Dreger LC, Kozyrskyj AL, HayGlass KT, Becker AB, MacNeil BJ. Lower cortisol levels in children with asthma exposed to recurrent maternal distress from birth. *J Allergy Clin Immunol* 2010;125:116-22.
101. Burke H, Leonardi-Bee J, Hashim A, Pine-Abata H, Chen Y, Cook DG, Britton JR, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. *Pediatrics* 2012;129:735-44.

102. Dezateux C, Stocks J, Dundas I, Fletcher ME. Impaired airway function and wheezing in infancy: the influence of maternal smoking and a genetic predisposition to asthma. *Am J Respir Crit Care Med* 1999;159:403-10.
103. Kulig M, Luck W, Lau S, Niggemann B, Bergmann R, Klettke U, Guggenmoos-Holzmann I, et al. Effect of pre- and postnatal tobacco smoke exposure on specific sensitization to food and inhalant allergens during the first 3 years of life. Multicenter Allergy Study Group, Germany. *Allergy* 1999;54:220-8.
104. Nafstad P, Kongerud J, Botten G, Hagen JA, Jaakkola JJ. The role of passive smoking in the development of bronchial obstruction during the first 2 years of life. *Epidemiology* 1997;8:293-7.
105. Environmental tobacco smoke: a hazard to children. American Academy of Pediatrics Committee on Environmental Health. *Pediatrics* 1997;99:639-42.
106. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. *N Engl J Med* 1998;339:1194-200.
107. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. *Thorax* 2002;57:226-30.
108. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. *Am J Respir Crit Care Med* 2007;175:783-90.
109. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. *Am J Respir Crit Care Med* 2003;168:1308-11.
110. Boulet LP, FitzGerald JM, McIvor RA, Zimmerman S, Chapman KR. Influence of current or former smoking on asthma management and control. *Can Respir J* 2008;15:275-9.
111. Westerhof GA, de Groot JC, Amelink M, de Nijs SB, Ten Brinke A, Weersink EJ, Bel EH. Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma. *Respir Med* 2016;118:122-7.
112. Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane K, McConnell R, et al. The effect of air pollution on lung development from 10 to 18 years of age. *N Engl J Med* 2004;351:1057-67.
113. Wong GW, Lai CK. Outdoor air pollution and asthma. *Curr Opin Pulm Med* 2004;10:62-6.
114. Zheng XY, Ding H, Jiang LN, Chen SW, Zheng JP, Qiu M, Zhou YX, et al. Association between air pollutants and asthma emergency room visits and hospital admissions in time series studies: A systematic review and meta-analysis. *PLoS One* 2015;10:e0138146.
115. Lim H, Kwon HJ, Lim JA, Choi JH, Ha M, Hwang SS, Choi WJ. Short-term Effect of Fine Particulate Matter on Children's Hospital Admissions and Emergency Department Visits for Asthma: A Systematic Review and Meta-analysis. *J Prev Med Public Health* 2016;49:205-19.
116. Breyse PN, Diette GB, Matsui EC, Butz AM, Hansel NN, McCormack MC. Indoor air pollution and asthma in children. *Proc Am Thorac Soc* 2010;7:102-6.
117. Khreis H, Kelly C, Tate J, Parslow R, Lucas K, Nieuwenhuijsen M. Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. *Environ Int* 2017;100:1-31.
118. Bowatte G, Lodge C, Lowe AJ, Erbas B, Perret J, Abramson MJ, Matheson M, et al. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. *Allergy* 2015;70:245-56.
119. Hehua Z, Qing C, Shanyan G, Qijun W, Yuhong Z. The impact of prenatal exposure to air pollution on childhood wheezing and asthma: A systematic review. *Environ Res* 2017;159:519-30.
120. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, Workman L, Sordillo JE, Camargo CA, Jr., Gillman MW, et al. Peanut, milk, and wheat intake during pregnancy is associated with reduced allergy and asthma in children. *J Allergy Clin Immunol* 2014;133:1373-82.
121. Maslova E, Strom M, Oken E, Campos H, Lange C, Gold D, Olsen SF. Fish intake during pregnancy and the risk of child asthma and allergic rhinitis - longitudinal evidence from the Danish National Birth Cohort. *Br J Nutr* 2013;110:1313-25.
122. Forno E, Young OM, Kumar R, Simhan H, Cledon JC. Maternal obesity in pregnancy, gestational weight gain, and risk of childhood asthma. *Pediatrics* 2014;134:e535-46.
123. Friedman NJ, Zeiger RS. The role of breast-feeding in the development of allergies and asthma. *J Allergy Clin Immunol* 2005;115:1238-48.
124. Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. *J Allergy Clin Immunol* 2005;115:1109-17.
125. Best KP, Gold M, Kennedy D, Martin J, Makrides M. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Am J Clin Nutr* 2016;103:128-43.
126. Bisgaard H, Stokholm J, Chawes BL, Vissing NH, Bjarnadottir E, Schoos AM, Wolsk HM, et al. Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring. *N Engl J Med* 2016;375:2530-9.

127. Nurmatov U, Devereux G, Sheikh A. Nutrients and foods for the primary prevention of asthma and allergy: systematic review and meta-analysis. *J Allergy Clin Immunol* 2011;127:724-33.e1-30.
128. Chawes BL, Bonnelykke K, Stokholm J, Vissing NH, Bjarnadottir E, Schoos AM, Wolsk HM, et al. Effect of vitamin D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: A randomized clinical trial. *Jama* 2016;315:353-61.
129. Litonjua AA, Carey VJ, Laranjo N, Harshfield BJ, McElrath TF, O'Connor GT, Sandel M, et al. Effect of prenatal supplementation with Vitamin D on asthma or recurrent wheezing in offspring by age 3 years: The VDAART randomized clinical trial. *Jama* 2016;315:362-70.
130. Cheelo M, Lodge CJ, Dharmage SC, Simpson JA, Matheson M, Heinrich J, Lowe AJ. Paracetamol exposure in pregnancy and early childhood and development of childhood asthma: a systematic review and meta-analysis. *Arch Dis Child* 2015;100:81-9.
131. Eyers S, Weatherall M, Jefferies S, Beasley R. Paracetamol in pregnancy and the risk of wheezing in offspring: a systematic review and meta-analysis. *Clin Exp Allergy* 2011;41:482-9.
132. Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Allen KJ, Robertson CF, Axelrad C, et al. Paracetamol use in early life and asthma: prospective birth cohort study. *BMJ (Clinical Research Ed)* 2010;341:c4616.
133. Andersen AB, Farkas DK, Mehnert F, Ehrenstein V, Erichsen R. Use of prescription paracetamol during pregnancy and risk of asthma in children: a population-based Danish cohort study. *Clin Epidemiol* 2012;4:33-40.
134. Migliore E, Zugna D, Galassi C, Merletti F, Gagliardi L, Rasero L, Trevisan M, et al. Prenatal Paracetamol Exposure and Wheezing in Childhood: Causation or Confounding? *PLoS One* 2015;10:e0135775.
135. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. *Lancet* 2008;372:1107-19.
136. Eder W, Ege MJ, von Mutius E. The asthma epidemic. *N Engl J Med* 2006;355:2226-35.
137. Drazen JM. Asthma: the paradox of heterogeneity. *J Allergy Clin Immunol* 2012;129:1200-1.
138. Bel EH. Clinical phenotypes of asthma. *Curr Opin Pulm Med* 2004;10:44-50.
139. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012;18:716-25.
140. Levine SJ, Wenzel SE. Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. *Ann Intern Med* 2010;152:232-7.
141. Galli SJ, Tsai M. IgE and mast cells in allergic disease. *Nat Med* 2012;18:693-704.
142. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. *Nat Rev Immunol* 2013;13:9-22.
143. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. *N Engl J Med* 2009;360:985-93.
144. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009;360:973-84.
145. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. *Nat Rev Immunol* 2010;10:838-48.
146. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. *Lancet* 2010;376:835-43.
147. Yang M, Kumar RK, Hansbro PM, Foster PS. Emerging roles of pulmonary macrophages in driving the development of severe asthma. *J Leukoc Biol* 2012;91:557-69.
148. Macdowell AL, Peters SP. Neutrophils in asthma. *Curr Allergy Asthma Rep* 2007;7:464-8.
149. Barnes PJ. Pathophysiology of allergic inflammation. *Immunol Rev* 2011;242:31-50.
150. Scanlon ST, McKenzie AN. Type 2 innate lymphoid cells: new players in asthma and allergy. *Curr Opin Immunol* 2012;24:707-12.
151. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. *Pharmacol Rev* 1998;50:515-96.
152. Fanta CH. Asthma. *N Engl J Med* 2009;360:1002-14.
153. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* 2008;118:3546-56.
154. Nelson HS. Prospects for antihistamines in the treatment of asthma. *J Allergy Clin Immunol* 2003;112:S96-100.
155. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. *Chest* 2010;138:682-92.
156. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. *J Allergy Clin Immunol* 2011;128:451-62.
157. Lotvall J, Akdis CA, Bacharier LB, Bjerner L, Casale TB, Custovic A, Lemanske RF, Jr., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunology* 2011;127:355-60.

158. Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, et al. Effect of bronchoconstriction on airway remodeling in asthma. *N Engl J Med* 2011;364:2006-15.
159. Duong HT, Erzurum SC, Asosingh K. Pro-angiogenic hematopoietic progenitor cells and endothelial colony-forming cells in pathological angiogenesis of bronchial and pulmonary circulation. *Angiogenesis* 2011;14:411-22.
160. Fahy JV, Dickey BF. Airway mucus function and dysfunction. *N Engl J Med* 2010;363:2233-47.
161. Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases. *Allergy* 2004;59:1139-52.
162. Mazenq J, Dubus JC, Gaudart J, Charpin D, Viudes G, Noel G. City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach. *Respir Med* 2017;132:1-8.
163. Marks GB, Colquhoun JR, Girgis ST, Koski MH, Treloar AB, Hansen P, Downs SH, et al. Thunderstorm outflows preceding epidemics of asthma during spring and summer. *Thorax* 2001;56:468-71.
164. Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, Bardin PG, et al. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. *The Lancet Planetary Health* 2018;2:e255-e63.
165. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. *J Allergy Clin Immunology* 2010;125:1178-87.
166. Greenberg H, Cohen RI. Nocturnal asthma. *Curr Opin Pulm Med* 2012;18:57-62.
167. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, Chung KF. Parameters associated with persistent airflow obstruction in chronic severe asthma. *Eur Respir J* 2004;24:122-8.
168. Lange P, Celli B, Agusti A, Boje Jensen G, Divo M, Faner R, Guerra S, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Engl J Med* 2015;373:111-22.
169. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2013;131:636-45.
170. Wenzel S. Severe asthma in adults. *Am J Respir Crit Care Med* 2005;172:149-60.
171. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. *Eur Respir J* 2004;24:822-33.
172. Hallstrand TS. New insights into pathogenesis of exercise-induced bronchoconstriction. *Curr Opin Allergy Clin Immunol* 2012;12:42-8.
173. Farooque SP, Lee TH. Aspirin-sensitive respiratory disease. *Annu Rev Physiol* 2009;71:465-87.
174. Kerstjens HA, Brand PL, de Jong PM, Koeter GH, Postma DS. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. *Thorax* 1994;49:1109-15.
175. Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. *Thorax* 1999;54:103-7.
176. Killian KJ, Watson R, Otis J, St Amand TA, O'Byrne PM. Symptom perception during acute bronchoconstriction. *Am J Respir Crit Care Med* 2000;162:490-6.
177. Miller MR, Hankinson J, Brusasco V, Burgos F, Casapuri R, Coates A, Crapo R, et al. Standardisation of spirometry. *Eur Respir J* 2005;26:319-38.
178. Tse SM, Gold DR, Sordillo JE, Hoffman EB, Gillman MW, Rifas-Shiman SL, Fuhlbrigge AL, et al. Diagnostic accuracy of the bronchodilator response in children. *J Allergy Clin Immunol* 2013;132:554-9.e5.
179. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40:1324-43.
180. Eid N, Yandell B, Howell L, Eddy M, Sheikh S. Can peak expiratory flow predict airflow obstruction in children with asthma? *Pediatrics* 2000;105:354-8.
181. Reddel HK, Marks GB, Jenkins CR. When can personal best peak flow be determined for asthma action plans? *Thorax* 2004;59:922-4.
182. Siersted HC, Hansen HS, Hansen NC, Hyldebrandt N, Mostgaard G, Oxhøj H. Evaluation of peak expiratory flow variability in an adolescent population sample. The Odense Schoolchild Study. *Am J Respir Crit Care Med* 1994;149:598-603.
183. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009;180:59-99.
184. Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? *Am J Respir Crit Care Med* 1995;151:1320-5.
185. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. *Thorax* 1992;47:162-6.

186. Boezen HM, Schouten JP, Postma DS, Rijcken B. Distribution of peak expiratory flow variability by age, gender and smoking habits in a random population sample aged 20-70 yrs. *Eur Respir J* 1994;7:1814-20.
187. Gannon PFG, Newton DT, Pantin CFA, Burge PS. Effect of the number of peak expiratory flow readings per day on the estimation of diurnal variation. *Thorax* 1998;53:790-2.
188. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. *Thorax* 2004;59:94-9.
189. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, et al. Guidelines for methacholine and exercise challenge testing-1999. *Am J Respir Crit Care Med* 2000;161:309-29.
190. Parsons JP, Hallstrand TS, Mastrorade JG, Kaminsky DA, Rundell KW, Hull JH, Storms WW, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. *Am J Respir Crit Care Med* 2013;187:1016-27.
191. Boulet LP. Asymptomatic airway hyperresponsiveness: a curiosity or an opportunity to prevent asthma? *Am J Respir Crit Care Med* 2003;167:371-8.
192. Pizzichini MM, Popov TA, Efthimiadis A, Hussack P, Evans S, Pizzichini E, Dolovich J, et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. *Am J Respir Crit Care Med* 1996;154:866-9.
193. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. *Eur Respir J* 2002;20:1s-52s.
194. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. *Am J Respir Crit Care Med* 2000;161:64-72.
195. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, Koskela H, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. *Am J Respir Crit Care Med* 2001;163:406-12.
196. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, Craig TJ, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. *J Allergy Clin Immunol* 2005;115:720-7.
197. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax* 2012;67:199-208.
198. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, Bel EH, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. *Lancet Respir Med* 2015;3:290-300.
199. Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Longitudinal relationship between sputum eosinophils and exhaled nitric oxide in children with asthma. *Am J Respir Crit Care Med* 2013;188:400-2.
200. Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, et al. Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study. *Respir Res* 2016;17:43.
201. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin A-C, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011;184:602-15.
202. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database Syst Rev* 2016;11:CD011439.
203. Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. *Cochrane Database Syst Rev* 2016;9:CD011440.
204. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for Asthma Treatment Algorithm studies. *Clin Exp Allergy* 2009;39:478-90.
205. American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. *Am J Respir Crit Care Med* 2005;171:912-30.
206. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. *Eur Respir J* 2014;43:343-73.
207. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, Sicherer S, et al. Allergy diagnostic testing: an updated practice parameter. *Ann Allergy Asthma Immunol* 2008;100:S1-148.
208. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. *Respir Med* 2011;105:930-8.
209. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. *Lancet* 2011;377:1032-45.

210. Postma DS, Kaplan A, Soriano JB, Grigg J, Guilbert TW, van Aalderen W, Roche N, et al. Cohort Analysis of Exacerbation Rates in Adolescent and Adult Patients Initiating Inhaled Corticosteroids for Asthma: Different Dose–Response Profile by Particle Size. *Pulmonary Therapy* 2017;3:113-24.
211. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, Suarez EA, Stempel D, Everard ML, Barnes N. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. *BMC Pulm Med* 2017;17:31.
212. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaildone GC, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* 2005;127:335-71.
213. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CG, Postma DS, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. *Eur Respir J* 1999;14:1038-43.
214. Juniper EF, Kline PA, Vanzieleghe MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. *Am Rev Respir Dis* 1990;142:832-6.
215. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N Engl J Med* 1997;337:1405-11.
216. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. *Am J Respir Crit Care Med* 2001;164(8 Pt 1):1392-7.
217. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. *Cochrane Database Syst Rev* 2005;CD002738.
218. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet* 2003;361:1071-6.
219. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med* 2000;343:332-6.
220. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. *N Engl J Med* 2000;343:1054-63.
221. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. *Am Rev Respir Dis* 1992;145:890-9.
222. Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, Erwin PJ, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin Immunol* 2013;131:724-9.
223. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. *Eur Respir J* 2007;30:452-6.
224. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. *Am J Respir Crit Care Med* 2009;179:19-24.
225. Raissy HH, Kelly HW, Harkins M, Szeffler SJ. Inhaled corticosteroids in lung diseases. *Am J Respir Crit Care Med* 2013;187:798-803.
226. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. *Respir Med* 2006;100:1297-306.
227. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. *Chest* 2002;121:1824-32.
228. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. *Med J Aust* 2003;178:223-5.
229. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. *Lancet* 2003;361:1071-6.
230. Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. *Lancet* 2017;389:157-66.
231. Szeffler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol* 2002;109:410-8.

232. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med* 2008;178:218-24.
233. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. *Allergy* 2006;61:518-26.
234. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. *Chest* 2004;126:213-9.
235. Shen TC, Chang PY, Lin CL, Wei CC, Tu CY, Hsia TC, Shih CM, et al. Risk of periodontal disease in patients with asthma: a nationwide population-based retrospective cohort study. *J Periodontol* 2017;88:723-30.
236. Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. *Curr Opin Pulm Med* 2012;18:85-9.
237. Hagan JB, Samant SA, Volcheck GW, Li JT, Hagan CR, Erwin PJ, Rank MA. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. *Allergy* 2014;69:510-6.
238. Foster JM, Aucott L, van der Werf RH, van der Meijden MJ, Schraa G, Postma DS, van der Molen T. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. *Respir Med* 2006;100:1318-36.
239. Foster JM, van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, van der Molen T. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. *Respir Res* 2006;7:131.
240. Mak VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. *Eur Respir J* 1992;5:1068-74.
241. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. *Thorax* 1993;48:233-8.
242. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med* 1999;159:941-55.
243. Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. *Eur Respir J* 2013;42:79-86.
244. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. *Am J Respir Crit Care Med* 1998;157:827-32.
245. Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis. *J Clin Endocrinol Metab* 2015;100:2171-80.
246. Weatherall M, James K, Clay J, Perrin K, Masoli M, Wijesinghe M, Beasley R. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. *Clin Exp Allergy* 2008;38:1451-8.
247. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. *N Engl J Med* 1997;337:8-14.
248. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. *JAMA* 1997;277:722-7.
249. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. *Eur Respir J* 2006;27:1168-74.
250. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. *Eur Respir J* 1998;12:130-5.
251. Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. *Lancet* 1993;342:776-8.
252. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. *Pulm Pharmacol Ther* 2010;23:65-70.
253. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. *Am J Respir Crit Care Med* 2011;183:675-8.
254. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. *Thorax* 2013;68:1105-13.
255. Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. *Pediatr Infect Dis J* 2000;19:215-8.
256. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. *Chest* 2013;144:1788-94.
257. O'Byrne PM, Pedersen S, Carlsson L-G, Radner F, Thoren A, Peterson S, Ernst P, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. *Am J Respir Crit Care Med* 2011;183:589-95.
258. Cazeiro C, Silva C, Mayer S, Mariani V, Wainwright CE, Zhang L. Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis. *Pediatrics* 2017;139.

259. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. *N Engl J Med* 2018;378:1865-76.
260. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. *N Engl J Med* 2018;378:1877-87.
261. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. *Lancet Respir Med* 2013;1:23-31.
262. Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, Blake KV, et al. Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. *JAMA* 2018;319:1485-96.
263. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2013;4:CD007313.
264. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. *Lancet* 1994;344:219-24.
265. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, Malo JL, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. *Am Rev Respir Dis* 1991;144:622-5.
266. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. *N Engl J Med* 1992;327:1420-5.
267. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). *BMJ* 2000;320:1368-73.
268. Wenzel SE, Lumry W, Manning M, Kalberg C, Cox F, Emmett A, Rickard K. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. *Ann Allergy Asthma Immunol* 1998;80:463-70.
269. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med* 1996;153:1481-8.
270. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults and children. *Cochrane Database System Rev* 2009;CD005307.
271. Peters SP, Bleeker ER, Canonica GW, Park YB, Ramirez R, Hollis S, Fjallbrant H, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. *N Engl J Med* 2016;375:850-60.
272. Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. *N Engl J Med* 2016;374:1822-30.
273. Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting beta2-agonists. *N Engl J Med* 2018;378:2497-505.
274. Main C, Shepherd J, Anderson R, Rogers G, Thompson-Coon J, Liu Z, Hartwell D, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. *Health Technology Assessment (Winchester, England)* 2008;12:1-174, iii-iv.
275. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. *J Allergy Clin Immunol* 2004;113:245-51.
276. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, et al. Overall asthma control: the relationship between current control and future risk. *J Allergy Clin Immunol* 2010;125:600-8.
277. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. *Eur Respir J* 2018;51.
278. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Laloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. *Lancet* 2006;368:744-53.
279. Demoly P, Louis R, Soes-Petersen U, Naya I, Carlsheimer A, Worth H, Almeida J, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. *Respir Med* 2009;103:1623-32.
280. Nelson JA, Strauss L, Skowronski M, Ciufu R, Novak R, McFadden ER, Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. *N Engl J Med* 1998;339:141-6.



281. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. *Pediatrics* 1997;99:655-9.
282. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. *Eur Respir J* 1997;10:2484-9.
283. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. *Eur Respir J* 1996;9:1684-8.
284. Tattersfield AE, Lofdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, Ekstrom T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. *Lancet* 2001;357:257-61.
285. Lazarinis N, Jørgensen L, Ekström T, Bjerner L, Dahlén B, Pullerits T, Hedlin G, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. *Thorax* 2014;69:130-6.
286. Anderson GP. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. *Clin Rev Allergy Immunol* 2006;31:119-30.
287. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129:15-26.
288. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr., Sorkness CA, Kraft M, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. *JAMA* 2001;285:2583-93.
289. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. *Cochrane Database Syst Rev* 2013;6:CD006924.
290. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. *Cochrane Database Syst Rev* 2013;3:CD006922.
291. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. *Ann Intern Med* 2008;149:33-42.
292. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. *Am J Respir Crit Care Med* 2008;178:1009-16.
293. Hernandez G, Avila M, Pont A, Garin O, Alonso J, Laforest L, Cates CJ, et al. Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies. *Respir Res* 2014;15:83.
294. Martinez FD. Safety of fluticasone plus salmeterol in asthma--reassuring data, but no final answer. *N Engl J Med* 2016;374:1887-8.
295. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. *Lancet* 2007;370:2118-25.
296. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. *Lancet* 2009;374:1754-64.
297. Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. *J Asthma* 2002;39:291-7.
298. Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. *Ann Intern Med* 2015;163:756-67.
299. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med* 1998;339:147-52.
300. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, Reiss TF. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. *Eur Respir J* 1998;11:1232-9.
301. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. *Arch Intern Med* 1998;158:1213-20.
302. Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, Mastalerz L, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. *Am J Respir Crit Care Med* 1998;157:1187-94.

303. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. *Cochrane Database Syst Rev* 2012;5:CD002314.
304. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. *BMJ* 1999;319:87-90.
305. Chauhan BF, Jeyaraman MM, Singh Mann A, Lys J, Abou-Setta AM, Zarychanski R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. *Cochrane Database Syst Rev* 2017;3:CD010347.
306. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. *Cochrane Database Syst Rev* 2014;1:CD003137.
307. Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. *Drug Saf* 2007;30:805-15.
308. Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). *Pharmacoepidemiol Drug Saf* 2007;16:620-6.
309. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. *J Allergy Clin Immunol* 2012;130:368-75.
310. Guevara JP, Ducharme FM, Keren R, Nihtianova S, Zorc J. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. *Cochrane Database Syst Rev* 2006:CD003558.
311. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *N Engl J Med* 2010;363:1715-26.
312. Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, Nething K, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. *Respir Med* 2014;108:1268-76.
313. Kerstjens HA, Disse B, Schroder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. *J Allergy Clin Immunol* 2011;128:308-14.
314. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med* 2012;367:1198-207.
315. Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis. *Chest* 2015;147:388-96.
316. Bateman ED, Kornmann O, Schmidt P, Pivovarov A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. *J Allergy Clin Immunol* 2011;128:315-22.
317. Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. *Cochrane Database Syst Rev* 2015:CD011438.
318. Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: A systematic review and meta-analysis. *JAMA* 2018;319:1473-84.
319. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. *Cochrane Database Syst Rev* 2014;1:CD003559.
320. Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. *Pediatr Allergy Immunol* 2015;26:551-6.
321. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients - Diagnosis and Management. A GINA Pocket Guide for Health Professionals V2.0. Fontana, WI, USA: GINA; 2019.
322. Alhossan A, Lee CS, MacDonald K, Abraham I. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. *J Allergy Clin Immunol Pract* 2017;5:1362-70.e2.
323. Zazzali JL, Raimundo KP, Trzaskoma B, Rosen KE, Schatz M. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. *Allergy Asthma Proc* 2015;36:283-92.
324. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med* 2013;187:804-11.
325. Casale TB, Chipps BE, Rosen K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. *Allergy* 2018;73:490-7.
326. Molimard M, Mala L, Bourdeix I, Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. *Respir Med* 2014;108:571-6.

327. Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosen K, Chipps BE, Luskin AT, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. *J Allergy Clin Immunol* 2017;140:162-9.e2.
328. Rivero A, Liang J. Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: A systematic review and meta-analysis. *Ann Otol Rhinol Laryngol* 2017;126:739-47.
329. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Jr., Calatroni A, Wildfire JJ, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. *J Allergy Clin Immunol* 2015;136:1476-85.
330. Pike KC, Akhbari M, Kneale D, Harris KM. Interventions for autumn exacerbations of asthma in children. *Cochrane Database Syst Rev* 2018;3:CD012393.
331. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med* 2011;364:1005-15.
332. Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. *J Allergy Clin Immunol* 2014;134:560-7.e4.
333. Iribarren C, Rahmaoui A, Long AA, Szefer SJ, Bradley MS, Carrigan G, Eisner MD, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. *J Allergy Clin Immunol* 2017;139:1489-95.e5.
334. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. *Clin Exp Allergy* 2009;39:788-97.
335. Ortega HG, Liu MC, Pavord ID. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014;371.
336. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012;380:651-9.
337. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. *Lancet Respir Med* 2016;4:549-56.
338. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Yancey SW, Ortega HG, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014;371:1189-97.
339. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. *Cochrane Database Syst Rev* 2017;9:CD010834.
340. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. *Pulm Pharmacol Ther* 2017;43:39-45.
341. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet* 2016;388:2115-27.
342. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2016;388:2128-41.
343. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med* 2017;376:2448-58.
344. Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2017;5:568-76.
345. Simpson EL, Akinlade B, Ardeleanu M. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med* 2017;376:1090-1.
346. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *The New England journal of medicine* 2018;378:2486-96.
347. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018;378:2475-85.
348. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. *Jama* 2016;315:469-79.
349. Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults with chronic asthma. *Cochrane Database Syst Rev* 2000;2.
350. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. *J Allergy Clin Immunol* 1989;84:688-700.

351. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database Syst Rev* 2007;CD000195.
352. O'Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. *Lancet* 1993;341:324-7.
353. Lederle FA, Pluhar RE, Joseph AM, Niewoehner DE. Tapering of corticosteroid therapy following exacerbation of asthma. A randomized, double-blind, placebo-controlled trial. *Arch Intern Med* 1987;147:2201-3.
354. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. *Lancet* 1986;1:181-4.
355. Rehrer MW, Liu B, Rodriguez M, Lam J, Alter HJ. A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma. *Ann Emerg Med* 2016;68:608-13.
356. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res* 2010;62:1515-26.
357. Guillevin L, Pagnoux C, Mouthon L. Churg-strauss syndrome. *Semin Respir Crit Care Med* 2004;25:535-45.
358. Kew KM, Undela K, Kotorsi I, Ferrara G. Macrolides for chronic asthma. *Cochrane Database Syst Rev* 2015;Cd002997.
359. Albert RK, Schuller JL, for the COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. *Am J Respir Crit Care Med* 2014;189:1173-80.
360. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, Verleden G, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. *Thorax* 2013;68:322-9.
361. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet* 2017;390:659-68.
362. Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. *Cochrane Database Syst Rev* 2010;CD008418.
363. Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. *BMJ open* 2017;7:e016688.
364. Anonymous. Using beta 2-stimulants in asthma. *Drug Ther Bull* 1997;35:1-4.
365. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. *Thorax* 2002;57:880-4.
366. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Selroos O, Sovijarvi A, et al. Comparison of a b2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. *N Engl J Med* 1991;325:388-92.
367. Stanford RH, Shah MB, D'Souza AO, Dhamane AD, Schatz M. Short-acting  $\beta$ -agonist use and its ability to predict future asthma-related outcomes. *Annals of Allergy, Asthma & Immunology* 2012;109:403-7.
368. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockcroft D, Blais L, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. *Am J Respir Crit Care Med* 1994;149:604-10.
369. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. *Thorax* 2005;60:740-6.
370. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. *Cochrane Database Syst Rev* 2013;8:CD000060.
371. Barnes PJ. Theophylline. *Am J Respir Crit Care Med* 2013;188:901-6.
372. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. *N Engl J Med* 1997;337:1412-8.
373. Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, Day A, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. *Am J Respir Crit Care Med* 1995;151:325-32.
374. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. *Eur Respir J* 1997;10:2754-60.
375. Baba K, Sakakibara A, Yagi T, Niwa S, Hattori T, Koishikawa I, Yoshida K, et al. Effects of theophylline withdrawal in well-controlled asthmatics treated with inhaled corticosteroid. *J Asthma* 2001;38:615-24.
376. Tee AK, Koh MS, Gibson PG, Lasserson TJ, Wilson AJ, Irving LB. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. *Cochrane Database Syst Rev* 2007;CD001281.

377. Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta(2)-agonists in adults with acute asthma. *Cochrane Database Syst Rev* 2012;12:CD002742.
378. Ahn HC, Lee YC. The clearance of theophylline is increased during the initial period of tuberculosis treatment. *Int J Tuberc Lung Dis* 2003;7:587-91.
379. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. *Eur Respir J* 1997;10:2216-24.
380. Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. *Respir Med* 1998;92:1059-65.
381. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. *Chest* 1997;112:29-33.
382. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. *Cochrane Database Syst Rev* 2000;2.
383. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. *Am J Respir Crit Care Med* 1996;153:509-14.
384. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. *Auranofin Multicenter Drug Trial. J Allergy Clin Immunol* 1996;98:317-24.
385. Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH. Auranofin in the treatment of steroid dependent asthma: a double blind study. *Thorax* 1992;47:349-54.
386. Jakobsson T, Croner S, Kjellman NI, Pettersson A, Vassella C, Bjorksten B. Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. *Allergy* 1994;49:413-20.
387. Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. *Clin Immunol* 1999;91:126-33.
388. Salmun LM, Barlan I, Wolf HM, Eibl M, Twarog FJ, Geha RS, Schneider LC. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. *J Allergy Clin Immunol* 1999;103:810-5.
389. Jolliffe DA, Greenberg L, Hooper RL, Griffiths CJ, Camargo CA, Jr., Kerley CP, Jensen ME, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. *Lancet Respir Med* 2017;5:881-90.
390. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, Kazani SD, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *Jama* 2014;311:2083-91.
391. Denlinger LC, King TS, Cardet JC, Craig T, Holguin F, Jackson DJ, Kraft M, et al. Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *Am J Respir Crit Care Med* 2016;193:634-41.
392. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. *J Allergy Clin Immunol* 2006;117:1054-62.
393. Shaheen SO, Newson RB, Rayman MP, Wong AP, Tumilty MK, Phillips JM, Potts JF, et al. Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma. *Thorax* 2007;62:483-90.
394. Pogson ZE, Antoniak MD, Pacey SJ, Lewis SA, Britton JR, Fogarty AW. Does a low sodium diet improve asthma control? A randomized controlled trial. *Am J Respir Crit Care Med* 2008;178:132-8.
395. Ernst E. Spinal manipulation for asthma: a systematic review of randomised clinical trials. *Respir Med* 2009;103:1791-5.
396. Ernst E. Homeopathy: what does the "best" evidence tell us? *Med J Aust* 2010;192:458-60.
397. Yang ZY, Zhong HB, Mao C, Yuan JQ, Huang YF, Wu XY, Gao YM, et al. Yoga for asthma. *Cochrane Database Syst Rev* 2016;4:CD010346.
398. Freitas DA, Holloway EA, Bruno SS, Chaves GS, Fregonezi GA, Mendonca KP. Breathing exercises for adults with asthma. *Cochrane Database Syst Rev* 2013;10:CD001277.
399. Bruton A, Lee A, Yardley L, Raftery J, Arden-Close E, Kirby S, Zhu S, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. *Lancet Respir Med* 2018;6:19-28.
400. Slader CA, Reddel HK, Spencer LM, Belousova EG, Armour CL, Bosnic-Anticevich SZ, Thien FC, et al. Double blind randomised controlled trial of two different breathing techniques in the management of asthma. *Thorax* 2006;61:651-6.

401. Pedersen S, Dubus JC, Crompton GK, Group AW. The ADMIT series--issues in inhalation therapy. 5) Inhaler selection in children with asthma. *Prim Care Respir J* 2010;19:209-16.
402. Brand PL. Key issues in inhalation therapy in children. *Curr Med Res Opin* 2005;21 Suppl 4:S27-32.
403. Kamps AW, Brand PL, Roorda RJ. Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. *Acta Paediatr* 2002;91:159-63.
404. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev* 2013.
405. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. *Arch Dis Child* 2010;95:365-70.
406. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. *J Allergy Clin Immunol* 1998;102:789-96.
407. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. *J Allergy Clin Immunol* 1997;99:773-80.
408. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2008;CD003135.
409. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. *Cochrane Database Syst Rev* 2004;CD004109.
410. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. *Cochrane Database Syst Rev* 2013;2:CD009611.
411. Vahlkvist S, Inman MD, Pedersen S. Effect of asthma treatment on fitness, daily activity and body composition in children with asthma. *Allergy* 2010;65:1464-71.
412. Rodrigo GJ, Castro-Rodriguez JA. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis. *Respir Med* 2013;107:1133-40.
413. Pedersen S. Do inhaled corticosteroids inhibit growth in children? *Am J Respir Crit Care Med* 2001;164:521-35.
414. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. *N Engl J Med* 2000;343:1064-9.
415. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, et al. Effect of inhaled glucocorticoids in childhood on adult height. *N Engl J Med* 2012;367:904-12.
416. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: Systematic review and meta-analysis. *PLoS One* 2015;10:e0133428.
417. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. *Cochrane Database Syst Rev* 2014;7:CD009878.
418. Hopp RJ, Degan JA, Biven RE, Kinberg K, Gallagher GC. Longitudinal assessment of bone mineral density in children with chronic asthma. *Ann Allergy Asthma Immunol* 1995;75:143-8.
419. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. *Pediatrics* 2004;114:469-73.
420. van Staa TP, Bishop N, Leufkens HG, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children? *Osteoporos Int* 2004;15:785-91.
421. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. *J Bone Miner Res* 2003;18:913-8.
422. Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, Faulkner K, et al. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. *Mayo Clin Proc* 2004;79:458-66.
423. Roux C, Kolta S, Desfougeres JL, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. *Pediatrics* 2003;111:e706-13.
424. Gray N, Howard A, Zhu J, Feldman LY, To T. Association between inhaled corticosteroid use and bone fracture in children with asthma. *JAMA pediatrics* 2018;172:57-64.
425. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC, Group CR. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. *Pediatrics* 2008;122:e53-61.
426. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. *Lancet* 1996;348:27-9.
427. Raissy HH, Sternberg AL, Williams P, Jacobs A, Kelly HW, Group CR. Risk of cataracts in the Childhood Asthma Management Program Cohort. *J Allergy Clin Immunol* 2010;126:389-92, 92.e1-4.

428. Selroos O, Backman R, Forsen KO, Lofroos AB, Niemisto M, Pietinalho A, Aikas C, et al. Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler. *Allergy* 1994;49:888-90.
429. Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, van Asperen PP. Safety of the newer inhaled corticosteroids in childhood asthma. *Paediatr Drugs* 2003;5:481-504.
430. Shaw L, al-Dlaigan YH, Smith A. Childhood asthma and dental erosion. *J Dent Child* 2000;67:102-6, 82.
431. Kargul B, Tanboga I, Ergeneli S, Karakoc F, Dagli E. Inhaler medicament effects on saliva and plaque pH in asthmatic children. *J Clin Pediatr Dent* 1998;22:137-40.
432. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2010:CD005535.
433. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C, Steinkamp G, Group VS. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). *Pediatr Pulmonol* 2009;44:1132-42.
434. de Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, Bennedbaek O, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. *Pediatr Allergy Immunol* 2009;20:763-71.
435. Lemanske RF, Jr., Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *N Engl J Med* 2010;362:975-85.
436. Stempel DA, Szeffler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. *N Engl J Med* 2016;375:840-9.
437. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. *Pediatr Pulmonol* 2003;36:391-8.
438. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. *Cochrane Database Syst Rev* 2009:CD007949.
439. Castro-Rodriguez JA, Rodrigo GJ. A systematic review of long-acting 2-agonists versus higher doses of inhaled corticosteroids in asthma. *Pediatrics* 2012;130:e650-7.
440. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting 2-adrenergic receptor agonists. *Pediatrics* 2011;128:e1147-54.
441. Szeffler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. *J Allergy Clin Immunol* 2005;115:233-42.
442. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. *J Pediatr* 2005;147:213-20.
443. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. *Pediatrics* 2005;116:360-9.
444. de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. *Eur Respir J* 2006;28:291-5.
445. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. *Cochrane Database Syst Rev* 2013;10:CD009585.
446. Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. *Ann Allergy Asthma Immunol* 2006;97:397-401.
447. Strunk RC, Bacharier LB, Phillips BR, Szeffler SJ, Zeiger RS, Chinchilli VM, Martinez FD, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. *J Allergy Clin Immunol* 2008;122:1138-44 e4.
448. Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van der Wouden JC. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. *Thorax* 2000;55:913-20.
449. Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise-induced bronchoconstriction. *Cochrane Database Syst Rev* 2000;2.
450. Armenio L, Baldini G, Bardare M, Boner A, Burgio R, Cavagni G, La Rosa M, et al. Double blind, placebo controlled study of nedocromil sodium in asthma. *Arch Dis Child* 1993;68:193-7.
451. Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review. *Pediatr Allergy Immunol* 2017;28:573-8.

452. Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. *Allergy Asthma Proc* 2017;38:250-63.
453. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics* 2001;108(2):E36.
454. Lemanske RF, Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. *Pediatrics* 2002;110:e55.
455. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *J Allergy Clin Immunol* 2009;124:1210-6.
456. Bossley CJ, Saglani S, Kavanagh C, Payne DN, Wilson N, Tsartsali L, Rosenthal M, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. *Eur Respir J* 2009;34:1052-9.
457. Williams SJ, Winner SJ, Clark TJ. Comparison of inhaled and intravenous terbutaline in acute severe asthma. *Thorax* 1981;36:629-32.
458. Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline against exercise-induced asthma in children: a dose-response study. *Eur Respir J* 1993;6:527-30.
459. McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. *Cochrane Database Syst Rev* 2003:CD003535.
460. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. *Cochrane Database Syst Rev* 2006:CD002885.
461. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. *N Engl J Med* 1981;304:71-5.
462. Brenner M, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. *Clin Allergy* 1988;18:143-50.
463. Magnussen H, Reuss G, Jorres R. Methylxanthines inhibit exercise-induced bronchoconstriction at low serum theophylline concentration and in a dose-dependent fashion. *J Allergy Clin Immunol* 1988;81:531-7.
464. Ellis EF. Theophylline toxicity. *J Allergy Clin Immunol* 1985;76:297-301.
465. Kuusela AL, Marenk M, Sandahl G, Sanderud J, Nikolajev K, Persson B. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. *Bambuterol Multicentre Study Group. Pediatr Pulmonol* 2000;29:194-201.
466. Zarkovic JP, Marenk M, Valovirta E, Kuusela AL, Sandahl G, Persson B, Olsson H. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. *The Bambuterol Multicentre Study Group. Pediatr Pulmonol* 2000;29:424-9.
467. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. *Pediatrics* 2009;123:e519-25.
468. Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC, Cabana MD. Preventing Exacerbations in Preschoolers With Recurrent Wheeze: A Meta-analysis. *Pediatrics* 2016;137.
469. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. *Am J Respir Crit Care Med* 2000;162:1500-6.
470. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. *J Allergy Clin Immunol* 2001;108:540-6.
471. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefer SJ, Bacharier LB, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006;354:1985-97.
472. Alangari AA, Malhis N, Mubasher M, Al-Ghamedi N, Al-Tannir M, Riaz M, Umetsu DT, et al. Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: a double-blind, randomized, controlled trial. *Chest* 2014;145:772-8.
473. Zeiger RS, Mellon M, Chipps B, Murphy KR, Schatz M, Kosinski M, Lampl K, et al. Test for Respiratory and Asthma Control in Kids (TRACK): clinically meaningful changes in score. *J Allergy Clin Immunol* 2011;128:983-8.
474. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, Fabbri LM, et al. Regular vs prn nebulized treatment in wheeze preschool children. *Allergy* 2009;64:1463-71.
475. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. *Pediatrics* 1999;103:414-21.
476. Teper AM, Colom AJ, Kofman CD, Maffey AF, Vidaurreta SM, Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. *Pediatr Pulmonol* 2004;37:111-5.
477. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. *Am J Respir Crit Care Med* 1999;160:126-31.



478. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone. *Arch Dis Child* 2001;85:143-8.
479. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. *Arch Dis Child* 1993;68:85-7.
480. Hofhuis W, van der Wiel EC, Nieuwhof EM, Hop WC, Affourtit MJ, Smit FJ, Vaessen-Verberne AA, et al. Efficacy of fluticasone propionate on lung function and symptoms in wheezy infants. *Am J Respir Crit Care Med* 2005;171:328-33.
481. Ilangoan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulized budesonide suspension. *Arch Dis Child* 1993;68:356-9.
482. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. *Lancet* 2006;368:754-62.
483. Pao CS, McKenzie SA. Randomized controlled trial of fluticasone in preschool children with intermittent wheeze. *Am J Respir Crit Care Med* 2002;166:945-9.
484. Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF, Jr., Szeffler SJ, Strunk RC, et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. *J Allergy Clin Immunol* 2011;128:956-63.e1-7.
485. Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. *Am J Respir Crit Care Med* 2001;164(2):256-9.
486. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics* 2001;108:E48.
487. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. *Am J Respir Crit Care Med* 2005;171:315-22.
488. Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. *Ann Allergy Asthma Immunol* 2011;106:518-26.
489. Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. *Chest* 2007;131:180-6.
490. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. *Am J Respir Crit Care Med* 2000;162:187-90.
491. Szeffler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. *J Allergy Clin Immunol* 2007;120:1043-50.
492. Kooi EM, Schokker S, Marika Boezen H, de Vries TW, Vaessen-Verberne AA, van der Molen T, Duiverman EJ. Fluticasone or montelukast for preschool children with asthma-like symptoms: Randomized controlled trial. *Pulm Pharmacol Ther* 2008;21:798-804.
493. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, Lee AJ, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. *Am J Respir Crit Care Med* 2007;175:323-9.
494. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. *Am J Respir Crit Care Med* 2008;178:854-60.
495. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. *Pediatrics* 2007;120:e702-12.
496. van der Wouden JC, Uijen JH, Bernsen RM, Tasche MJ, de Jongste JC, Ducharme F. Inhaled sodium cromoglycate for asthma in children. *Cochrane Database Syst Rev* 2008;CD002173.
497. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. *Pediatrics* 2004;113:e87-94.
498. Leflein JG, Szeffler SJ, Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, Smith JA. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. *Pediatrics* 2002;109:866-72.
499. Castro-Rodriguez JA, Beckhaus AA, Forno E. Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: Systematic review with meta-analysis. *Pediatr Pulmonol* 2016;51:868-76.
500. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, Jackson DJ, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial.[Erratum appears in JAMA. 2016 Jan 26;315(4):419], [Erratum appears in JAMA. 2016 Jan 12;315(2):204]. *JAMA* 2015;314:2034-44.

501. Stockholm J, Chawes BL, Vissing NH, Bjarnadottir E, Pedersen TM, Vinding RK, Schoos AM, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* 2016;4:19-26.
502. Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. *J Pediatr* 2004;145:172-7.
503. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F, Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. *Cochrane Database Syst Rev* 2005:CD001279.
504. Pollock M, Sinha IP, Hartling L, Rowe BH, Schreiber S, Fernandes RM. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. *Allergy* 2017;72:183-200.
505. Burgers J, Eccles M. Clinical guidelines as a tool for implementing change in patient care. Oxford: Butterworth-Heinemann; 2005.
506. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, et al. A 10 year asthma programme in Finland: major change for the better. *Thorax* 2006;61:663-70.
507. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. *BMJ* 1999;318:527-30.
508. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. *Am J Respir Crit Care Med* 2006;174:605-14.
509. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010;182:E839-42.
510. Partridge MR. Translating research into practice: how are guidelines implemented? *Eur Respir J Suppl* 2003;39:23s-9s.
511. Baiardini I, Baido F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? *Curr Opin Allergy Clin Immunol* 2009;9:228-33.
512. Boulet LP, Becker A, Bowie D, Hernandez P, McIvor A, Rouleau M, Bourbeau J, et al. Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. *Can Respir J* 2006;13 Suppl A:5-47.
513. Harrison MB, Legare F, Graham ID, Fervers B. Adapting clinical practice guidelines to local context and assessing barriers to their use. *CMAJ* 2010;182:E78-84.
514. Boulet LP, FitzGerald JM, Levy ML, Cruz AA, Pedersen S, Haahtela T, Bateman ED. A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. *Eur Respir J* 2012;39:1220-9.
515. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. *CMAJ* 1997;157:408-16.
516. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. *Allergy* 2007;62:216-23.
517. National Asthma Council Australia. Australian Asthma Handbook, [www.asthmahandbook.org.au](http://www.asthmahandbook.org.au). Melbourne, Australia: National Asthma Council Australia; 2014.
518. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. August 2007. Available from: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.
519. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458-65.
520. ADAPTE Framework. Available from <http://www.adapte.org>. 2012.
521. Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson N. Lost in knowledge translation: time for a map? *J Contin Educ Health Prof* 2006;26:13-24.
522. Bereznicki B, Peterson G, Jackson S, Walters EH, Gee P. The sustainability of a community pharmacy intervention to improve the quality use of asthma medication. *J Clin Pharm Ther* 2011;36:144-51.
523. Zeiger RS, Schatz M, Li Q, Solari PG, Zazzali JL, Chen W. Real-time asthma outreach reduces excessive short-acting beta2-agonist use: a randomized study. *The Journal of Allergy & Clinical Immunology in Practice* 2014;2:445-56, 56.e1-5.
524. Forsetlund L, Bjorndal A, Rashidian A, Jamtvedt G, O'Brien MA, Wolf F, Davis D, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev* 2009:CD003030.
525. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, et al. Changing provider behavior: an overview of systematic reviews of interventions. *Med Care* 2001;39:112-45.

526. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. *Health Technol Assess* 2004;8:iii-iv, 1-72.
527. Mold JW, Fox C, Wisniewski A, Lipman PD, Krauss MR, Harris DR, Aspy C, et al. Implementing asthma guidelines using practice facilitation and local learning collaboratives: a randomized controlled trial. *Ann Fam Med* 2014;12:233-40.
528. Baskerville NB, Liddy C, Hogg W. Systematic review and meta-analysis of practice facilitation within primary care settings. *Ann Fam Med* 2012;10:63-74.
529. Lougheed MD, Minard J, Dworkin S, Juurlink MA, Temple WJ, To T, Koehn M, et al. Pan-Canadian REspiratory STandards INitiative for Electronic Health Records (PRESTINE): 2011 national forum proceedings. *Can Respir J* 2012;19:117-26.
530. Damiani G, Pinnarelli L, Colosimo SC, Almiento R, Sicuro L, Galasso R, Sommella L, et al. The effectiveness of computerized clinical guidelines in the process of care: a systematic review. *BMC Health Serv Res* 2010;10:2.
531. Martinez-Gonzalez NA, Berchtold P, Ullman K, Busato A, Egger M. Integrated care programmes for adults with chronic conditions: a meta-review. *Int J Qual Health Care* 2014;26:561-70.
532. Cochrane Effective Practice and Organisation of Care Group (EPOC). Available at <http://epoc.cochrane.org>. 2013.
533. Franco R, Santos AC, do Nascimento HF, Souza-Machado C, Ponte E, Souza-Machado A, Loureiro S, et al. Cost-effectiveness analysis of a state funded programme for control of severe asthma. *BMC Public Health* 2007;7:82.
534. Renzi PM, Ghezzi H, Goulet S, Dorval E, Thivierge RL. Paper stamp checklist tool enhances asthma guidelines knowledge and implementation by primary care physicians. *Can Respir J* 2006;13:193-7.
535. Nkoy F, Fassl B, Stone B, Uchida DA, Johnson J, Reynolds C, Valentine K, et al. Improving pediatric asthma care and outcomes across multiple hospitals. *Pediatrics* 2015;136:e1602-10.
536. Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. *Can Respir J* 2005;12:265-70.
537. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. *Lancet* 2010;376:803-13.
538. Towns SJ, van Asperen PP. Diagnosis and management of asthma in adolescents. *Clin Respir J* 2009;3:69-76.